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Abstract 
 
 The search for genes that influence human performance and health constitutes 
a popular topic of current research. One such genetic constituent that has caused much 
interest over the last 20 years is the angiotensin converting enzyme insertion/deletion 
polymorphism (ACE I/Dp). There is much controversy in the literature regarding the 
role (if any) of this polymorphism as effects and effect size vary between populations 
of different origin and training status. The aim of this thesis was to analyse at the 
whole organism level whether skeletal muscle plasticity explains the association of the 
ACE I/D polymorphism with metabolic fitness.   
 Regular endurance exercise reduces the risk of a plethora of diseases, but the 
exact molecular mechanisms are not fully understood – the ability of muscle to adapt 
to exercise stimulus is key. Trained individuals demonstrated clear physiological 
differences of aerobic processes such as increased oxygen usage, greater power output 
and reduced body fat that would be expected (T-Test: p<0.001). By contrast, when 
examining metabolite changes, at rest, in the local muscle there were few (n=6) non-
polar (lipid species) metabolite (assessed by mass spectrometry) differences between 
the trained and untrained. However, after an acute exercise bout working muscle in 
trained individuals displayed a significant up-regulation of (n=76) non-polar 
metabolites (Repeated ANOVA: p=0.0004), illustrating that training produces 
significant adaptations in substrate metabolism at the local level.  
 Would there be a genetic component contributing towards these physiological 
and local muscle differences? Individuals with the ACE I-allele (insertion sequence) 
had increased capillary density, and there were significant differences in transcripts, 
together with both polar and non-polar metabolites in the untrained population at rest 
and following an acute exercise bout. These differences were lost in the trained 
population. In a different population (Swiss) capillary density was increased following 
a training programme in the absence of the I-allele – in contrast to the other population 
(British). However, gene expression response of important factors, to exercise was 
preserved. 
 In conclusion, a trained population demonstrated enhanced non-polar 
metabolism in the working muscle after an exercise bout, and the dominant stimulus of 
regular exercise over-rides the influence of the ACE I/Dp. Nurture over-rides nature. 
1 
 
 
Chapter 1 
 
 
 
 
 
 
Literature review; 
Skeletal Muscle, the Cardiovasculature, 
Physical Activity and the Role of the ACE 
I/D Genotype 
 
 
 
 
 
 
 
 
 2 
1 Literature Review: Skeletal Muscle, the Cardiovasculature, Physical 
Activity and the Role the ACE I/D Genotype 
 
1.1. Skeletal muscle: Importance for health and disease 
 
 The evidence for the multitude of health benefits attributed to physical activity 
is now without question. Physical activity not only greatly improves an individual’s 
quality of life (QOL) but also significantly reduces the economic burden to society as 
a whole, (POST, 2001; WHO, 2001, 2003; DoH, 2004, 2005). Despite solid evidence 
of positive health benefits, physical activitys importance, in both prevention and 
treatment of diseases, is under-valued and poorly communicated. Possibly one of the 
fundamental reasons regarding this “lack of interest” to embrace and acknowledge 
physical activity as a genuine intervention (in the management of disease) is the 
paucity of concrete evidence that details exactly how it confers health benefits (Coffey 
& Hawley, 2007). 
 In the post-industrial world (within the last 75 years) inactivity-related diseases 
have increased in frequency: diseases of “lifestyle”, chronic diseases such as coronary 
heart disease, diabetes, stroke, obesity, osteoporosis and certain cancers (to name the 
main ones). The risk of developing one or more of the first four listed increase 
significantly with a concomitant decrease in physical activity levels (Khaw et al., 
2008). These four diseases are all related to a malfunctioning metabolism, where too 
little physical activity coupled with excessive energy consumption have become 
manifest in a disease phenotype. These metabolic diseases are associated with 
increased relative risk of disability, reduced QOL and even mortality (Rao, 2005; 
Butland et al., 2007). A much under-valued organ that plays a significant role in the 
development and (potential) prevention of these metabolic diseases is muscle.  
However, the exact function of muscle in the aetiology of these diseases is 
undervalued (Vaag, 1999; Booth et al., 2002) and not understood.  It is known that 
muscle phenotype (visible traits) is conditioned by nurture (e.g. environment and 
behaviors), but exactly how does this occur and how does physical activity influence 
the way in which muscle responds and adapts (plasticity)?  There is a shortage of 
scientific information on signaling mechanisms, coupled with how they relate and 
integrate through different system levels, which produce adaptations in muscle. Figure 
 3 
1 illustrates the different system levels with an intact whole-organism (human). 
Substrates, including fat, carbohydrate (CHO) and to a lesser extent, proteins, are used 
to derive the energy needed for muscle contraction.  The metabolism of these 
substrates can converge on the mitochondria to produce the body’s main energy 
molecule, adenosine triphospate (ATP).  This process does not only provide the ATP 
to enable muscle contraction, but also by-products such as urea from protein 
degradation, water and carbon dioxide from CHO and fat metabolism, and heat. 
 
 
Even though we (humans) are all extremely similar, e.g. we all belong to the same 
family of Homo sapiens (modern human lineage), physiologically and genetically 
there are small yet significant subtle differences between each of us, which result in 
vastly different phenotypes. Even genetically identical twins will adapt differently, 
 
Figure 1. Different system levels in an intact whole-organism. 
(1) Heart and Lungs represent the key organs involved in extraction and delivery/removal of O2 and 
CO2, (2) Ultrastructures involved in delivery/removal (capillaries), energy production (mitochondria), 
and movement (muscle fibre) – image provided courtesy of Hans Hoppeler, (3) Genes represent the 
“bottom” level in the whole system, which provide the blueprint for all the proteins required for 
physiological functioning. (A) Illustration from Linstedt & Conley (2001).  
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right from gene regulation/expression to physiological adaptations. Therefore it is not 
the genetic make-up that is crucially important, but something else. Rennie highlighted 
that muscles response (Figure 2) to differing types of exercise (endurance or 
resistance) produced completely different muscle phenotypes (Rennie, 2005). The 
pertinent point highlighted was that the muscle response was not due to different 
genetic differences, as the two humans pictured are genetically identical twins (Figure 
2).  
 
 
1.1.1 Skeletal muscle and the vascular system 
 
 It is now well recognised that our modern lifestyle (energy rich diet and 
physical inactivity) is associated with an increased prevalence of chronic diseases. 
These well documented and studied chronic diseases (cardiovascular disease (CVD), 
obesity, DMII, stroke, certain cancers, and osteoporosis) are mainly the result of a 
malfunctioning metabolism of which the cardiovascular system (CVS) and muscle 
play a critical role in. The major cause of morbidity and mortality in modern society is 
coronary heart disease (CHD), of which hypertension is the number one risk factor for 
developing CHD (Dickson & Sigmund, 2006). The risk of becoming hypertensive 
(>140/90 mmHg), in modern societies, during a lifetime surpasses 90% (Messerli et 
al., 2007). Hypertension cost the US economy in the late 1990’s $286.5 billion (Booth 
 
Figure 2. Genetically identical twins, aged 23, July 2
nd
 1969. 
Both elite athletes, one an endurance runner the other a strength/field athlete (guess which is which!). 
Both images are from Rennie (2005). 
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et al., 2000). The cost to the European economy of CVD in 2006 was just under €110 
billion (BHF, 2009). It is not just the loss of human life or QOL that is concerning 
governments across the globe. The American Heart Association (AHA) estimates that 
one-third of the US adult population is hypertensive, which includes a third that is 
undiagnosed (Dickson & Sigmund, 2006).  
 Muscle can be thought of as a metabolic sink (Hamilton & Booth, 2000), an 
organ that can “absorb” or utilise substrates. Muscle produces movement, but this is 
only sustainable (past very short bursts, e.g. you can run 100 metres whilst holding 
your breath: glycolysis) with an adequate supply of oxygen (O2) and energy substrates, 
plus the removal of carbon dioxide (CO2) and other waste products. This is the role of 
the CVS or vasculature, which perfuse (to varying degrees) all tissues. The heart 
provides the force and the vasculature the conduits through which these metabolites 
are delivered (and removed) to the various tissues. The distribution of blood through 
the body, and resulting change with physical activity is illustrated in Figure 3 
(Astrand, 2003).  
 Depending on the activity (sitting, eating, sleeping or physical activity) the CVS 
is constantly responding to changes. Effeciently regulating blood flow between 
different tissues and activity means many levels of control are required. At a whole-
body level neuronal, hormonal and mechanical/chemical receptors play a crucial role 
in regulating blood flow to all tissues. 
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However, arguably the most important factor is the vascular system itself. The 
vascular system (excluding the pump – heart) is basically made up of delivery 
(arteries, aterioles, to capillaries) and drainage (venules and veins) vessels with 
varying physical properties. The delivery vessels (although not the final vessels: 
capillaries) can alter their diameter to both maintain blood pressure and 
decrease/increase blood flow. The arteries have the largest diameter; with thick 
(relatively) walls that facilitate blood flow directly from the heart and can withstand 
high arterial pressures. The capillaries are the final vessels and and have a diameter 
barely wider than a single red blood cell (RBC) to enable diffusion of substrates into 
tissues, most importantly into (for muscle work) muscle.  
 Whilst all tissues/organs require an adequate blood flow, muscles influence on 
the CVS (due to its dynamic and energy needs) provides the biggest challenge, as the 
 
Figure 3. Relative distribution of blood to major organs at rest and during strenuous exercise. 
The size of the black squares is roughly proportional to the minute volume of blood flow. (Not 
included is an estimated blood flow of 5% to 10% to fatty tissues at rest, about 1% during 
strenuous exercise) (Astrand, 2003). 
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greatest amount of blood vessels perfuse it. The average human body contains over 
100,000 miles of blood vessels (McArdle et al., 1996), of which it is estimated that 
capillaries constitute 60,000 miles (Junqueira & Carneiro, 2005). Repetitive and 
sustained muscle contraction, as in endurance exercise, significantly increases the 
local working muscles requirement for not only O2, but for substrate delivery and, CO2 
and waste removal. The body systems must react and increase blood supply to the 
working musculature to enable continuation of exercise and to supply the substrates 
after exercise has been terminated to replenish depleted stores of lipids, CHO and 
amino acids (AA).  With repeated exercise sessions the chronically altered gene 
expression will result in beneficial CVS adaptations, including significant increases in 
local muscle structures (capillary and mitochondrial density) and properties 
(vasodilatation) (Lindstedt & Conley, 2001; Atherton et al., 2005; Laughlin & 
Roseguini, 2008). For example, at rest the heart pumps approximately 5 L of blood 
min
-1
, during strenuous exercise this can rise to 40 L min
-1
 (Ekblom, 1968), this huge 
change requires an efficient and concerted interconnected physiological and molecular 
response. The vascular network/structure is of particular importance because small 
changes in diameter of the conducting vessels equal large changes in blood flow and 
maintenance of blood pressure, which are both vital, especially during physical 
activity. Blood pressure must remain adequate to supply the brain with O2 and all 
other organs despite the decrease in supply, which has been re-directed to the working 
muscle (Figure 3).  
 At a local ultra-structural level there are several key factors that facilitate 
enhanced O2 delivery, including an up-regulation of vasodilatory peptides (nitric oxide 
– NO, bradykinin – BK, endothelium-derived hyperpolarising factor – EDHF (Clifford 
& Hellsten, 2004; Luksha et al., 2009)), anti-clotting factors (thin the blood thus 
facilitating delivery) and increasing the number of open capillaries (Rattigan et al., 
2007) to enhance the surface area for diffusion.  
 8 
  
 
      
 
Figure 5. Cross-sectional area of human vastus lateralis muscle, stained for fast myosin 
(red). 
Taken from the one of the author’s participants. 
 
       
Figure 4. Cross-sectional area of human vastus lateralis muscle, stained for capillaries (lectin). 
Taken from the one of the author’s participants.  
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Figures 4 and 5 show sections from muscle biopsies stained for both capillary density 
and fibre type. Human muscle is predominantly composed of a combination of slow 
(oxidative) or fast (glycolytic), with increased capillarity favouring oxidative – versus 
glycolytic - fibres (Laughlin & Roseguini, 2008) (Although, the actual muscle fibre 
itself does not ultimately dictate the capillary number or density (Egginton & Gaffney, 
2010)). A study by Zoladz, et al. (2005) clearly showed (Figure 6) there was a 
difference, in capillary density, between untrained individuals and aerobically or 
strength trained individuals, but no difference between the two different trained groups 
(Zoladz et al., 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is generally accepted that endurance training promotes a shift towards a slow muscle 
phenotype and increases capillary density – which will have significant athletic 
(increased capillary:fibre ratio and O2 delivery) and health implications (Andersen & 
Henriksson, 1977; Hawley, 2002). For example, blood flow to supply muscle in 
exercising animals ranges from 60 – 400 ml/min for fast and slow fibre types, 
respectively (Hamilton & Booth, 2000), and a high percentage of fast fibre types is 
linked to metabolic diseases such as obesity and diabetes type 2 (DM2),  (Hamilton & 
Booth, 2000) – see van Loon and Goodpaster, (2006) and Consitt, et. al., (2009) too.  
 
Figure 6. Capillary density in vastus lateralis muscle and training status.  
(A): untrained students, (B): endurance athletes, (C): strength/power athletes. *significant 
difference between (A) and the two trained groups (B) and (C), but no difference between 
these two (p<0.05) (Zoladz, et al. 2005). 
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 Muscle can act like a metabolic sink utilising plasma glucose, free fatty acids, 
and triacylglyerides (TAG) – a very positive consequence of regular endurance type 
exercise. Yet if these metabolites are chronically elevated they can have a negative 
effect on human health due to excessive exposure. Low density lipoproteins (LDL) 
become oxidised and forms plaques in arterioles, which eventually leads to 
arteriosclerosis – a narrowing of the arteries.  
 Contracting muscle (specifically skeletal muscle) directly and positively impacts 
on many other organs: sustained skeletal muscle contraction such as during endurance 
type exercise results in increased heart rate. Over time the heart will hypertrophy, 
resulting in a decreased resting heart rate and reduced blood pressure (Mitchell & 
Victor, 1996). Studies have demonstrated that sympathetic tone is reduced after 
exercise training – contributing to decreased peripheral resistance and reduced 
hypertension (Serne et al., 2006; Hansen et al., 2010; Green et al., 2011).  Lipid 
metabolic pathways will also be prefentially utilised (something that elite endurance 
athletes benefit from through years of training), and glucose regulation (including a 
heightened sensitivity to insulin – resulting in less production) better controlled. Both 
of these two adaptations will result in reduced adipose storage (decresed risk of 
developing obesity) and decreased risk of developing DM2 – two of the most 
prevalent diseases of our modern lifestyle – both strongly linked and correlated with 
an excess of Calories and sedentariness. 
 There are clear beneficial adaptations resulting from regular endurance type 
exercise (also see Figures 9, 10, 14 and 15). Both visable to the eye (leaness, muscle 
definition, efficiency of movement), and clearly measureable at the physiological level 
(reduced heart rate and increased stroke output, greater oxygen uptake, increased 
muscle mass, increased capillary density, increased mitochondrial density, more 
compliant and reactive CVS, increase bone density – to name some). However, what 
role do specific genes or gene variants have on these adaptations in trained and 
untrained populations and even different ethnicities? This is a question this project 
aims to explore (see 1.2.7. Aims and Objectives of the research project).  
 
 
 
 
 11 
1.1.2 Energy stores and supply of skeletal muscle 
 
 The two previous sections introduced both the importance of muscle and CVS 
that perfuses it. This section introduces the third main component that drives muscle 
work, energy substrates and their stores.  
 Endurance trained muscle is much more than just a force generating organ to 
enable movement: “skeletal muscle is an endocrine organ producing and releasing 
myokines (molecules released by contracting muscle: most notably cytokines and 
specifically interleukin-6 (IL-6); they can exert endocrine or paracrine effects; nitric 
oxide (NO) is another example) in response to contraction, which can influence 
metabolism in other tissues and organs” (Pedersen & Febbraio, 2008). Most 
importantly muscle makes a significant contribution to energy substrate storage and 
utilisation. 
 Muscle is not the only organ that requires energy, to contract to provide 
movement, in the form of ATP.  Table 1 from (McClave & Snider, 2001) illustrates 
the various energy demands of organs in the human body at rest. Comparing absolute 
weights muscle appears to contribute little towards daily energy consumption. 
However, due to its sheer volume its role in energy expenditure is crucial.  When you 
factor into the equation its ability to increase/decrease in size, quality and efficiency 
muscles importance to both energy expenditure and overall well-being heighten 
further.  
Table 1. Energy requirements of various major human organs or tissues at rest. 
Organ or Tissue 
Metabolic Rate 
(kcal/kg/day) 
Overall REE  
(%) 
Weight  
(Kg) 
Body Weight 
(%) 
Adipose 4.5 4 15 21.4 
Muscle 13 22 28.2 40 
Other 12 16 23.2 33.1 
Liver 200 21 1.8 2.6 
Brain 240 22 1.4 2.0 
Heart 400 9 0.3 0.5 
Kidneys 400 8 0.3 0.5 
 
Other refers to bone, skin, intestines and glands. Note: the lungs have not been measured for 
methodological reasons but have been estimated at 200 kcal/kg similar to the liver (McClave & 
Snider 2001). 
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There may be a limited amount of glucose that can be stored within the human body, 
but there is no limit to the amount lipids that can be stored (in fat cells – adipose 
tissue), which can be clearly witnessed by the burgeoning waistlines over the past 
three decades. Lipids can be stored subcutaneously (under the skin), viscerally (around 
organs) and within muscle (intramuscular triglycerides – IMTG), for the moment we 
will focus on IMTG stores. It was originally thought that high IMTG levels were 
associated with decreased insulin sensitivity, and thus increased risk of developing 
type 2 diabetes (DM2) and obesity (Consitt et al., 2009; Muoio, 2010).  
 
 
 
 
 
 
 
 
 
 
 
 
 
However, the ‘athletes/metabolic paradox’ where endurance training increases IMTG 
stores (van Loon & Goodpaster, 2006) and increases insulin sensitivity has somewhat 
clouded this line of thought. The IMTG droplets can be visualised in Figure 7 
(Schrauwen-Hinderling et al., 2006) and are often located adjacent (see Figure 8) to 
muscle mitochondria (van Loon & Goodpaster, 2006), potentially enhancing their 
availability to be utilised (van Loon & Goodpaster, 2006).  
 
 
 
 
 
 
 
Figure 7. Stained section of rat tibialis anterior muscle. 
 
Red fluorescent signal (Oil Red O) is the staining of intramyocellular lipids. The blue staining 
signal is the laminin of the cell membrane (Schrauwen-Hindering, et al., 2006). 
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The increased use of lipids from IMTG stores for energy production (plus increased 
insulin sensitivity) in endurance trained people contrasts with obese and DM2 people 
(van Loon & Goodpaster, 2006). This suggests that it is not the amount of IMTG 
accumulated, but how it is accumulated (or turned over), which points to the very 
complex nature of physiological adaptations and the potential benefits of regular 
physical activity. Figure 9 illustrates this point, and Figure 10 provides further 
evidence of the importance of physical activity (especially aerobic type physical 
activity) and the relationship between the development of slow type fibre phenotype – 
and potential negative implications for health for humans with lower percentages (van 
Loon & Goodpaster, 2006; Consitt et al., 2009). 
  
 
 
 
 
 
 
 
 
  
 
 
Figure 8. Electron micrograph of longitudinal section of muscle.  
(courtesy of Hans Hoppeler) 
li: lipid droplet, mc: central mitochondria, mf: myofilaments. 
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Unlike lipid stores, there is a finite capacity for glucose storage (glycogen – see table 
2), with muscle being the primary site of glucose load conversion (over 90%) to 
glycogen (Greenberg et al., 2006).  As glucose is the only fuel (apart from utilisation 
of ketones during pro-longed starvation) source of the brain it is vitally important that 
blood glucose levels are maintained at around 5 mmol/l. At the beginning of exercise 
hepatic glycogenolysis provides most of the glucose for ATP re-generation, but as 
exercise continues muscle glycogen breakdown supplies the majority of glucose for 
energy production (McArdle et al., 1996).  
Again we find that the mechanisms and amount of storage and usage, of glycogen, in 
physical activity endurance trained individuals is different (to sedentary). Endurance 
training (ET), providing CHO intake is sufficient, enhances glycogen storage, whilst 
sparing its utilisation by increased lipid oxidation (from white adipose tissue - WAT 
and IMTG). For example, if glycogen is the only energy source during relatively high 
endurance exercise (80% of VO2max) it will be depleted in 60 – 90 minutes (Jones, 
2004). Total (average) glycogen (liver + muscle), at an oxidation rate of 2.5 g/min 
would last for approximately 2 hours (at approximately 80% of VO2max) (Frayn, 
2003). Table 2 provides an example of the amount of energy substrates in a typical 
person.  
 
 
 
        
   Figure 9. Contrasting metabolic pathways of inactivity and endurance exercise. 
 
Inactivity coupled with excessive energy intake results in elevated IMTG storage, which produces a 
series of deleterious metabolic events possibly leading to DM2. Endurance exercise also elevates 
IMTG, but this is shown to be beneficial, allowing IMTG to act as a pool of nearby energy 
substrates, without the negative build up of potentially harmful metabolites (van Loon & Goodpaster, 
2006). 
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Table 2.  Energy content of metabolic substrates (approximate values) of a typical 65kg person 
expending 10MJ/day. 
 
*not all body protein can be utilised (original reference Frayn, 2003) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The contrasting substrate utilisation processes and storage adaptations (as highlighted 
above) between different populations (trained, untrained (sedentary) and DM2) 
illustrates nicely how regular exercise can beneficially influence health. DM2 is a very 
modern disease and correlates strongly with increasing obesity (Williams & Pickup, 
2004; WHO, 2005), of which both diseases correlate with sedentary type behaviour. 
DM2 individuals have a significantly greater risk of developing cardiovascular 
diseases (CVD) (Morrish, et al., 2001; Huxley et al., 2006). Figures (and related 
studies) 9 and 10 highlight local adaptations (in muscle) that occur with regular 
exercise (especially of aerobic type) and why these contribute to reductions in the risk 
of developing DM2 and the resulting CVD.  
 
 
  
 
 
 
 
 
 
Figure 10. Fibre type and lipid content in humans: trained, sedentary and diabetic. 
This simple figure illustrates the potential benefits of regular endurance training; 1) an enhanced 
percentage of slow fibre types and a concomitant increase in lipid stores. Note the similar fibre type 
and lipid content of both sedentary and diabetic individuals. Data provided are mean + SEM; 
*significantly lowered compared to values observed in trained athletes; #significant difference 
between type I and II muscle fibres (van Loon & Goodpaster, 2006). 
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The third major (potential) fuel, protein, can be broken down to release amino  
acids (AA), which can be oxidised during physical activity, even though its primary 
function is not energy provision: AA are crucial in providing structural and regulatory 
functions within the body (Tarnopolsky, 2004). Despite the intense marketing and 
media hype espousing the importance of large intakes of protein supplements (and 
individual amino acids) if energy requirements are met (from a mixed diet) then 
protein requirements will be adequately met – even in elite endurance athletes 
(Maughan, 2002; Tarnopolsky, 2004). Regular physical activity (especially of an 
aerobic nature) will result in increased amounts/activity of enzymes (related to energy 
metabolism, especially lipid related: for example; lipoprotein lipase (LPL), fatty acid 
binding proteins (FABP), carnitine-palmitoyl transferase-1 and -2 (CPT-1,-2)). Also, 
increased capillaries, haemoglobin, and myoglobin (as a result of regular exercise) – 
could in theory increase amino acid requirements (Tarnopolsky, 2004).     
 Human skeletal muscle can oxidise eight amino acids (Smith & Rennie, 1996), 
but the branch chain amino acids (BCAA) are preferentially oxidised during exercise 
(Lamont et al., 1999; McKenzie et al., 2000). Despite the obvious requirement of 
protein ingestion and turnover, its importance in relation to energy provision is likely 
minimal (providing carbohydrate intake is sufficient). It is estimated that oxidation of 
AA contributes between 1 – 6% of total energy provision – during endurance exercise 
(Tarnopolsky, 2004), although some estimates range up to 20% (Rennie et al., 2006).  
 The carbon skeletons of AA (transaminated by enzymes within muscle cells) 
directly participate in ATP synthesis (via glycogenic or ketogenic pathways) (McArdle 
et al., 1996). As the physiological functions of fibre types (in relation to type I and 
type II fibres – ignoring intermediate fibre types, which are likely of a small 
percentage) are different could the amount and utilisation vary during and recovering 
from exercise? In a resistance exercise study by Blomstrand and Essen-Gustavsson 
there were significant changes in levels of alanine, tryptophan, isoleucine and leucine; 
and glutamate, serine, alanine, tyrosine, methionine, valine, phenylalanine, isoleucine 
and leucine in plasma concentration during exercise and recovery respectively 
(Blomstrand & Essen-Gustavsson, 2009). What is most interesting from this study is 
the difference in concentrations or utilisation of AA between type I and type II fibres. 
The reduction in type II fibres, of glutamate, was twice that of type I fibres (70% 
versus 32%), suggesting the former make a greater contribution to force production 
 17 
(Blomstrand & Essen-Gustavsson, 2009), which is generally well evidenced (Astrand, 
2003; Jones, 2004). The concentrations of glutamate (decreased), and the BCAA 
(increased) were significantly different in type II versus type I fibres, immediately 
following a bout of resistance exercise (Blomstrand & Essen-Gustavsson, 2009).  
However, in an earlier study, (2002) by Blomstrand and Essen-Gustavsson, on the 
concentrations of AA, there was no significant difference in reduction of any AA 
(between type I and II fibres) following endurance exercise (cycling) (Essen-
Gustavsson & Blomstrand, 2002). Although, aspartate, glutamate and arginine levels 
were all significantly lower, at rest, in type I fibres compared to type II. What was 
interesting in this study was, all the participants were endurance trained cyclist, and 
the day before they participated in glycogen depleting exercise (and did not eat until 
after the exercise test the following day). Therefore, did this muscle glycogen 
depletion influence AA usage, which resulted in an equal (relative) reduction in both 
fibre types? The authors seemed to think so. This depletion in AA would certainly 
make physiological sense, as AA (especially the BCAA) can be broken down (within 
muscle) and their carbon skeleton by-products utilised directly to produce glucose in 
gluconeogenesis (McArdle, 2005). (NB: in Blomstrand and Essen-Gustavsson fibre 
types were classified and pooled into groups of type I and type II – then the pooled 
types were weighed and then analysed for free AA). 
 
1.1.3 Skeletal muscle phenotype and the influence of physical activity 
 
The CVS and associated vessels (most importantly capillaries – where 
diffusion takes place) are responsive to external demands – by dilating/constricting 
and facilitating delivery and removal of substrates to muscle. Muscle itself is a very 
responsive/plastic organ. Muscle may comprise ~40% of a healthy males mass, but 
this is not fixed and will decrease with inactivity and increase with physical activity. 
Therefore muscle responds, or displays a plasticity to the environmental demands 
placed upon it (Figure 2). This plasticity involves an interaction between nature 
(genotype) and nurture (environment), which results in particular traits (e.g. increase 
force, fatigue resistance and underlying pathways such as a greater oxidative capacity 
etc) called a phenotype.  
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The contribution of nature versus nurture debate is hotly debated, with those 
leaning towards one or the other as the predominant influencing factor. In the author’s 
opinion the influence of nature (genes) has been greatly exaggerated. Genes do not 
directly control any biological function or phenotype. Plus, when you factor in the 
number of genes which are up-/down-regulated by exercise, it becomes clearly 
apparent that to state any single gene or multitude of genes contributes a greater 
influence than environmental factors is overly simplistic. There is no gene for exercise 
– there is the conscious decision to perform the exercise and then there is the resultant 
adaptation. The striking differences in physiques of the two twins in Figure 2 
illustrates the strong influence of environment. 
 A study by Janssen, et al. (2000) demonstrated increasing body mass is related 
to decreasing muscle mass (as a percentage of total body mass), which means 
increasing fat mass, equalling obesity (Janssen et al., 2000), (Figure 11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In another study by Lee, et al. (1999) the benefits of being fit at different levels of 
body fatness and relative risk (RR) of dying from CVD are illustrated (Figure 12). The 
most pertinent point to take note of here is that it is better to be physically active (fit) 
and obese than lean and unfit – with relation to developing (and dying) from CVD. 
                    
Figure 11. Relationship between relative muscle mass and body weight.  
Solid lines, regression lines. Men: skeletal muscle mass = -0.208 (weight) + 43.4; SEE = 4.1. 
Women: skeletal muscle mass = -0.169 (weight) + 53.1; SEE = 4.3 (Janssen et al., 2000). 
 
 
 
 
 
 
Ref: 2000 Janssen, fig.4b 
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These two simple illustration highlight the relationship (and importance) of regular 
physical activity and skeletal muscle clearly plays a key role.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research in the past decade highlights that the adjustments of the muscle phenotype, 
to a dominant stimulus like strenuous exercise, is specifically mediated by the 
activation of exercise-regulated gene expression signalling pathways (Fluck & 
Hoppeler, 2003; Booth & Neufer, 2005). This signalling response is specific for the 
type of exercise and induces pronounced adjustments in the levels of diffusible gene 
copies (transcripts/mRNA) in the recovery from the muscle stimulus. These significant 
adjustments in gene expression are translated via coupled protein adjustments, which 
then produce adaptations in contractile and metabolic function of muscle. Over time 
and with repetition (training) the exercise stimulus results in an accumulated 
adaptation of muscle strength and fitness. This is matched by the linear increase of 
biological variables from the level of single molecules up to muscle movement (Fluck, 
2006).  
 
        
Figure 12. Body fat percentage and cardiovascular disease RR.  
Fit lean men comprised the reference category, represented by the heavy line at 1.0. Unfit men were 
the lowest quartile of oxygen uptake (mL
●
kg
-1●
min
-1
) in each age group, and fit refers to all other 
men. Body fatness categories were, in percentage body fat, lean (<16.7%), normal (16.7% to 
<25.0%), and obese (≥25.0%). Numbers above the bars represent the number of deaths (Lee et al., 
1999). 
 
 
 
 
 
 
 
Ref: Lee et al 1999,  
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Figure 13 (from Fluck, 2006) illustrates the results of measures in trained versus an 
untrained population, analysing different systems (molecular: mRNA, ultra-structure: 
mitochondria, and function: VO2max).  There are clear statistical significant 
differences illustrated, but these results should come as no surprise. 
 The ability to utilise oxygen, at a whole-body level (a marker of cardiovascular 
fitness), will be related to processes at the molecular level.  The blood vessels are 
essentially conduits for transporting metabolites (in this instance nutrients and oxygen) 
to the working muscle.  Oxygen usage cannot simply be increased by delivering more 
oxygen to the working muscle – there needs to be metabolic processes in place that 
can utilise the nutrients and oxygen more efficiently. Simply put: there is an increase 
in the number of metabolite/energy producing biological “factories” – mitochondria 
(ultra-structure), which is mirrored by the increase in production of molecules 
(mRNA) which make up the  mitochondrial organelle (to facilitate increased oxygen 
usage), and finally this is matched by a significantly higher usage of oxygen at the 
functional level (whole-body). Therefore individuals that partake in regular physical 
activity have a markedly different phenotype than sedentary individuals.    
  A detailed look into training-induced adaptations of muscle suggests that the 
 
Figure 13. From the molecular to functional level: differences in trained and untrained participants. 
■ Trained □ Untrained. Normalised VO2max consumption, mitochondrial volume and mitochondrial 
RNA levels of various respiratory proteins in m. Vastus lateralis of endurance runners vs. untrained 
participants. mRNA levels are relative to 28S rRNA. Values are means ± s.e.m. Black boxes denote 
those mRNAs being encoded by mitochondrial DNA. Trained participants had been exposed to years 
of endurance training and competition. Significant differences between values from endurance-
trained vs. untrained participants are indicated: *P<0.05. Enzyme list:  COX1, cytochrome c oxidase 
subunit 1; COX4, cytochrome c oxidase subunit 4; FUM, fumerase; SDH, succinate dehydrogenase; 
NADH6, nicotinamide adenine dinucleotide hydrogenase (Fluck, 2006). 
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molecular response predicts how a given exercise stimulus instructs these adaptations 
(Schmutz et al., 2006).  A considerable inter-individual variability is observed to an 
initial bout of exercise, which is pronounced in the untrained state (Fluck, 2006; 
Schmutz et al., 2006). A systematic analysis indicates that the activation of gene-
mediated pathways primarily relates to the exercise stimulus and the prior history 
(phenotype) of the challenged muscle (Fluck & Hoppeler, 2003) Therefore genetic 
predisposition, phenotypic conditions (training state) and environmental influences 
(nutrition) are key factors that define this prior muscle phenotype (Pilegaard et al., 
2005; Fluck, 2006).   
The manifestation of a particular set of related phenotypes such as an increase 
in the density of capillaries, mitochondria, and stroke volume of heart results in the 
development of an endurance phenotype. The complexity of the different systems and 
signalling pathways, plus environmental influences makes unravelling key 
components extremely challenging. Due to interactivity and possible redundancy in 
single bottlenecks a network approach is indicated (Oosterhof et al., 2011), e.g. the 
possibility of discovering single components and/or single systems responsible for 
phenotypic changes is extremely remote when studying complex processes, especially 
those which evolve over many decades. 
 There are a number of related physiological changes resulting from being 
regularly physically inactive (Table 3) and physically active (Table 4). The heart 
(obviously a key organ in the CVS) undergoes beneficial adaptations resulting from 
regular endurance type exercise. Left ventricular hypertrophy and an associated 
increase in stroke volume coupled with a decrease in heart rate are just two adaptations 
that occur (in the heart) in an individual who regularly participates in endurance type 
physical activity (Gledhill et al., 1994; Moore & Palmer, 1999).  In muscle at the 
ultra-structural (or cellular) level, both capillary and mitochondrial density increase 
with regular endurance type physical activity (Gavin et al., 2004; Schmutz et al., 
2006; Zoll et al., 2006; Coffey & Hawley, 2007). These adaptations are necessary to 
meet the increased demand, on substrate supply via capillaries and mitochondrial 
metabolism required to fuel muscle contraction during sustained endurance physical 
activity.  
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Table 3. Unhealthy conditions precipitated by physical inactivity and resulting healthcare costs in 
the United States. 
 
Unhealthy Condition  Annual Cost of Condition (USD, $, Billions) 
Increased resting BP 286.5 
Obesity 238 
Type 2 diabetes 98 
All cancers 107 
Osteoporosis 6 
Sacropenia 300 
Back pain 28 
Gallstone disease 5 
 
There may be some overlap among some of the reported unhealthy conditions regarding cost, overt 
disease classification, and possibly with regard to biological mechanism. The main aim of the table is to 
illustrate the diversity of diseases that can develop with physical inactivity. The original references, for 
each unhealthy condition, can be found in the original article in Table 2 (Booth et al., 2000). 
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The next section will introduce the complexity at the molecular level, and related 
physiological adaptations to regular physical activity. 
 
 
 
 
 
Table 4. Beneficial effects of habitual physical activity. 
 
Increase in maximal oxygen uptake and cardiac output – stroke volume  
Reduced heart rate at given oxygen uptake  
Reduced blood pressure  
Reduced heart rate  x  blood pressure product 
Improved efficiency of heart muscle  
Improved myocardial vascularisation  
Favourable trend in incidences of cardial morbidity and mortality  
Increased activity of “aerobic” enzymes  in skeletal muscle  
Reduced lactate production  at a given percentage of maximal oxygen uptake  
Enhanced ability to use free fatty acid as a substrate during exercise, is glycogen saving  
Improved endurance during exercise  
Increased metabolism; advantageous from a nutritional view point  
Counteracts obesity  
An increase in the HDL-LDL ratio  
Improved structure and function of ligaments, tendons and joints  
Increased muscular strength  
Reduced perceived exertion at given work rate  
Increased release of endorphins  
Reduced platelet aggregation?  
Counteracts osteoporosis  
Can normalise glucose tolerance  
 
 
Please see reference 32 from the original article (Astrand, 1992), which this table was 
adapted from. 
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1.1.4 Molecular (and physiological) changes to physical activity, and health 
impact  
 
 The previous section looked at the physiological and beneficial health changes 
that result from regular physical activity. Figure 13 illustrated how molecular changes 
(mRNA) resulted in altered local adaptations (structure: mitochondria number) and 
linked physiological differences (increased VO2max) in trained versus untrained 
humans. This section will expand on important molecular responses to regular 
physical activity and how they may result in important health protective effects. 
 As already alluded too, the blood vessels of the CVS are inextricably linked 
with the health and well-being of an individual. A crucial constituent of the vascular 
system is the vessel wall, which is obviously in constant contact with the circulating 
blood. Blood vessels are made up of several layers (see Figure 14), each producing 
different factors, which will impact on the functioning of any part of the vascular 
system.  
 
We can see from Figure 14 that there are many molecular factors and events taking 
place within blood vessel walls. Shear stress (the viscous friction on the endothelial 
cell surface layer by blood flow: Jacobsen et al., 2009), produced as the blood flows 
 
 
Figure 14. Basic structure of a blood vessel – cross-sectional 
Abbreviations. NO: nitric oxide, PGH2: prostaglandin H2, HSP-90: heat shock protein 90, ET-1: 
endothelin, TGF-β: transforming growth factor beta, PDGF: platelet derived growth factor, FGF-2: 
basic fibroblast growth factor, NADPH: nicotinamide adenine dinuncleotide phosphate oxidase 
(Stenmark et al., 2006). 
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over the endothelial cells, will alter these biological events, which will (over time) 
result in adaptations. Sustained laminar shear stress (LSS), which occurs in the 
linear/straight parts of the blood vessels (Pan, 2009; Traub & Berk, 1998) as produced 
by aerobic exercise has been shown (in vitro) to act as a stimulus for differentiation of 
human umbilical vein endothelial cells (HUVEC), which act as a protective/anti-
atherosclerotic phenotype (Leung et al., 2008). LSS is the “streamlined blood flow 
where viscous forces are predominant over inertial forces”; Pan, 2009. Therefore LSS 
blood flow is thought to be good, whilst oscillatory/low shear stress flow is thought to 
be bad and results in the development of lesions, located at branch points in the 
vasculature (Pan, 2009).  A study by Wasserman et al., (2002) identified at least 107 
genes as candidates for regulation by LSS (Wasserman et al., 2002). Figure 15 
illustrates a small number of endothelial genes regulated by LSS – as a result of 
exercise. 
 
 
Whilst the vast majority of people take up physical activity and cardiovascular type 
exercise to lose weight, the greatest benefits may result from non-traditional 
improvements (i.e. improved glucose/lipid metabolism, and a more plastic vascular 
system) that occur through regular aerobic type exercise – those that result in the 
development of a healthy endothelium and CVS (Thijssen et al., 2010). Significant 
improvements in both conduit and resistance vessel endothelium function, in the 
absence of any improvements in traditional risk factors have been reported (Green et 
al., 2003). Figure 16, again from Leung et al., (2008) illustrates nicely the beneficial 
 
                   
Figure 15. Direct effects of exercise on cells lining blood vessels 
Endothelial Cells (EC) and Vascular Smooth Muscle Cells (VSMC).  
See ref. Lueng, 2008 for specific details of genes in diagram (and full names) (Leung et al., 2008). 
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effects of exercise on CVD risk factors including some proposed key molecular factors 
and processes thought to be involved/occurring and also highlights differences in 
arterio- and angio-genesis. 
 
 
 
Figure 16. Benefits of exercise on vascular remodelling 
See ref. Leung, 2008 for specific details of  mentioned factors in diagram (and full names). 
Most of the diseases of the CVS result from the malfunction of the blood vessel wall 
and vascular growth processes. There are three types of basic mechanisms of vascular 
growth: vasculogenesis (embryonic blood vessel formation), angiogenesis (sprouting 
or splitting of existing vascular capillary structures) and arteriogenesis (increase in 
diameter and wall thickness of arterial vessels) (Egginton, 2009; Persson & 
Buschmann, 2011). However, it is the latter two processes that are importantly altered 
by regular physical activity and in disease states. “A sustained increase of fluid shear 
stress (FSS) leads to activation of the endothelium” (Buschmann & Schaper, 1999). 
Whilst angiogenesis and arteriogenesis are two separate processes, initiated by 
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hypoxia and mechanical (stretch) and/or FSS respectively both share common factors 
like vascular endothelial growth factors (VEGF) and fibroblast growth factors (FGF) 
(Buschmann & Schaper, 1999).  An example, of how angiogenesis and arteriogenesis 
can be affected differently by a disease state is illustrated in Figure 17.  
 Diabetes Mellitus (DM) is characterised by the malfunctioning control of blood 
glucose levels, by either destruction of the pancreatic cells that produce insulin (type I: 
DM1) or the desensitisation to insulin (type II: DM2) to allow glucose entry into cells 
for energy processes. The author proposes that defective neovascularisation signalling 
leads to increased angiogenesis and decreased arteriogenesis (Simons, 2005), which 
may be linked to the development of microvascular damage within the eye 
(retinopathy) and atherosclerosis (plaque development) – two diseases of the CVS that 
people with diabetes have an increased risk of developing.  
 
         
                               
Figure 17. Proposed paradigm of neovascularisation abnormalities in diabetes  
 
AGE = advanced glycosylated end-products. Defective VEGF signalling results in impaired Flk-1 
activation that affects a number of processes thought to be involved in arteriogenesis, including 
endothelial cell growth and migration, monocyte and endothelial progenitor cell (EPC) recruitment, 
and EPC release by bone marrow. As a result, arteriogenesis is impaired. At the same time, decreased 
VEGF sensing, due to impaired Flk-1 activation results in increased serum VEGF levels that lead to 
pathological angiogenesis (retina artheroma) (Simons, 2005). 
. 
Simons (2005) provides an insight into how DM2 may contribute to deleterious effects 
at a cardiovascular level. At its heart, diabetes is a disease where glucose homeostasis 
malfunctions, resulting in increased risk of many cardiovascular related conditions 
(Williams & Pickup, 2004).  DM2 is probably the most strongly evidenced and classic 
lifestyle disease (linked to obesity), one resulting from excessive energy intake 
 28 
coupled with inactivity (Williams & Pickup, 2004). DM2 is a metabolic disease, and 
has been steadily increasing over the last couple of decades, and approximately 400 (in 
the UK) people each day are newly diagnosed with diabetes (85% are DM2) 
(Diabetes, 2010) with no signs of abating. Figure 18 illustrates some very interesting 
physiological responses in DM2 participants compared to those without DM2. These 
findings (Figure 18 – D) suggest that impaired vascular function and reduced femoral 
blood flow affect low intensity exercise in DM2 patients (Lalande et al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other studies have also demonstrated (in DM2 patients) a blunting of stroke volume 
(Baldi et al., 2003), reduced cardiac output (Roy et al., 1989), and impaired diastolic 
function (Baldi et al., 2006). An obvious dysfunction of DM2 is raised blood glucose 
levels and studies have observed reduced blood flow is related to plasma blood 
glucose levels in patients with DM2 (Kingwell et al., 2003). 
 Glucose is not the only energy substrate, when its metabolism malfunctions, 
that can result in a diseased state. LDL, which are important transporters of fat from 
 
Figure 18. Responses to low-intensity exercise in patients with DM2 
(A) Heart rate, (B) stroke volume indexed to fat-free mass, (C) cardiac output indexed to fat-free 
mass, and (D) responses to low-intensity exercise in patients with DM2 (black circles) and 
controls (white circles). * P<0.05 between controls and DM2 patients: †P<0.05 from rest to 
exercise in both groups (Lalande et al., 2008). 
 
 
 
 
 
 
Ref: Lalande et al 2008 
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the blood to cells, are also strongly associated with a narrowing of arteries with 
increasing circulatory level and upon oxidation (oxLDL) (Hockley, 2007; Packard & 
Libby, 2008). However, as LDL is composed of different sub fractions, it may be the 
relative proportion of these and not the total amount in circulation that is important 
(Halle et al., 1997). It is also possible that regular training, apart from favourably 
altering the sub-fraction content of LDL (Halle et al., 1997), beneficially alters how 
LDL is metabolised. Figure 19 illustrates a significant reduction in femoral mean 
dilation (FMD) in sedentary older men versus exercised older men and the correlation 
to LDL-C levels (Walker et al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. LDL-C and FMD relationship between sedentary versus exercising older men  
Relationships between plasma LDL-C (low density lipoprotein-cholesterol) concentrations and 
brachial FMD (femoral mean dilation) in (a) young exercising men, (b) older non-exercising 
men, and (c) older exercising men. For each panel, men with optimal/near optimal and 
borderline high plasma LDL-C concentrations are pooled (Walker et al., 2009). 
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Much like the contrasting development of laying down of IMTG stores within muscle 
(between trained healthy individuals and DM2 people – Figure 9) angiogenesis is 
equally complex. And it is how new blood vessels are formed and altered that is vitally 
important – not simply an up-regulation (of genes) or increase in density (capillaries) 
or change in vessel wall thickness. 
 “The first bout of exercise, after a period of rest, increases blood flow past 
endothelial cells (EC) in vessels, which, in turn, increases endothelial cell NOS (nitric 
oxide synthase - eNOS) protein activity, ultimately increasing its product NO” (Booth 
et al., 2002). Release of NO may be the crucial factor that initiates the angiogenic 
pathway (Spurway & Wackerhage, 2006). 
 There is much evidence to suggest that exercise up-regulates NO (Hudlicka et 
al., 2000; Silveira et al., 2003; Prior et al., 2004; Leung et al., 2008; Woodman, 2008), 
and low levels/bioavailability of NO have been shown to correlate with increased risk 
of cardiovascular diseases (Naseem, 2005; Kocaman, 2009; Napoli & Ignarro, 2009). 
NO (and eNOS, which produces NO from endothelial cells) is an important molecule 
with potent vasodilatory actions, anti-atherogenic properties (Zhou et al., 2001; Endres 
et al., 2003; Kojda & Hambrecht, 2005; Naseem, 2005; Rush & Aultman, 2008; 
Napoli & Ignarro, 2009; Yung et al., 2009), involved in important antiapoptotic and 
antiproliferative signalling pathways (Shyy & Chien, 2002) and antioxidant 
stimulatory functions (Kojda & Hambrecht, 2005). Consequently, NO is a marker of 
endothelial and vascular health (Kojda & Hambrecht, 2005; Napoli & Ignarro, 2009). 
Arterial stiffness (prognostic indicator in vascular diseases – cardiovascular arterial 
disease: CAD, DM2) amongst other factors is related to reduced endothelial 
production of NO (Woodman, 2008). NO also opposes the action, at the level of 
vascular smooth muscle cells (VSMC), to the bodys most potent vasoconstrictor, 
angiotensin 2 (Ang2) (Brillante et al., 2008).  
 The evidence for the beneficial effects of regular physical activity is 
overwhelming, but the fine details explaining these benefits are sorely missing. 
Uncovering how molecular mechanisms work, in response to regular physical activity, 
will provide essential evidence to justifiably prescribe exercise/physical activity – just 
like a doctor currently prescribes medicine.    
 Cytochrome c oxidase (CYC1) may be amongst one of the most important 
antioxidant enzyme. CYC1 secures electron flow in electron transport chain (ETC) 
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thus decreasing potential superoxide (O2-) formation. And the more mitochondria 
present (up-regulated by regular endurance type physical activity) equals more CYC1, 
which demonstrates an important and potentially beneficial molecular/ultra-structural 
adaptation to regular endurance type exercise. However, exercise does increase free 
radical production, which if not buffered can exert toxic effects (Ji, 2002; Banerjee et 
al., 2003). A study by Zoll, et al., (2006) demonstrated a significant increase in gene 
transcripts encoding factors of the ETC and antioxidant enzymes – following six 
weeks of endurance training (Figure 20) (Zoll et al., 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Although it is well established that many genes are differently expressed following 
endurance type exercise (Schmutz et al., 2006; Klossner et al., 2007), it was thought 
that these [genes] and regulatory genes returned to baseline levels if exercise was 
discontinued (Pilegaard et al., 2000; Wittwer et al., 2004). However Figure 21 
(Wittwer et al., 2004) illustrates the biological functions of proteins encoded by 
 
Figure 20. Gene expression changes after endurance training (in hypoxia) 
**p<0.01, *p<0.05, † p<0.10, †† NO directly induces up-regulation of both these factors. (See Zoll, 
2006 for an explanation of each of the abbreviated genes) 
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mRNA’s found to be different between the Vastus lateralis muscles of professional 
cyclists with many years of training and untrained subjects. The authors state “this 
indicates that permanent transcriptional changes (of regulatory genes) could contribute 
to the phenotypical differences of human muscle in a highly trained endurance-trained 
steady state” (Wittwer et al., 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Therefore, an individual that regularly performs endurance type physical activity will 
likely have a very different expression of genes which relate to the altered 
physiological function and resulting phenotype(s). This phenotype will invariably be 
one that favours decreased risk of developing chronic diseases relating to the 
cardiovascular system.  Booth and Neufer (2005) conclude that humans have 
developed a body that is primed for regular physical activity. Bramble (2004) also 
theorises, with good evidence, that humans have evolved over tens of thousands of 
years to be very efficient (and truly unique) endurance runners – with specific 
physiological adaptations rarely seen in other animals, such as achilles tendon, large 
gluteus maximus muscles, weight of head towards back (aids stabilisation), ability to 
sweat (Bramble & Lieberman, 2004).  
 
Figure 21. Important differences in proteins with many years of training 
Summary of the biological functions of proteins encoded by the mRNAs found to be different 
between the vastus lateralis muscles of professional cyclists with many years of training 
compared to untrained participants (Wittwer et al., 2004). 
 33 
 As already alluded to, physical activity affects many system levels in the 
human body, which produces many beneficial changes. Phenotypes do not result from 
simple linear genetic interactions. Genes interact with other genes, which result in 
increased expression and stabilisation of mRNA to provide protein expression, which 
then results in the production of an end product – and over time physiological 
adaptations. Measuring gene expression, in isolation, can be misleading as increased 
gene expression does not necessarily correlate with increased translation, protein 
expression and altered function (Mata et al., 2005). A relatively new field of study is 
metabolomics – “The metabolome is the quantitative complement of all low-molecular 
weight molecules present in cells in a particular physiological or developmental state” 
(Hollywood et al., 2006).  Recent studies have already been analysing the 
metabolomic response to exercise in blood plasma (Yan et al., 2009; Lehmann et al., 
2010; Lewis et al., 2010; Oberbach et al., 2011). Metabolomics is attractive (much as 
transcriptomics first was when microarrays were developed) as it allows the 
simultaneous study of 100’s (if not 1000’s) of metabolites. Studying metabolite levels 
is also important because these are the end-products resulting from interactions 
between genes and the environment (Nicholson, 2006). These end-product 
mebabolites can then be further studied – in combination and in vitro – which is 
exactly what Lewis et al., (2010) did. They found several metabolites that were 
significantly altered in response to endurance exercise – plasma markers of glycolysis, 
AA catabolism, and lipid metabolism. Some of these metabolites (niacinamide, 
glycerol, glucose-6-phosphate, pantothenate, and succinate) were then added to 
cultured myotubes, which resulted in a significant increase in the nur77 pathway 
(Burke et al., 2010; Lewis et al., 2010). Nur77 has been shown to be induced after 
exercise in muscle (Chao et al., 2007), plus is a transcriptional regulator of glucose 
and lipid metabolism genes, in muscle (Chao et al., 2007).  
 The biggest focus (as with much research) driving metabolomics is the hope of 
new discoveries of biomarkers for various diseases, which could eventually serve as 
targets for new pharmacological therapies (Holmes et al., 2008). However, as exercise 
induces many beneficial pathways related to health and disease, studying the 
metabolomic response to exercise may lead to more specific exercise 
recommendations and some have even suggested the production of medicines that 
mimic the beneficial effects of exercise – “gymnominmetics” (Burke et al., 2010). A 
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good example of the potential importance of using a metabolomic approach is 
represented by Yan, et al. (2009), where – amongst other investigations – they looked 
into metabolite differences (relating to energy usage and metabolism) between rowers 
and controls at rest, and found many important significant increases in blood serum of 
the rowers (see table 5) (Yan et al., 2009).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Studying the metabolite response, in concert with gene expression, ultra-structure 
adaptations and physiological changes, strengthens any resulting correlations and 
similarities resulting from a study intervention.   
       
 
 
 
Table 5. Serum metabolites significantly elevated in rowers compared to controls.     
Related Metabolic 
Pathway  
Retention 
Index  
Metabolites  
Control 
Subjects  
Rowers  
Glucose metabolism  1187.3  Alanine 122.8 ± 12.8  359.3± 21.4c  
 1192.7  Lactate  1467.5 ± 134.5  3406.2± 212.1c  
 2056.3  β-D-Methylglucopyranoside  8.14e6 ± 2.46e6  4.69e6± 1.49.e6c  
Oxidative stress  1563.6  Cysteine  312.5± 26.0  487.7± 30.5c  
 1627.8  Glutamic acid  32.6± 3.7  51.0± 2.7c  
Energy metabolism  1833.8  Citric acid  57.0 ± 12.8  40.3± 2.9b  
Lipid metabolism  2037.1  Palmitic acid  260.4 ± 22.3  150.0± 11.9c  
 2203.1  Linoleic acid  185.2 ± 21.7  83.0± 10.7c  
 2208.1  Oleic acid  242.3 ± 27.6  93.5± 16.3c  
Amino acids  1227.5  Valine  209.9 ± 44.8  467.7± 35.0c  
 1781.0  Glutamine  369.3 ± 26.0  533.4± 43.7b  
Unidentified  1193.7  CPU_DB5_1193.7_Sa  1.61e6 ± 1.18e6  7.85e6± 1.95e6c  
 1303.9  CPU_DB5_1303.9_Sa 2.70e6 ± 7.73e5  4.24e6± 1.36e6b  
 
Concentrations of metabolites (μM) are given as means ± SE of 12 control subjects and 16 rowers. 
a
Peak areas normalised against internal standard. 
b
Mean difference is significant at the 0.05 level; 
c
mean difference is significant at the 0.01 level, compared with the control (MANOVA). 
CPU_DB5_RIx_S, unidentified compounds in serum samples with DB-5 capillary column with 
GC/TOF-MS, Lab of metabolomics, China Pharmaceutical University (CU; RI, retention index; x, 
retention time index value) (Yan et al., 2009). 
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1.1.5 Genetic make-up influences disease risk and athletic performance 
 
 Whilst all humans obviously share a large overlap in genetic make-up there are 
discrete differences owing to gene polymorphisms and single nucleotide mutations 
that over time may influence metabolism (Pilegaard et al., 2000; Tunstall et al., 2002). 
Due to the density of blood vessels, energy processing and requirements, muscle’s 
influence on whole-body metabolism is enormous. Whilst each individual can 
condition their own muscle, the scope of this varies considerably between individuals. 
And this is purely a result of genetic constitution (training stimulus being equal).   
 In 2005 the latest report on the Human Gene Map for Performance and Health-
Related Fitness Phenotypes was produced (Rankinen et al., 2006). The report 
highlighted 10 different phenotypes and 242 related loci, ranging from endurance to 
lipids, inflammation and hemostatic phenotypes all of which will have great potential 
to affect metabolic processes.  
 One of the reasons why elite athletes are such an interesting and suitable group 
of individuals to study is (mainly) because (researchers’ reason) any “special” 
performance phenotype (trait) that they are displaying will have likely arisen as a 
consequence of their genetic make-up (e.g. specific gene or interaction of genes). 
However, slowly, other factors are emerging, which are diluting the importance given 
to genetic make-up in the development of sporting performance. “...no one is 
genetically designed into greatness and few are biologically restricted from attaining 
it” (Shenk, 2010). The study of transgenerational epigenetic inheritance is uncovering 
further evidence that it is the environmental exposures, which shape phenotypes and 
not genes (Morgan & Whitelaw, 2008; Whitelaw & Whitelaw, 2008; Arai et al., 2009)  
 “To what extent are individual differences in performance determined by 
genetic factors, and to what degree by nongenetic factors?” (Klissouras, 1976). This 
statement when substituting health for performance is as equally pertinent as it was 35 
years ago. Eating healthily and being physically active is no guarantee of good health, 
but the risks of developing chronic diseases are greatly reduced. Better healthcare and 
treatment including long-term medication have increased longevity, but at what cost? 
A life lacking in important nutrients and high in processed (high salt, refined sugars 
and saturated fat) foods, combined with chronic alcohol intake, cigarette smoking and 
stress will take its toll on an individual’s health....eventually. Regardless of lifestyle 
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some people are more prone to develop certain diseases and/or have greater athletic 
ability. Therefore it is logical to presume some people must have protective/beneficial 
(and others deleterious/negative) mechanisms. And an individual’s genetic make-up 
will significantly contribute to these mechanisms. 
 One simple method to analyse the affect of genes on performance is to study 
twins (identical versus non-identical). Maximum oxygen uptake (VO2max) is 
classically used to assess aerobic (endurance) performance, with higher levels 
generally associated with greater sporting performance (Joyner & Coyle, 2008). 
VO2max “....represents the integrative ability of – the heart to generate a high cardiac 
output, total body haemoglobin, high muscle blood flow and muscle oxygen 
extraction, and in some cases the ability of the lungs to oxygenate the blood” (Joyner 
& Coyle, 2008). Although the importance placed on O2 uptake is often over 
emphasised, and that there are many other components (technique/efficiency, muscle 
composition, energy stores and energy pathways, cardiovascular system, and mental 
strength.....etc – see Joyner, 2008 for a good review), which play an equal role in 
endurance performance (Lindstedt & Conley, 2001; Joyner & Coyle, 2008). However, 
measuring maximum oxygen uptake (VO2max) is a simple and reliable method for 
providing an indication of aerobic (endurance) performance.  
 There is a huge amount of variability of VO2max, both at baseline between 
individuals and in response to training (Bouchard et al., 1997; Timmons et al., 2005). 
How important is genetics to both baseline and trainability of VO2max? Figure 22 
illustrates the intrapair differences of VO2max between identical and non identical 
twins. The authors stated that the difference between monozygotic (MZ) and dizygotic 
(DZ) twins (relating to intrapair variance) was significant, P<0.01 (Klissouras, 1976).  
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There is no sporting performance (to this author’s knowledge) that is the result of a 
single gene – and it is unlikely there ever will be. “No genes can act in a vacuum, nor 
[can] phenotypes....develop and be actualised without the action of environmental 
forces”, (Klissouras, 1997). However, evidence from epidemiology studies does point 
towards genes influencing a component of exercise-related phenotypes (Rankinen & 
Bouchard, 2008). Table 6 illustrates the main phenotypes (associated and 
investigated), papers published and number of different loci studied up to 2005 
(Rankinen & Bouchard, 2008).   
 
 
 
 
 
 
 
 
Figure 22. Intrapair values of maximal oxygen uptake for identical and non identical twins  
 
Identical (○) and non identical (●) twins. This graph illustrates that VO2max is largely determined by 
genetics. The intrapair VO2max differences for the identical twins (depicted by open circles) is 
minimal – if the circles are on the line there is no difference. Whilst the intrapair differences for the 
non-identical twins (depicted by closed circles) is much more variable. In the original study the 
authors state that because the intrapair differences are so small (between the identical twins) these 
differences could be explained by experimental measurement errors (Klissouras & Marisi, 1976). 
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A study looking at endurance performance related polymorphisms identified 23 where 
at least one significant association study was published (Williams & Folland, 2008). 
The authors concluded that the possibility of one individual holding all 23 
polymorphisms was 1:1212 trillion. The authors of this study also developed a total 
genotype score (0-100), which was used in another study looking at 14 endurance 
related polymorphisms – see table 7 (Ahmetov et al., 2009).   
 In 2010 Rankinen (Rankinen et al., 2010) reviewed only the very highest 
quality studies (in accordance with their study criteria) published (between 2008 and 
2009) on exercise, fitness, performance genomics and health. The genomic variations 
that they reviewed were all related to important fitness and/or health linked 
phenotypes (ACTN3 R577X gene polymorphism), endurance 
performance/cardiovascular phenotype (mtDNA haplogroups, K1F5B and ITGB1 
genes), regulation of blood flow (NOS3 gene) obesity (FTO gene), DM/insulin-
glucose metabolism (PPARG, PPARD, PPARGC1A, NDUFB6 and ENPP1 genes), 
and lipid metabolism (APOE gene). The authors concluded that there was not enough 
high quality evidence to demonstrate conclusively that any gene or variant was 
associated with a particular performance/health phenotype.   
 
 
 
Table 6. Number of research articles and genetic loci summarised in the 2005 update of the Human 
Gene Map for Performance and Health-Related Phenotypes.* 
Phenotype # of papers # of loci 
Endurance 53 37 
Strength and anaerobic 23 20 
Hemodynamics 44 48 
Body composition 37 34 
Insulin and glucose 16 25 
Lipids, inflammation, hemostatic 32 21 
Chronic diseases 7 7 
Exercise intolerance 52 31 
Physical activity 6 14 
 
     *See reference 29 in original article (Rankinen & Bouchard 2008). 
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Table 7. Candidate genes for endurance performance: their full names, functions of gene products, 
associated phenotypes and interactions.  
 
 
 
 
 
 
Gene Function 
ACE 
Regulates circulatory hemeostasis through the synthesis of vasoconstrictor 
angiotensin II and the degradation of vasodilator kinins  
AMPD1 
Regulates muscle energy metabolism by catalysing the deamination of 
adenosine monphosphate to inosine monophosphate 
HIF1A 
Regulates the transcription of numerous genes in response to hypoxic stimuli. 
Genes responsive to HIF1 are involved in the processes of erythropoiesis, 
angiogenesis, and metabolism and include those encoding erythropoietin, 
VEGF PPARα and glycolytic enzymes 
NFATC4 
Regulates cardiac hypertrophy, glucose and lipid metabolism, expression of 
the skeletal myosin heavy chain genes; regulates expression of PPARG 
PPARA 
Regulates liver, heart and skeletal muscle lipid metabolism, glucose 
homeostasis, mitochondrial biogenesis, cardiac hypertrophy, expression of 
UCP2 and UCP3 
PPARD 
Regulates fatty acid β-oxidation, glucose utilisation, mitochondrial biogenesis, 
angiogenesis, muscle fibre type, expression of PPARGC1A, UCP2, UCP3 and 
VEGFA genes 
PPARG 
Plays a critical physiological role as a central transcriptional regulator of 
adipogenic and lipogenic programs, insulin sensitivity and glucose 
homeostasis 
PPARGC1A 
Regulates fatty acid oxidation, glucose utilisation, mitochondrial biogenesis, 
thermogenesis, angiogenesis, formation of muscle fibres; co-activates PPARα, 
PPARδ; regulates TFAM and VEGFA expression 
PPARGC1B 
Regulates fatty acid oxidation, mitochondrial biogenesis, formation of muscle 
fibres; co-activates PPARα and PPARγ 
PPP3R1 
Confers calcium sensitivity, dephosphorylates and activates NFATC4. 
Regulates skeletal muscle and heart metabolism/hypertrophy, expression of 
HIF1A, PPARA, PPARD, PPARGC1A 
TFAM 
Involved in mitochondrial transcription regulation, proliferation of 
mitochondria and mitochondrial biogenesis 
UCP2 
Uncouples oxidative phosphorylation from ATP synthesis; regulates lipid 
metabolism and energy expenditure 
UCP3 
Uncouples oxidative phosphorylation from ATP synthesis; regulates lipid 
metabolism and energy expenditure, transports fatty acid anions out of 
mitochondria 
VEGF 
Growth factor active in angiogenesis, vasculogenesis and endothelial cell 
growth; expression of VEGFA is regulated by HIF1 and calcineurin/NFAT 
signaling 
 
Abbreviations: ACE, angiotensin I-converting enzyme; AMPD1, Adenosine monophosphate 
deaminase 1; HIF1A, Hypoxia-inducible factor 1, α-subunit; NFATC4, Nuclear factor activated T 
cells, cytoplasmic, calcineurin-dependent 4; PPARA, Peroxisome proliferator-activated receptor α; 
PPARD, Peroxisome proliferator-activated receptor δ; PPARG, Peroxisome proliferator-activated 
receptor γ; PPARGC1A, Peroxisome proliferator-activated receptor γ coactivator 1-α; PPARGC1B, 
Peroxisome proliferator-activated receptor γ coactivator 1-β; PPP3R1, Protein phosphatise 3, 
regulatory subunit B, alpha isosform (calcineurin subunit B); TFAM, Mitochondrial transcription 
factor A; UCP2, Uncoupling protein 2; UCP3, Uncoupling protein 3; VEGFA, Vascular-endothelial 
growth factor A. Please see the original reference (Ahmetov et al., 2009) 
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The brief overview presented in this section highlights the importance of performing 
research that is designed to try and uncover mechanisms behind supposed genetic 
associations – such is the variability in study findings. Only by trying to uncover 
molecular mechanisms and linking them to different system levels will it be possible 
to gain an insight into the influence (if any) of genes or specific variants (or groups - 
haplotypes). 
 To further highlight the difficulties and controversies of studying a single gene 
or gene variant and health or sporting performance phenotype the next section will 
look solely at one well studied (and potentially important) gene variant. 
 
1.2.1 Introduction to ACE, ACE I/Dp research and controversies 
 
 The angiotensin converting enzyme (ACE) is the key regulatory enzyme in the 
renin-angiotensin system (RAS). The classical actions of the RAS (Figure 23) involve 
control of fluid balance and blood pressure (BP), and therefore it plays an important 
role in cardiovascular homeostasis, health and disease (Dzau et al., 2001; Hall, 2003; 
Heeneman et al., 2007; Fyhrquist & Saijonmaa, 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Simplified overview of the ‘classic’ circulating renin angiotensin system  
Whole arrows indicate pathways of which the clinical significance has been demonstrated. Dashed 
arrow indicates pathway deduced from animal or cell culture experiments, not yet conclusively shown 
to be clinically relevant (Fyhrquist & Saijonmaa 2008). 
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Any scepticism regarding ACE’s importance and role in CVD was firmly banished 
with the development of two effective medicines: the first being ACE inhibitors 
(ACEI) in 1977 (Ferreira, 2000), and then subsequently, angiotensin 1 receptor 
blockers (ATR1B) a few years later in the early 1980’s (Skrbic & Igic, 2009).  ACEI 
are now a primary medicine prescribed in the treatment of, not just high BP, but also 
for individuals with CVD (Dzau et al., 2001). ACEI primarily act by reducing the 
catalytic activity of ACE thereby preventing the conversion of angiotensin 1 (Ang1) to 
angiotensin 2 (Ang2) (Figure 23). The latter, Ang2, is an important vasoconstrictory 
peptide of the vasculature. ACEI are believed to inhibit Ang2 production at both the 
systemic and tissue level depending on the pharmacology used (Dzau et al., 2001). 
Therefore a frequent gene polymorphism that affected ACE activity levels may 
possibly correlate with outcomes in CVD risk. A study by Defoor, et al., (2006) 
highlighted an improvement in aerobic power in ACE II genotypes (see below for 
description of genotypes) of patients with coronary artery disease (Defoor et al., 
2006).   
 In 1990 Rigat, et al., (1990) discovered a 287bp Alu sequence in the ACE gene 
(Figure 24), classified when present as an insertion (I) or when absent (deletion: D), 
commonly termed the ACE I/D polypmorphism (ACE I/Dp) (Rigat et al., 1990). This 
study demonstrated a linear relationship with the ACE I/Dp and an increase in 
serum/plasma ACE activity (ACE DD>ID>II). This observation was subsequently 
confirmed by many later studies (Butler et al., 1999; Agerholm-Larsen et al., 2000; 
Prasad et al., 2000; Arcaro et al., 2001).  
 Their discovery, together with the invention of real-time polymerase chain 
reaction (RT-PCR, (Deepak et al., 2007)), produced a spurt of interest in the ACE 
I/Dp and disease (mainly CVD related). The search terms ACE Polymorphism + 
Hypertension or Infarct or Diabetes or Coronary have resulted in 1640, 1060, 685 and 
228 research studies respectively (Gard, 2010) since Rigat’s study in 1990. Other areas 
of research (not exhaustive) include dementia, depression, Parkinson’s disease, and 
cancer (Gard, 2010), but the interest in these areas of disease is much less (the most 
research was on cancer studies identified, and these were only 58).  Interestingly, the 
more recent article (Ceyhan et al., 2011) reported a significant association with poor 
coronary collateral circulation in ACE I/Dp subjects without the I allele – and they 
hypothesised this may be because of endothelial dysfunction. The majority (far from 
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conclusive) of evidence points towards an increased risk of CVS diseases in carriers 
with the ACE D allele (see section 1.2.6).  
 In 1998, a new research area developed, (Montgomery et al., 1998) 
investigating the influence of the ACE I/Dp and human performance. This article 
commented on the significant increase in frequency of the I allele in mountain 
climbers and (in a second study) an increase in duration of repetitive elbow flexion 
(following a physical training programme) – also in I allele carriers. Section 1.2.6 
provides an overview of the ACE I/Dp and human performance research.  
 Even with all the controversies and disagreement in the literature, there does 
not appear to be a decreasing interest in the ACE I/Dp. Since 1996 (obviously a slight 
delay from Rigat, et al’s study) 70 to 119 articles are identified, based on PubMed 
searches, have been published yearly on ACE I/Dp. To date this year (01/01/11 - 
09/11/11) 86 articles have been published. Much of the highlighted controversy in the 
literature revolves around the effect of the ACE I/Dp and human performance. 
Ethnicity, underpowered studies and mixed sporting populations have all been cited as 
reasons (main) for disagreement in study findings (Woods, 2009). 
 
ACE I/Dp controversies: The following sub-section does not intend to address every 
controversy or to explain the disparity in the literature. What it does intend to do is 
highlight why, when studying single polymorphisms like the ACE I/Dp and relating 
them to complex phenotypic traits, like those of the cardiovascular system or human 
performance, a different experimental approach is required to better understand 
physiological effects in whole-organisms, such as humans. 
 Due to the central role of ACE in the CVS and the importance of the CVS in 
human performance much of this section will concentrate on the literature surrounding 
the ACE I/Dp and studies of the CVS (plus human performance). However, to help 
better understand the complexity, a range of different studies on the possible 
interaction of the ACE I/Dp within an intact whole-organism will be covered. The 
main aim is to bring together studies looking at different system levels to build a 
picture of how the ACE I/Dp may be influencing phenotypic adaptations. An example 
of the different types of ACE/ACE I/Dp studies, are illustrated in Figures 24 - 32.  
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The presence (insertion) or absence (deletion) of a 287 bp sequence (Alu – see section 
1.2.5. for more information) is what defines the ACE I/Dp, and this Alu sequence may 
affect the efficiency of transcription and/or activity of the resulting protein: “We 
believe the amplitude of the ‘Alu phenomenon’ in both human genome and 
transcriptome has been only partially uncovered” (Hasler & Strub, 2006). 
 
 
 
 
 
 
 
 
 
 
The ACE enzyme has two active sites (see section 1.2.2.), which are both capable of 
converting Ang1 to Ang2 (van Esch et al., 2008). However, it has been demonstrated 
that the C-domain is the main Ang1 to Ang2 converting site, and is the only active 
domain in the D-allele (van Esch et al., 2008) (see section 1.2.2. for more detail). 
 
 
Figure 25. Different domains and effeciencies of the ACE protein 
 
 
 
 
 
 
 
 
 
Figure 24. Location of the ACE I/D polymorphism 
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The authors of the original study (who discovered the ACE I/Dp – (Rigat et al., 1990)) 
stated that 47% of the phenotypic variance of serum ACE was accounted for by ACE 
I/Dp. Although its (ACE I/Dp) influence may not be quite as high (Danser et al., 
2007). Figure 26 (A), relating to levels of ACE in cardiac – left figure – and plasma – 
right figure) come from studies, which state that the ACE I/Dp accounts for 22% and 
31% respectively (Danser et al., 1995; Osterop et al., 1998). Research by Danser and 
group concentrate more on the pharmacological effects of ACEI, and may possibly 
ignore important contributions of environmental factors like sweating, exercise and 
stress – all of which would influence serum ACE and potentially Ang2 production and 
effects – thus phenotypic differences of serum ACE may well be as high (if not 
higher) than originally stated (Rigat et al., 1990).   
Figure 26 (B), illustrates where ACE is localised (which is where most active 
conversion occurs – (Danser et al., 2007)) attached to endothelial cells lining 
capillaries (Schaufelberger et al., 1998) as can be visualised here. In the same study an 
immunohistochemical staining of Ang2 was also illustrated, which showed a 
remarkably similar staining pattern – which is to be expexted as ACE produces Ang2. 
 
 
 
 
Figure 26. Levels of ACE (A) and location in skeletal muscle (B) 
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 From Figure 27 we can clearly see that exercise increases Ang2 levels (Woods et al., 
2004) significantly – although there is little evidence to suggest ACE I/Dp influences 
this response. This is not that surprising for a number of reasons, some of which are: 
very low baseline circulating levels, very short half-life (30 seconds), and the actual 
techniques (from withdrawing blood, adding inhibitor chemicals to prevent 
degradation/potentiation, to actually running the assay and interpreting the results) 
required to accurately measure Ang2 (see section 1.2.3. for more information).  
 
 
 
 
 
 
 
 
 
 
In Figure 28 Buikema, et al., (1996) demonstrated a greater efficiency in converting 
Ang1 to Ang2 in ACE DD genotypes and methacholine-induced relaxation was also 
smaller in patients with the D allele. Figure 28 also illustrates the significant 
differences (P<0.0001) in flow-mediated dilation (FMD) in ACE II genotypes 
compared to both ACE ID and DD genotypes (Tanriverdi et al., 2005). See section 
1.2.6. for further details.  
 
Figure 28. Varying vasodilatory response in artery diameter in ACE I/D polymorphism subjects 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. Ang2 levels at rest, during and post exercise 
 
 
 
 
 
 
 
 
 
 
Concentrations of metabolites (μM) are given as means ± SE of 12 control subjects and 16 rowers. 
aPeak  
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Figure 30. Relative I allele frequency of Olympic standard runners and controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Much of the research surrounding sporting performance and the ACE I/Dp 
proposes those individuals with the I allele have increased endurance capacity (see 
section 1.2.6. for much greater detail and references) although the evidence is far from 
clear cut. In Figure 30 it can be clearly seen that ACE II individuals (Japanese healthy 
untrained participants) had a significantly (P<0.05) greater percentage of type I muscle 
fibres than ACE DD individuals (Zhang et al., 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30 would appear to add to the theory that the ACE I allele is in some way 
related to an enhanced aerobic capacity. There is a significant (P=0.009 for linear 
               
Figure 29. Sections of human skeletal muscle and percentage of fibre types in ACE II vs. ACE DD 
      
 
 
 
 
 
 
 
 
 
 
Concentrations of metabolites (μM) are given as means ± SE of 12 control subjects and 16 rowers. 
aPeak  
 47 
trend) difference in ACE I allele frequency with increasing running distance (Myerson 
et al., 1999). Please see section 1.2.6. for further details. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. It is well documented that certain ethnic populations are dominating long 
distance running events (see section 1.1.5.). What is also now recognised is the 
significant ACE I/Dp allelic variation between different ethnic groups – as highlighted 
here (Salem & Batzer, 2009). 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. ACE I/D polymorphism allele frequency and ethnicity 
 
 
 
 
 
 
 
 
 
 
Concentrations of metabolites (μM) are given as means ± SE of 12 control subjects 
and 16 rowers. aPeak  
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Figure 32. The diversity of studies conducted on the ACE I/Dp really is quite 
remarkable. A study by Hamdi, et al. (2004) demonstrated, in vitro, human endothelial 
cells from ACE II participants had lower Ang2 levels and a 20-fold increased viability 
after slow starvation compared to ACE DD cells (Hamdi & Castellon, 2004). 
 
Much of the early studies on the ACE I/Dp concentrated on single associations 
(endurance performance, blood pressure, coronary events), but as we can see in 
Figures 24 - 32 there are many factors to consider before making conclusions 
concerning the influence of a 287bp Alu sequence in a non-coding part of a gene. The 
ACE is a very important enzyme, with a key role in regulating vaso –constriction/-
dilation. But there are many factors that interact to produce a particular phenotype, 
whether this be a specific disease or improved athletic performance. To truly 
understand what effect a specific variant within this enzyme can have it is imperative 
that as many linked-systems as possible are studied in concert. Figures 26 and 28-32 
illustrates that any one study can suggest anything and another may support this 
theory. For example Figures 28, 29 and 30 all highlight significant differences in the I 
versus D allele: increased vasodilatory response, increased percentage of type I fibres, 
and increased performance in long distance running, respectively. These three studies 
all point towards increased capacity to deliver energy substrates and remove waste 
products (enhanced vasodilation) and better capacity to utilise these increased 
           
                          
Figure 32. ACE I/D polymorphism and endothelial cell survival after slow starvation 
     
 
 
 
 
 
 
 
 
 
 
Concentrations of metabolites (μM) are given as means ± SE of 12 control subjects and 16 rowers. 
aPeak  
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substrates (increased oxidative fibres). This results in a superior performance over 
longer running distances. 
 This section has introduced how a single polymorphism in a key regulatory 
gene (of blood pressure) has been studied in relation to health and sporting 
performance. The next section goes back to the beginning of the discovery of the ACE 
gene and explains more about the RAS and its importance.  
 
1.2.2 RAS and ACE: brief history and key discoveries 
 
 To truly understand a system (or anything) it helps to know its history. Table 8 
below highlights the major discoveries of the RAS.   
 
Table 8. Major discoveries of the renin angiotensin system (RAS). 
Year Discovery 
1836 Bright (1836) discovered renal disease related to left ventricular hypertrophy (LVH) 
(Bright, 1836) 
1872 High blood pressure measured for the first time (Mahomed, 1872) 
1898 Renin discovered (Tigerstedt, 1898) 
1940 Pressor substance discovered (later to be called angiotensin) (Braun-Menendez, 1940) 
1956 Full RAS characterised (Skeggs et al., 1956) 
1965 Snake venom tested for potential inhibition of ACE (Erdos & Yang, 1967) 
1972 Development of first ACEI begins (Byers & Wolfenden, 1972) 
1977 First orally active ACEI synthesized (Ondetti et al., 1977) 
1982 Angtiotensin type I receptor blockers developed (Furukawa, 1982) 
1988 Concept that RAS operates at the local tissue level as well as systemically (Dzau, 1988) 
1990 Insertion sequence discovered in ACE gene related to decreased ACE activity (Rigat et al., 
1990) 
2000 ACE2 (Donoghue, 2000) 
2003 Orally active renin inhibitor first developed (Wood et al., 2003) 
 
 
Systemic versus local RAS: RAS was once thought of as purely an endocrine system 
with Ang2 conversion occurring in plasma and exerting its effects (vasoconstriction, 
sodium and water retention, and growth stimulation) upon binding to receptors 
(Abdel-Rahman et al., 2004). More recently it is accepted that components of the RAS 
exist in virtually all cells (Muller & Luft, 1998; Lavoie & Sigmund, 2003; Haulica et 
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al., 2005; Fyhrquist & Saijonmaa, 2008) and has diverse actions (Watanabe et al., 
2005). Whether the entire set of components function locally is still a matter of debate 
(Danser, 2003; Fyhrquist & Saijonmaa, 2008). It is possible that one or more RAS 
components are taken up from the circulation (Abdel-Rahman et al., 2004). Further, 
there is evidence of novel local effects of Ang2 including: proliferation, hypertrophy, 
protein synthesis (Li et al., 1998; Gordon et al., 2001; Jones & Woods, 2003), 
enhanced noradrenaline release (Saxena, 1992), ROS generation (Touyz & Schiffrin, 
2000), increased energy expenditure (Cassis et al., 2002), increases fatty acid and 
TAG synthesis (Jones et al., 1997), to name just a few. Owing to a lack of 
understanding of the quantitative importance of local versus systemic effects and 
potentially novel functions, the role of the RAS in the development of many diseases 
(mainly CVD’s) remains elusive. Although RAS (and its primary effector molecule 
Ang2) undoubtedly play important roles in development of many diseases especially 
those related to the CVS (Mehta & Griendling, 2007; Touyz, 2000; Heeneman et al., 
2007).   
Related ACE molecules: ACE is not the only enzyme that can generate Ang2. Ang2 
has been shown to be generated by chymase and cathepsin D via Ang1, and by 
elastase, cathepsin G and tissue plasminogen activator (t-PA) directly from 
angiotensinogen (AGN) (Belova, 2000; Danser, 2003; Rush & Aultman, 2008). Other 
angiotensin peptides can also be generated from Ang1 by ACE2 and other peptidases 
(Haulica et al., 2005). It is reported that alternative Ang2 generation (other than by 
ACE) is roughly 40% (Rush & Aultman, 2008). However, the importance of 
alternative angiotensin generation is questionable. This is mainly due to the difficulties 
in accurate Ang2 measurement (see below), and differences between species (Danser, 
2003). In addition in vitro studies may be providing misleading results. For example, a 
study by Kokkonen, et al., (1997), clearly demonstrated that chymase Ang2 generation 
(in the heart) was strongly inhibited by proteases in the interstitial fluid (Kokkonen et 
al., 1997). These inhibitory proteases would not be present in vitro and this would give 
misleading results, e.g. that chymase generates a significant proportion of Ang2, when 
in fact in a whole organism it doesn’t (Zisman et al., 1995; Kokkonen et al., 1997). 
Evidence seems not to support the fact that Ang2 generation by any enzyme other than 
ACE is likely (in vivo) (Jorde et al., 2000; Saris et al., 2000; Campbell et al., 2004; 
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Danser et al., 2007). However, Table 9 lists some of the more studied possible ACE-
Ang2 generating alternative enzymes.  
 
Table 9. Alternative (potentially) ACE-Ang2 generating enzymes. 
Component Significance Site of origin and action 
- Chymase Most likely an in vitro phenomenon, as 
located deep within the adventia and 
becomes inactivated if released into 
interstitial fluid (Danser et al., 2007) 
Chymases are mostly found in 
mast cells and extracellular fluid 
(Urata et al., 1993; Wolny et al., 
1997). Detected throughout 
tissues, and in the adventia of 
vessel wall (Okunishi et al., 
1984) 
- Cathepsin G Possibly involved in local production of 
Ang2, modulating local blood flow due 
to inflammation (Dzau, 1989) 
Chymotrypsin-like proteinase of 
neutrophils and spleen (Belova, 
2000). 
- Kallikrein Probably not significant in vivo, as act 
(interestingly) kiningenase generating 
kinins at high pH (8-9) and Ang2 
generating at low pH (4-6.5) (Maruta & 
Arakawa, 1983; Sasaguri et al., 1997) 
Produced as an inactive 
precursor by the liver 
(prekallikrein) (Corvol et al., 
1995) 
- t-PA In vivo can be secreted at sites of vessel 
damage / inflammation, and during 
hypoxia connected with restriction of 
normal blood flow (Belova, 2000)  
Produced by the endothelium, 
and concentrated in blood vessel 
walls (Loscalzo & Braunwald, 
1988) 
Other angiotensins  
- Ang(1-7) Interacts with NO and opposes actions 
of Ang2 (Watanabe et al., 2005; 
Ferrario, 2006) 
No specific origin or action. 
Generated by ACE2 from Ang2 
(but can be generated from Ang1 
or Ang2 by other peptidases. 
(Fyhrquist & Saijonmaa, 2008) 
- Ang3 Generated from Ang2 by 
aminopeptidase A, and causes 
vasoconstriction (similar to Ang2). 
(Fyhrquist & Saijonmaa, 2008)  
No specific origin or action. 
General vasoconstriction. 
- Ang4 May have important regulatory 
functions in cognition, renal 
metabolism and cardiovascular damage 
(Savoia & Schiffrin, 2006; Ruiz-Ortega 
May be generated from Ang3 by 
aminopeptidase M. (Fyhrquist & 
Saijonmaa, 2008) 
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et al., 2007) 
Ang2 Receptors  
- AGTR-1 Mediates most of the known effects of 
Ang2 (Watanabe et al., 2005).  
Widely distrusted in all organs, 
basically the effector molecule of 
Ang2 (Mehta & Griendling, 
2007) 
- AGTR-2 Opposes actions of AGTR-1, upon 
binding Ang2 (Carey & Padia, 2008). 
Mainly expressed in foetal tissue, 
and possibly during wound 
healing (Mehta, 2007}. 
Vasodilatory effects when 
activated. 
- AGTR-4 Mediates the effects of Ang4 
(Watanabe et al., 2005). 
Found in a range of tissues, 
including adrenal gland, kidney, 
lung and heart, and appreciable 
levels found in the brain. (Abdel-
Rahman et al., 2004) 
 
 
Figure 25 illustrates the structure of ACE and that the majority (>90% - (Cushman & 
Cheung, 1971)) is found bound to endothelial cells of all blood vessels within tissues 
(Nash, 1992). Plus that conversion of Ang1 to Ang2 is mediated locally by tissue ACE 
(Maassenvandenbrink, 1998). Therefore it could be more beneficial to inhibit ACE at 
the local tissue level. This also may help to explain why patients with normal or low 
levels of systemic RAS activity can be effectively treated with ACEI (Brunner et al., 
1979; Dzau et al., 2001).  
Angiotensin Converting Enzyme Inhibitors (ACEI):  In 2001-2002 the NHS spent just 
under one billion (£947,000,000) on anti-hypertensive prescription drugs (15% of total 
prescription costs) of which ACEI were the most costly contributing over one-quarter 
(£270,000,000) of the total costs (NEHGDG, 2004). ACEI are first line medicines for 
many CVD’s and approximately £5.2 million is spent daily on cardiovascular 
medication in the UK (Bourn, 2007). The National Institute for Clinical Excellence 
(NICE) recommends that ACEI be indefinitely prescribed following myocardial 
infarction (NICE, 2007). It is clear to see that ACEI are ubiquitously prescribed, yet 
much needs to be understood about how they influence their many health benefits as, 
like virtually all drugs, they are not without substantial side-effects (see Table 10).   
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 ACEI also potentiate the health benefits of BK as degradation will be slowed. 
In principle ACEI all have very similar actions (bind to and reduce ACE activity), but 
the potency and tissue retentiveness varies considerably. For example, quinaprilat has 
the greatest and captopril the least potency and tissue retentiveness (Dzau et al., 2001). 
There are two active catalytic binding (although they may not have the same catalytic 
activity – but do produce the same product) sites on ACE (N- and C-domain – Nd, Cd 
–; amino- and carboxy-terminal respectively, (see Figure 28) (van Esch et al., 2005), 
although the Cd is thought to be the main binding-site for conversion of Ang1 to Ang2 
(van Esch et al., 2008; Zhao & Xu, 2008). To add yet further complexity it has been 
demonstrated that only the Cd is active in the ACE DD genotype, whereas both 
domains are active in the ACE II genotype (van Esch et al., 2008). In addition to these 
factors, ACE (Ang2 signalling cascade) is known to decrease with age (providing no 
related diseases that would significantly increase ACE-Ang2 signalling are present) 
(Cambien et al., 1988; Dzau et al., 2002), increased in atherosclerosis (Diet et al., 
1996), and its activity decreased potentially by certain plant bioactive compounds, as 
found in green and Rooibos tea (Persson et al., 2010). All these factors highlight the 
complexity of the RAS (and this is only one small part of the RAS) and may also 
contribute towards much of the conflict between ACE related studies.   
 ACEI decreases Ang2 production which decreases – vasoconstriction, 
adhesion of monocytes, smooth muscle cell (SMC) growth/proliferation and 
migration, PAI-1 and thrombogenesis, matrix degradation, oxygen free radical 
production, endothelial dysfunction; ACEI potentiates BK action (reduced 
degradation) which increases – vasodilation, antiadhesion of monocytes, eNOS 
expression, PAI-1 and fibrinolysis, antiremodelling effect, antioxidant effect, 
preserved endothelial dysfunction (Bertrand, 2004; Ferrari, 2005). As with all drugs 
there are negative side-effects and ACEI are no exception (Table 10).  
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Table 10. Potentially negative side effects of ACEI. 
 
Adverse Effect  Reference  
Hypotension – usually due to taking along other hypertensive 
drugs and/or low sodium intake  
(Brown & Vaughan, 1998a) 
Hyperkalemia – due to decrease in aldosterone  (Warren & O'Connor, 1980) 
Renal function impairment – decreased glomerular filtration 
(reversible)  
(Kastner et al., 1984) 
Cough – mechanism unknown, possibly due to stimulation of 
vagal C fibres by increased levels of bradykinin or substance P  
(Dicpinigaitis, 2006) 
Angioedema – although quite rare (0.1-0.2% of prescribed 
patients)  
(Israili & Hall, 1992) 
Fetel abnormalities – although ACEI should not be prescribed 
is a women is trying to become pregnant and should be ceased 
immediately if they are pregnant  
(Pryde et al., 1993; Sedman et 
al., 1995) 
Neutropenia – very rare (<0.05% of patients)  (DiBianco, 1986) 
Skin rash  (DiBianco, 1986) 
Nephrotic syndrome  (DiBianco, 1986) 
 
 
1.2.3 Angiotensin 2, receptors and signalling 
 
 Ang2 controls cell signalling via binding to seven-transmembrane receptors 
which activate G-protein dependent biochemical cascades (Touyz & Schiffrin, 2000). 
And the Ang2 type-1 receptor (AT1R) is thought to control most of the physiological 
actions of Ang2 (including Ang2 induced vascular functions) (Sadoshima, 1998; 
Mehta & Griendling, 2007). These are the classical physiological effects associated 
with blood pressure regulation such as vasoconstriction and aldosterone release and 
the regulation of growth and inflammation including general cell remodelling (Touyz 
& Schiffrin, 2000; Mehta & Griendling, 2007).   
AT2R is another Ang2 receptor in humans. It is however mainly expressed during 
foetal development (Shanmugam & Sandberg, 1996) and with tissue regeneration 
during wound healing, in the heart and vascular system (Nakajima et al., 1995), and 
binds Ang2 with similar affinity as the type 1 receptor (Jones & Woods, 2003). AT2R 
is thought to antagonise the action of AT1R through the stimulation of vasodilatation, 
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apoptosis, and anti-proliferative/-hypertrophy/-thrombotic (Fyhrquist & Saijonmaa, 
2008).  
Measurement of ACE and Ang2: To help understand the implication of the RAS in 
human disease and performance it is vitally important to accurately assess the activity 
of ACE and its main product the Ang2 peptide. Whilst ACE activity (plasma) has been 
shown to be very stable – blood samples can be safely left for up to 3 hours and levels 
are maintained (Jalil et al., 1999), and are stable within individuals (Alhenc-Gelas et 
al., 1991) the story is not the same for Ang2. There are consequently a number of 
biological and technical limitations concerning the measurement of ACE and Ang2, as 
described next. ACE activity is: 1) mainly at the tissue level (Dzau et al., 2002), and 
measures typically ignore the fact that only 10% of total ACE activity is found 
circulating (Cushman & Cheung, 1971), 2) altered by the health of the endothelium, 
e.g. upregulated by atherosclerosis (Diet et al., 1996; Dzau et al., 2002), 3) influenced 
by genetics, e.g. ACEI/Dp, ethnicity (Payne et al., 2007), and 4) decreases (and then 
stabilises) with age (Cambien et al., 1988; Dzau et al., 2002). Also, accurately 
quantifying Ang2 (circulating) is very challenging for a number of reasons: 1) its half-
life is (in circulation) estimated to be 30 seconds (van Kats et al., 1997), but with an 
intracellular half-life of 15 minutes (van Kats et al., 1997), 2) generation and 
degradation of Ang2 in vitro as a consequence of freezing and thawing (Nussberger et 
al., 1986; Abdel-Rahman et al., 2004), 3) cross-reactivity of different angiotensins 
with Ang2 (Lijnen et al., 1978; Nussberger et al., 1986), and 4) venous sampling is not 
reflective of arterial delivered Ang2 (Lijnen et al., 1978). These considerations suggest 
explanations for the inconsistency regarding the relationship between increased ACE 
activity (and ACE I/Dp) and Ang2 production/levels. 
 There is also the small, but very important matter of individual dietary 
differences, which affect the RAS, mainly sodium (Staessen et al., 1987). Plus there 
are bioactive components in food that mimic ACEI’s, which will again affect ACE 
levels (Actis-Goretta et al., 2006). Finally, Ang2 levels are at extremely low 
concentrations in human plasma, estimated to be less than 1 – 149 pg/ml (Lijnen et al., 
1978; Nussberger et al., 1986; Staessen et al., 1987; Hespel et al., 1988), which makes 
accurate assaying difficult, especially in samples with very low levels.      
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1.2.4 ACE, bradykinin and vasodilation 
 
An intriguing fact of long-term treatment with ACEI is that this results in the 
elevation of ACE levels (Fyhrquist et al., 1980). Yet, they [ACEI] still convey 
beneficial effects like decreased: Ang2, anti-inflammatory factors, free radical 
production and endothelial dysfunction, and increased: BK, vasodilation, antioxidants, 
antiadhesion of monocytes and preserved endothelial function (Bertrand, 2004; 
Ferrari, 2005). The possible reason for this may be due to the reduced inactivation of 
BK, which is a molecule with strong vasodilatory properties. ACE not only activates 
Ang2 it also inactivates BK, and ACEI reduce this – therefore potentiating BK’s 
vasodilatory functions. This is an important observation: that ACE has a much greater 
affinity for BK than Ang1. Therefore, the benefits of ACEI may not be entirely due to 
a reduction in Ang2 and vasoconstriction, but also reside in the increase in BK-
mediated vasodilation (Jaspard et al., 1993). BK (and kinins) exerts more than 
vasodilatory effects, it has many known cardiovascular effects, some of which are: 
increased vascular permeability induction of hypotension (Bhoola et al., 1992), 
induction of anti-inflammatory pathway (Brown & Vaughan, 1998a; Woods, 2009).   
 BK binds to one of two receptors, of which BK receptor 2 (BK2R) is 
constitutively expressed, whilst BK1R is expressed (normally) after tissue injury 
(Muscogiuri et al., 2008). Upon binding to BKR2, BK activates the eNOS and this 
produces NO (Erusalimsky & Moncada, 2007; Muscogiuri et al., 2008). The NO 
molecule is so small that it diffuses freely through cell membranes. It is produced by a 
variety of cells including (importantly) endothelial cells and human muscle fibres 
(Clifford & Hellsten, 2004). NO has also been implicated in many important 
biological functions (Filippin et al., 2009). Its main effect is to induce a vasodilatory 
response in the vasculature (Clifford & Hellsten, 2004; Filippin et al., 2009). Thus 
BK, through activation of NO, opposes the action of Ang2.  Figure 33 illustrates some 
of the key signalling interactions induced by BK2R activation by BK and its activation 
of NO. 
 
 
 
 
 57 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
1.2.5 ACE I/Dp and Alu sequences: A brief overview 
 
The 287bp Alu sequence in the ACE gene giving rise to the ACE I/Dp (figure 
27A) belong to the short interspersed elements (SINE) family. SINEs are composed of 
repetitive sequences ranging in length from 90 – 300 bps, which are a type of 
transposable element (TE) (Caporale, 2006). These account for the vast majority of 
genetic material in the human genome, making up approximately 45% (Caporale, 
2006). Alu sequences are randomly spread throughout the human genome and 
constitute approximately 10% of the total genome (Hasler & Strub, 2006). Originally 
thought to be junk DNA, partly because they were situated in non-coding stretches of 
DNA, evidence is now suggesting they may “actually be major originators of genetic 
change and diversity, facilitating populations to adapt and evolve when changes occur 
in the environment” (Costa, 2008). It is also suggested that Alu’s can be an alternative 
source for splicing when present in intronic (the case in the ACE I/Dp) regions of 
human genes (Hasler & Strub, 2006; Costa, 2008). Also they are an important point 
for regulation of gene expression by epigenetic mechanisms (Brohede & Rand, 2006; 
Costa, 2008). There is a very strong correlation between the ACE I/Dp and serum 
ACE activity levels (Rigat et al., 1990; Butler et al., 1999; Prasad et al., 2000; Arcaro 
 
dd  
 
Figure 33. Overview of Kallikrein-Kinin system 
Those particularly relevant to the author’s research are highlighted in red. 
See Couture and Girolami 2004 for abbreviations and further details. 
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et al., 2001). Danser et al., (1995) also demonstrated that the prediction on higher 
levels in ACE activity, in ACE genotypes lacking the 287bp Alu, held firm in cardiac 
tissue (Danser et al., 1995).  
However, as Ang2 is the product and effector molecule, of ACE, its activity or 
levels are of greater importance. It is generally reported that ACE activity is not 
correlated with Ang2 levels (Danser et al., 1999; van Dijk et al., 2000; Wang et al., 
2008). This statement may not hold true for a number of reasons: 1) As stated earlier 
(section 1.2.3) it cannot be stressed enough how difficult accurately quantifying Ang2 
is, 2) The ACE has two catalytic domains, but the Cd is thought to be the only active 
Ang1-to-Ang2 converting domain and is the only domain active in the ACE DD 
genotype (van Esch et al., 2008), 3) Even after accurate measurement of Ang2 this 
may not reflect the local concentrations within cells, especially as ATR1-bound Ang2 
has a prolonged half-life of approximately 30 times that of circulating Ang2 (van Kats 
et al., 1997), 4) It may not be the exact levels of ACE or Ang2 that are important but 
how efficiently Ang1 can be converted to Ang2, which has been demonstrated to be 
enhanced in the ACE DD genotype (Ueda et al., 1995; Brown et al., 1998b; Prasad et 
al., 2000; San Jose et al., 2009; Woods, 2009), 5) Increased shedding, which elevates 
ACE levels in circulation, has also been shown to be affected by the ACE I/Dp, with 
significantly higher circulating levels in those (rather strangely) individuals with the 
heterozygote ACE I/Dp (van Esch et al., 2008), 6) Finally (as mentioned earlier), age, 
ethnicity, sex, and vascular health all effect (and confound) ACE expression and will 
thus circulating levels. 
 
1.2.6 An overview of ACE I/Dp research and motivation 
 
 Hypertension was responsible for 13 million deaths in 2004 (WHO, 2009). 
51% of the victims of a lethal stroke and 45% of ischaemic heart disease are directly 
attributable to hypertension.  A healthy CVS is of paramount importance to reduce and 
prevent the chronic diseases plaguing modern societies.  
Cardiovascular system and remodelling: Hypertension results from a detrimental 
remodelling of the CVS, brought on mainly by environmental factors; physical 
inactivity, smoking, excessive alcohol, excessive energy intake and poor dietary 
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choices of which the exact contributions are still debated. In short hypertension is the 
major risk factor for the development of CVD.  
 Maintenance of systolic blood pressure is essential to perfuse tissues and 
organs with adequate blood supply to deliver nutrients, oxygen and remove waste 
products while not damaging the blood vessels mechanically. Blood pressure is 
regulated by a complex interplay of many factors, including: hormones, central 
nervous system, heart rate/stroke volume and blood vessel structure (Schork, 1997). 
However, one of the most significant physiological changes that determine all vascular 
pathologies, especially hypertension, is vascular remodelling (Heeneman et al., 2007). 
The vascular wall is exposed to a continuous flow of blood, which causes shear stress 
and luminal pressure (Heeneman et al., 2007). Acute changes in shear stress and 
luminal pressure cause alterations in vessel diameter, which if caused by physical 
activity can be beneficial because the pressure impacts on dilated vessels. But 
chronically elevated shear stress and luminal pressure, together with inflammatory 
processes, result in structural changes, and ultimately in cardiovascular pathologies, 
chiefly hypertension and atherosclerosis (Heeneman et al., 2007). Ang2 is one of the 
key molecules involved in the vasoconstrictory phenotype, which comprises vascular 
remodelling, including hypertrophy and inflammation (Jones & Woods, 2003). This 
anticipated relationship fostered a considerable interest in the Rigat’s finding on the 
regulation of ACE activity by the ACE I/Dp. Was there really a genetic component 
that affected ACE activity? If there was then surely this would also result in an 
increased (D allele)/decreased (I allele) risk of developing cardiovascular diseases, 
especially those related to the development and progression of hypertension?  
The cardiovascular link and ACE I/Dp: Individual studies have shown conflicting 
findings, but the majority of evidence points towards studies with positive findings 
showing an association of increased CVD risk with the D allele, see Sayed-Tabatabaei, 
(2006), and Agerholm-Larsen et al., (2000) for a review and meta-analysis 
respectively (Agerholm-Larsen et al., 2000; Sayed-Tabatabaei et al., 2006). It is 
generally thought that any influence of the ACE I/Dp will be very small due to the 
extremely complex nature and development of CVD (Sayed-Tabatabaei et al., 2006), 
which includes a combination of genetic and environmental factors (such as smoking, 
nutrition, stress, chemicals, and exercise).  
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Energy metabolism and substrate delivery: A person that has been regularly physically 
active over many years will certainly have a very different physiology including the 
vascular and muscle makeup than a person who has been sedentary all their life (see 
Figures 6, 10-12, 15, 16, 19, 21).  
 The vascular system and final delivery vessels are greatly influenced by the 
key [ACE] regulatory enzyme of a major vasoconstrictor, Ang2. These delivery 
vessels, in addition to transporting and removing oxygen and carbon dioxide 
respectively, provide important metabolic substrates that fuel muscle contraction. 
These substrates are critical determinants of sustained muscle work, which limits 
exercise performance (Holloszy et al., 1998). With the onset of muscle contraction the 
resting vasoconstrictory normal state is overridden causing blood vessels to dilate and 
thus facilitate delivery of energy substrates to drive muscle work (Murrant & Sarelius, 
2000). Evidence also suggests that the ACE I/Dp may have an important influence on 
substrate utilisation. Kinins (powerful vasodilatory molecules), which are degraded by 
ACE, increase Glut-4 translocation to sarcolemma and increase glucose transport 
(Dietze & Henriksen, 2008). The I-allele is associated with increased insulin 
sensitivity and increased uptake of glucose and glycogen stores (Vigano et al., 2009). 
ACEI and AT1RB consistently relate to improvements in insulin sensitivity and 
progression to DM2 (Scheen, 2004; Muscogiuri et al., 2008). BK increases tyrosine 
kinase activity, which increases IRS-1, which increases Glut-4 in SKM and glucose 
transport by increases in PI3 kinase, BK also stimulates phosphofructokinase 
(Muscogiuri et al., 2008). ACEI (mirror the I-allele) and AT1RB consistently relate to 
better improvement in glucose disposal and insulin sensitivity (Muscogiuri et al., 
2008).  
 There is also some evidence that fatty acid delivery and metabolism may be 
importantly altered, due to the ACE I/Dp, although there are few studies investigating 
this. Total cholesterol and LDL levels have been shown to be higher in ACE DD 
genotypes, compared to ACE ID or ACE II genotypes (Kim, 2009). Although an 
earlier study found no difference in LDL between ACE I/Dp genotypes, but did find a 
trend for reduced levels of TAG (P=0.06) in ACE II genotypes compared to ACE ID 
or DD genotypes (Arcaro et al., 2001). 
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 The RAS system regulates vascular space, and any factor that contributes 
towards altered functioning (like possibly the ACE I/Dp) could have important 
consequences for both disease progression and human performance.   
Influence of ethnicity: Ethnicity is an often over-looked confounding factor when 
studying disease, especially those that develop over decades, such as cardiovascular 
diseases. ACEI, which are used in first line treatment of hypertension, are less 
effective in reducing blood pressure in blacks than whites (VACSGoAA, 1982; 
Materson et al., 1993) and that there may be a different mechanism in which ACEI 
lower blood pressure in blacks (Weir et al., 1995). Studies have shown that there are 
differences in efficacy of ACEI between ACE IDp with 100 times more ACEI needed 
to block Ang1-Ang2 conversion in ACE II’s vs. DD’s (van Esch et al., 2008).  
 South Asians have an increased risk of developing cardiovascular diseases, and 
DMII (Gupta et al., 2006; Gholap et al., 2011), respectively – and at a much younger 
age (Gupta et al., 2006). A study on the ACE IDp with ethnicity suggested there was 
an interaction effect, which produced different vasodilatory responses in blacks versus 
whites (Gainer et al., 2001). Also, the often quoted association between ACE activity 
levels and the ACE IDp (DD>ID>II) relates to Caucasian populations. For example, 
the ACE IDp is not associated with serum ACE activity in black South African 
populations (Payne et al., 2007). It is often quoted in the literature that the allelic 
frequency of the ACE I/Dp is 1:2:1 (DD:ID:II). However, there is clear evidence that 
this is not the case across all populations (see Figure 31). There appears to be a 
distinctly increased frequency of the D allele in European populations of 0.55 (mean D 
allele frequency from 69 separate studies – Agerholm-Larsen et al., 2000). There has 
also been a study which reported no significant correlation with ACE activity and the 
ACE I/Dp in African-American children, even though the ACE I/Dp frequencies were 
not significantly different from the white children in the study (Bloem et al., 1996). 
Thus, studying mixed populations even if subjects appear to be from one ethnic 
population (without knowing family ethnic history) could potentially hide any ACE 
I/Dp association. 
Human performance: Montgomery’s original article (Montgomery et al., 1998) 
commented on the significant increase in frequency of the I allele in mountain 
climbers and (in a second cohort) an increase in duration of repetitive elbow flexion 
(following a physical training programme) – also in I allele carriers. They concluded 
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there may be an association with the I allele and improved endurance performance. 
Subsequent studies have agreed (Gayagay et al., 1998; Myerson et al., 1999; Alvarez 
et al., 2000; Scanavini et al., 2002; Collins et al., 2004; Hruskovicova et al., 2006; 
Thompson et al., 2006). A number also shown no association (Taylor et al., 1999; 
Rankinen et al., 2000b; Frederiksen et al., 2003; Scott et al., 2005; Day et al., 2007; 
McCauley et al., 2009; Papadimitriou et al., 2009) or the opposite, i.e. the association 
of the D allele with endurance performance (Zhao et al., 2003; Lucia et al., 2005; 
Amir et al., 2007; Muniesa et al., 2010). See a review article by Puthucheary, et al. 
(2011) for a further insight into the types of studies conducted on the ACE gene and 
human performance, since the link was first proposed (Puthucheary et al., 2011).  
 Rather than looking for associations (which many of the studies in the current 
literature did) with the ACE I/Dp and human performance (endurance or strength) or 
trainability it may be its influence on the ACE product, Ang2, which is of most 
interest. Evidence suggests that ACE I/Dp-dependent modulation of exercise 
performance is mediated by the effects of the ACE product, Ang2, on capillary and 
fibre growth in muscle (Greene, 1998; Schaufelberger et al., 1998; Booth et al., 2002; 
Zhang et al., 2005; de Resende & Greene, 2008).  
 
1.2.7 Aims and Objectives of the research project 
 
 The aim of this research project was to investigate the effects of endurance 
exercise on substrate metabolism and to examine whether the ACE I/Dp genotype (via 
its link to angiotensin 2 levels) was associated with metabolic responses to exercise. 
There were four main objectives: 
1. To compare physiological phenotype of endurance trained versus sedentary 
young men (chapter 3). 
2. To examine whether endurance trained and sedentary young men show 
different metabolic responses to a single bout of exercise (chapter 3).  
3. To examine whether the ACE I/Dp genotype is associated with energy 
metabolism in a British population (chapter 4). 
4. To examine whether the association between ACE I/Dp genotype and energy 
metabolism that was observed in the British population was also evident in a 
cohort from Switzerland (chapter 5). 
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2. Methods 
 
2.1. Experimental Methods 
 
Ethical approval (see appendix 1): The studies conformed to the latest revision of the 
Declaration of Helsinki and were approved by the ethics committee of the Faculty of 
Science and Engineering at Manchester Metropolitan University.  All participants 
provided informed, written consent prior to participation in the study and were free to 
withdraw from the study at any time if they so wished. 
 
ACE I/Dp Genotyping  
 
DNA was extracted from mucosal swabs using a custom designed protocol as follows: 
Mucosal swabs were collected with ear buds, extracted with 800 μl of methanol and 
vortexed, soaked then briefly centrifuged, and then left to evapourate. When all the 
methanol has evapourated the pellet is frozen at -80
o
C overnight (this introduces 
breaks into the DNA, which enhances the accessibility of the primers to the single 
complementary sequence in the large chromosome). The next day the pellet was 
resuspended in 100 μl of sterile water, soaked, vortexed, heated for 15 minutes then 
centrifuged at 10, 000 rpm for 10 minutes. Supernatant (containing DNA) was 
transferred into aliquots and stored at -20
o
C until needed. ACE I/Dp genotyping was 
performed by polymerase chain reaction (PCR) as described by Evans et al. 1994 
(Evans et al., 1994). The primers corresponded to those established previously for the 
identification of the ACE I/Dp genotype (for details see Genbank number X62855). 
Detection of the 66 bp amplicon, specific for the I-allele in intron 16 of the ACE gene 
was achieved by a combination of ACE1 (5’-catcctttctcccatttctc-3’), and ACE3 (5’-
atttcagagctggaataaaatt-3’) primers. ACE2 (5’-tgggattacaggcgtgatacag-3’) and ACE3 
(5’-atttcagagctggaataaaatt-3’) primers were applied to detect the 83 bp amplicon 
specific to the absence of the insertion sequence (i.e. the D-allele).  
 PCR reactions were run with a mix of the three primers using SybrGreen 
Master Mix (Applied Biosystems) on a Biorad DNA machine controlled by the MJ 
Opticon Monitor software (Biorad). The protocol involved 45 standard cycles of 
denaturing at 95
o
C for 15 seconds followed by annealing and extension at 55
o
C for 
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one minute. Amplicon identification followed using a melting curve analysis between 
a temperature range of 65
o
C to 85
o
C. The amplified sequence identity for the ACE I-
allele and ACE D-allele was validated by sequencing of the PCR products with the 
specific primers (Microsynth, Balgach, Switzerland). The presence of the short 
amplicon for the I-allele was identified by a lower melting temperature (73.07
o
C 
±0.15) compared to the amplicon for the longer D-allele (74.91
 o
C ±0.17). The 
difference in melting temperatures between the two alleles was highly significant 
(p<2.53
-38
, T-Test, n=28). Samples with poor signal to noise ratio were re-run in 
separate reactions with the specific primer pair for amplification of either the I-allele 
or D-allele. 
 
One-legged cycling peak power/oxygen uptake test (VO2peak test) 
 
Participants will complete two incremental exercise tests (peak power/VO2peak tests) 
to the limit of tolerance for one-legged cycling exercise (Davies & Sargeant, 1975) on 
the electrically braked cycle ergometer (Jaeger ergo-line 2000, Germany).  These two 
tests will be separated by at least 72 hours. The non-exercised leg will rest on a fixed 
chair and that corresponding ergometer pedal removed. Saddle and handlebar 
positions will be adjusted for each participant and the positions recorded to allow 
accurate replication of the test conditions in the acute endurance test (see below). The 
exercising foot was then taped securely in place, with strong electrician’s tape. Each 
participant was instructed to concentrate on driving down with the leg and not pulling 
up, plus they were also instructed to focus on generating the power from their 
exercising leg and not moving their body – especially near the end of the test.  
 Following a four minute warm-up period at of increasing intensity (per minute) 
from 10 to 40W, cycling with one leg, the external work rate was increased by a 
further 5W every 10 seconds. A pedal frequency of 80 rev.min
-1
 was maintained 
throughout the exercise period. The test was terminated when the pedal rate fell 
consistently below 60 rev.min
-1
, despite strong verbal encouragement.  Pulmonary gas 
exchange was measured breath-by-breath (Cosmed K4b2, Italy) and VO2peak and 
peak power (W) was determined using standard techniques. Peak power was taken as 
the highest value recorded during either one-legged test. One-legged VO2peak was 
recorded as the highest 30 second average oxygen uptake during either of the two 
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tests. Heart rate was monitored throughout with a Polar heart rate monitor (Polar 
Electro, Kempele, Finland).   
 Immediately following termination of the test, the participants were 
encouraged to perform an active recovery by cycling at a very low external work load 
using two legs.  This should have reduced sensations of local muscle fatigue and light-
headedness. 
 
Two-legged cycling oxygen uptake VO2max 
 
Each participant completed (at least) two incremental exercise tests to the limit of 
tolerance for two-legged exercise on an electrically braked cycle ergometer (Jaeger 
ergo-line 2000, Germany). Each test was separated by at least 24 hours.  Following a 
four-minute warm-up period at 40W, the external work rate was increased by a further 
5W every 10 seconds until volitional exhaustion.  A pedal frequency of 80 rev.min
-1
 
was maintained throughout the exercise period.  The test was terminated when the 
pedal rate fell consistently below70 rev.min
-1
.  Pulmonary gas exchange was measured 
breath-by-breath (Cosmed K4b2, Italy) and the gas exchange threshold and VO2max 
was determined using standard techniques. VO2max was recorded from either of the 
two tests with the highest 30 second average oxygen uptake.   Heart rate was 
monitored throughout with a suitable device (Polar Electro, Kempele, Finland).  
Saddle and handlebar positions were adjusted for each participant and the positions 
recorded to allow accurate replication in each test.  Immediately following termination 
of the test, the participants were encouraged to perform an active recovery by cycling 
at a very low external workload.  This should have reduced sensations of local muscle 
fatigue and light-headedness. 
 
Respiratory Expired Ratio 
 
Pulmonary gas exchange was measured breath-by-breath (Cosmed K4b2, Italy).  To 
calculate the RER at the beginning of the test a 15 second time period was averaged at 
approximately 2 minutes into the exercise bout (warm-up period at very low 
resistance) for both one- and two-legged tests. To calculate the RER at maximum 
exertion an average of 15 seconds was taken approximately 15 seconds from the end 
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of the test.   Heart rate was monitored throughout with a suitable device (Polar Electro, 
Kempele, Finland). 
 
Quadriceps muscle volume 
 
Magnetic resonance imaging (MRI) was used to measure muscle volume of the 
quadriceps femoris muscle group of the exercising leg (one-legged VO2peak test) 
using a 0.2-T G-scan MRI scanner (Esaote, Genova, Italy). Participants were scanned 
in the supine position with the leg fully extended and relaxed, and held firmly (but 
comfortably) in place. 
 Serial cross-sections (each measuring 3.1 mm in thickness, with a 18.6 mm 
inter-slice gap) were acquired from the lateral femoral condyle to the greater 
trochanter using a turbo 3-D T1 protocol. Total volume (cross sectional area x 
thickness) of the quadriceps muscles was analysed in each slice using image 
processing software (OsiriX version 3.3.2, 32-bit). Total quadriceps muscle volume 
was estimated based on the integration of volume from each slice and the inter-slice 
gap using a modified method described by Seynnes et al. 2008 (Seynnes et al., 2008).  
 
Body fat percentage 
 
We measured substrates involved in exercise metabolism, and fat plays an important 
role in this, hence we wanted to accurately measure body fat percentage. Dual Energy 
X-ray Absorptiometry (DEXA) – Lunar Prodigy Advance (GE Healthcare, Waukesha, 
Wisconsin, USA) – was used to assess each participant’s whole body fat percentage. 
There is a theoretical risk involved by the radiation imposed. In reality, that risk is 
rather low, as total body equivalent dosage is expected to be 0.4 microSievert. This 
could be compared to the background radiation of more than 2000 microSievert per 
year, or to the additional radiation of 10 microSievert per hour of air flight. 
 Each participant removed all their clothing apart from their underwear (shorts). 
They were then positioned, per whole-body composition analysis protocol, 
appropriately on the DEXA scanner and ankles and knees secured in place to ensure 
actual whole-body analysis. A QA check was performed before each scan – only upon 
passing this check did the scanning proceed. 
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Acute cycling endurance test 
 
The cycle ergometer (Jaeger ergo-line 2000, Germany) was set-up according to 
measurements recorded during the one-legged VO2peak test, including the important 
securing of the exercising leg/foot to the cycle pedal. There was a warm-up period of 8 
minutes, which allowed for a progressive increment in Watts – the actual increment 
per minute varied from 10 – 30 W depending on the steady-state power output 
calculated. After 20 minutes cycling one-legged at 60% peak power the external work 
load (W) was increased by 5 W every 10 seconds. Pulmonary gas exchange was 
measured breath-by-breath (Cosmed K4b2, Italy) and VO2peak and peak power (W) 
were determined using standard techniques.  Heart rate was monitored throughout with 
a Polar heart rate monitor (Polar Electro, Kempele, Finland).   
 Immediately following termination of the test, the participants were 
encouraged to perform an active recovery by cycling at a very low external work load 
using two legs.  This should have reduced sensations of local muscle fatigue and light-
headedness. 
 
Serum metabolite measures 
 
Total cholesterol, HDL, triglycerides, glucose and ketones were measured at rest 
(fasted) and immediately following exercise with a CardioChek ST Analyzer (Test 
Medical Systems @ home). LDL was also calculated by using the Friedewald formula: 
LDL = total cholesterol – HDL – triglycerides/5 (Friedewald et al., 1972). Blood was 
sampled via finger-pricks or drawn from the upper arm via the median cubital arm (for 
five participants only). 
 Participants were seated before blood sampling begun. If blood was drawn via 
finger-pricks then the finger would be cleaned with an alcohol swab and left to air dry. 
A self-projecting/retracting lancet would then pierce the skin. Blood would gently be 
massaged (if needed) and the first drops wiped away. Gentle massaging of the finger 
would continue (if needed) and the blood would be drawn up into to heparinised 
capillary tubes and fixed in place (using blu-tak) on a rocking plate (to further ensure 
the sample did not coagulate). Another two capillary tubes collected blood (30ul x 3 
tubes) and were placed onto the rocking plate. Sometimes a fresh finger-prick was 
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required to obtain sufficient blood. Upon collecting enough blood the appropriate 
metabolite analysis strip would be placed into the CardioChek ST Analyzer and 15ul 
of blood dispensed (with a special capillary plunger) onto the analyzer window.   
 
Muscle biopsies:  
Technique One (Chonchotome) 
 
A small (~ 50-100 mg) biopsy was taken from the vastus lateralis muscle of the non-
exercising leg, of the quadriceps, at 50% of femur length as assessed by prior 
ultrasound analysis (an acetate was used to draw around the knee cap and identifying 
marks – moles/scars – also drawn on to ensure accurate placement for taking biopsy). 
Participants were asked if they have ever had an adverse reaction to a local 
anaesthetic; if not local anaesthetic (2% Lidocaine) was infiltrated under the skin.  
After the skin had been shaved and sterilized an incision in the skin was made to the 
chonchotome to sample a piece of the vastus lateralis muscle.  Once the sample was 
taken it was rapidly wiped on a sterile surface to remove excess blood and cut in two 
pieces.  The first piece (for molecular analysis) was rapidly placed in iso-pentane 
(which itself was submersed in liquid nitrogen) to help reduce the chances of damage 
to the muscle ultrastructure (which can happen if rapidly cooled/placed straight into 
liquid nitrogen) and then liquid nitrogen. The second sample was immediately 
mounted on cork (orientating the fibres longitudinally) using Tissue-Tek, and then the 
above protocol followed. All samples were then stored at -80
o
C until later analysis.
   
Technique Two (Fine-needle) 
 
Biopsies two and three (30 minutes and 8 hours post exercise) were performed with a 
spring-loaded and reusable instrument; the ACE-Onecut Disposable Biopsy (14 Gauge 
x 150 mm, product code ONE-141502, UK BIOPSY Ltd, Great Britain). Both these 
samples were for molecular analysis and the same protocol was followed as in 
technique one. 
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Capillary Density Determination 
 
Sections were stained with lectin to identify capillaries (Ahmed et al., 1997). Sections 
were left to dry (once removed storage at -80
o
C), fixed in acetone (4
o
C) for 15 
minutes, incubated in HEPES-buffer for 10 minutes, incubated in peroxide for 30 
minutes (to reduce background staining), incubated in HEPES-buffer for 5 minutes, 
incubated in lectin (Ulex Europeus) in HEPES 1% BSA (2000ug/ml). The capillaries 
were visualised using a Vectastain ABC and DAB substrate kit (Vector Laboratories, 
Peterborough, UK) before mounting in gelatine-glycerol. 
 The capillaries were analysed using the method of capillary domains (Degens 
et al., 1992). This method not only takes into account the overall indices of capillary to 
fibre ratio (C/F) and capillary density (CD), but also takes into account the 
heterogeneity in capillary spacing. Photomicrographs were taken of cross-sections of 
the vastus lateralis muscle (scale?) and the outlines of the muscle fibres together with 
the location of each capillary were digitised on a calibrated digitising tablet (Model 
MMII 1201, Summagrahics Digitisers, Austin, Tex, USA. The overall capillary 
density (CD) was defined as the number of capillaries mm
-2
 of tissue. Capillary 
domains, defined as the area surrounding a capillary delineated by equidistant 
boundaries from adjacent ones, were constructed and their surface area calculated. 
From the overlap of the domains with muscle fibres, the local capillary to fibre ratio 
(LCFR) and capillary fibre dendity (CFD) were obtained. The LCFR for a fibre was 
defined as the sum of the fractions of each domain area overlapping the fibre. This 
variable has the continuous distribution and is more sensitive than, for example, 
capillaries around a fibre. It importantly also allows determination of the capillary 
supply to a fibre even when it lacks direct capillary contacts. CFD, which is LCFE 
divided by the FCSA, provides the capillary density of that fibre and is expressed as 
the number of capillaries mm
-2
. 
 
Fibre type percentage determination 
 
Immunohistochemical determination of fast, slow, and hybrid fibre types was carried 
out on 10 μm cryosections using monoclonal antiobodies specific for fast myosin (My-
32, Sigma) or slow myosin (MAB1628, Chemikon).  
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 Slides with 10 μm cryosections (from vastus lateralis muscle) were removed 
from  -80
o
C freezer and left to thaw. Sections were then fixed in acetone, quenched 
with peroxidise (3% H2O2 in Methanol), washed with PBS, blocked with 3% 
BSA/PBS, incubated with primary monoclonal mouse antibody (specific for fast/slow 
fibre), washed in PBS, reacted with peroxidise-conjugated anti-mouse IgG (A-2304 
Sigma, 1:2000 in 0.3% BSA/PBS), washed in PBS, detected immunoreactivity with 
substrate AEC (Sigma Chemicals, Buchs, Switzerland), incubated in sterile water to 
stop, counterstained with hematoxylin, placed in tap water to develop, washed in PBS, 
and before allowing sections to dry Aquatex was added and coverslide placed over 
sections.  
 
Gene expression analysis 
 
RNA isolation and real-time PCR: Cryosections from VL muscle were sampled in 
frozen tubes, and RNA was extracted using a modified Qiagen protocol (purification 
of total RNA from animal tissues) as follows: 
25 μm cryosections were cut (10mm3 per sample) on a cryostat, and sections 
transferred to 2.0 ml cryo-vial tubes and stored at -80
o
C. After adjusting to -20
o
C , 333 
μl of lysis buffer (RLT-buffer, Qiagen AG, Basel, Switzerland; and β-
mercaptoethanol) pre-heated to 45
o
C was added and the muscle sections immediately 
homogenized (on ice) with a rotor-stator homogenizer (Polytron PT1200, 
KINEMATICA AG, Lucerne, Switzerland) for 10 seconds, 567 μl of DEPC water was 
added (washing around homogenizer tip to collect all sample) and immediately 
homogenised, finally 100 μl of proteinase K was added to the sample. The sample was 
then left at 45
o
C for 90 minutes for proteins to digest.  The sample was then 
centrifuged for 10 minutes at 7500 rpm and supernatant transferred into sterile 15 ml 
tubes, 1 ml of RLT buffer + β-mercaptoethanol (vortex) then 1 ml of EtOH – 4oC 
(vortex) was added, this solution was then added (in 700 μl volumes) to RNeasy 
columns and centrifuged at 13, 000 rpm for 15 seconds, the column had a final wash 
and spin (at 13, 000 rpm) with RW1 buffer after which 10 μl of DNase + 70 μl RDD 
buffer was added to the column and left to digest for 30 minutes. Another 350 μl of 
RW1 buffer was applied to the column and centrifuged at 13, 000 rpm for 15 seconds, 
two success washes of the column with 500 μl of RPE buffer (and centrifuge at 13, 
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000 rpm for 15 then 120 seconds) were applied. RNA from the column was then 
eluted into RNase free tube  with two success applications of 50 μl of DEPC water – 
applied to the middle of the column filter – incubated for 60 seconds and centrifuged 
for another 60 seconds at 13, 000 rpm. 10 μl of sodium Acetate (pH 5.2) then 250 μl 
EtOH (vortex and spin at 13, 000 rpm for 120 seconds) was added to the sample and 
left overnight at -20
o
C. Sample was centrifuged at 10, 000 rpm for 30 minutes (at 4
o
C) 
then supernatant removed. The remaining pellet was then very carefully washed with 
70% EtOH (previously stored at -20
o
C) centrifuged at 10, 000 rpm for 5 minutes (at 
4
o
C), the supernatant removed, RNA pellet was then left to air dry for approximately 
60 minutes. 3 x 2 μl of DEPC water were added next to the pellet and gently tapped 
into the pellet, 1 μl was then removed and diluted (1:9, for RNA quantification using a 
spectrophotometer, absorption at A260). 5 μl of dissolved RNA was left in the sample. 
100 ng RNA was reverse transcribed and subjected to real-time polymerase chain 
reaction (RT-PCR) for selected transcripts – see table 18 chapter 3. Reactions were run 
with Sybr Green master mix (Applied Biosystems) on a Biorad DNA machine 
controlled by the MJ Opticon Monitor software (Biorad). Due to a low quantity of 
RNA, used per reaction (3 ng), we altered the standard protocol (50 standard cycles 15 
sec 95ºC, 1 min 55ºC) to include an extra step, after annealing (1 min 55ºC), of 15 sec 
75ºC to reduce non-specific binding – this was performed after a hot start on same 
amounts of cDNA. Primers were used as established (Zoll et al., 2006) or designed 
with the online NCBI Primer-Blast primer design tool (Rozen & Skaletsky, 2000) and 
synthesized at Sigma-Genosys. Signals were expressed per input amount of cDNA 
using the delta cycle threshold (Ct) method and transcript signals were standardized to 
28S rRNA. Amplification was assessed by a combination of analysis of melting curve 
and Ct. Briefly, for amplification to be deemed successful there must have been a 
single clearly identifiable melting peak together with a clear exponential increase 
(sigmoid curve) and plateau (although a plateau may not be seen for very low 
abundant cDNAs that show up/amplify late). All primers passed both these conditions 
apart from AT2R, BK2R and HMWK. 
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Muscle Metabolite Analysis – Mass Spectrometry 
 
This analysis was carried out in collaboration with Prof. Royston Goodacre from the 
University of Manchester. The author’s part in this specific part of the study was 
limited to the initial muscle biopsy preparation before passing over to University of 
Manchester who did the actual metabolite analysis (as described below). The protocol 
for extraction of muscle metabolites was established in preliminary experiments. 
Based on these results the following protocol was adopted. 
Sample preparation: 
Extraction SOP (Yu Lin, 2007): 
Washed samples 2-3 x in 0.85% NaCl to remove residual blood, keeping sample (30 
or 40 mg FW fine ground in ball mill) on ice, add 690 µl of CHCl3 : MeOH (1 : 1) 
(All solvents of HPLC grade or better), vortexed for 10 sec and shake at 4
o
C (cold 
room) for 15 min, centrifuged at max speed for 5 min (cryofuge at 3
o
C) and remove 
supernatant to a clean 2 ml tube on ice,  310 µl of H2O added, vortexed and then 
centrifuged at max speed and 3
o
C for 5 mins to aid phase separation, polar extracts 
were normalised for sample weight differences by amending the volume of extract 
dried down (please see Table metabolomics below),  Aliquots of the polar phase to a 
clean labelled 2 ml tubes (take care not to disturb interphase),  the remaining polar 
phases were pooled to produce a QC sample, to the polar extract 100 ul IS2 (to correct 
for analytical error) was added, polar samples were dried (fully) in a speed vacuum 
concentrator for ~ 4-6h, and stored at -80 
o
C, non-polar samples are directly flash 
frozen in liquid nitrogen and stored at -80 
o
C in CHCl3. 
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Sample analysis: 
Focused upon LC-MS based techniques, as this has the potential to reveal a greater 
depth of information than Gas Chromatography-MS (GC-MS). 
 Samples were analysed using the Thermo LTQ Orbitrap MS system since it 
offers the greatest sensitivity. Metabolites were recovered in the non-polar and polar 
phase. After derivatization the non-polar phase (chloroform) was subjected to direct 
infusion mass-spectrometry (DIMS). The polar phase was dried down, resuspended in 
equal proportion of solvent (per mg of tissue) and subjected to separation by liquid 
chromatography-mass-spectrometry in positive (LCMS_ESI+) and negative 
(LCMS_ESI) electrospray ionisation mode.  
 
Polar samples  
Polar samples (methanol and water phase of the extract) were reconstituted in a small 
volume of water (50ul) to maximise sample concentration and run on a Waters UPLC 
in a gradient from high aqueous to high organic (A: Water acidified with formic acid 
and B: Acetonitrile acidified with formic acid).  Data were collected on the Thermo 
Table metabolomics 
Pre-Exercise samples Post-Exercise samples
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1 25 1 24 375.0 1 25 18 25 360.0
3 27 2 32 281.3 3 27 19 31 290.3
4 62 3 27 333.3 4 62 20 26 346.2
6 24 4 18 500.0 6 24 21 27 333.3
7 26 5 45 200.0 7 26 22 22 409.1
8 40 6 38 236.8 8 40 23 26 346.2
9 37 7 39 230.8 9 37 24 26 346.2
10 3 8 20 450.0 10 3 25 29 310.3
11 4 9 21 428.6 11 4 26 20 450.0
12 42 10 18 500.0 12 42 27 20 450.0
13 53 11 33 272.7 13 53 28 21 428.6
16 51 12 22 409.1 16 51 29 26 346.2
17 57 13 18 500.0 17 57 30 21 428.6
18 11 14 18 500.0 18 11 31 39 230.8
19 45 15 19 473.7 19 45 32 26 346.2
20 49 16 34 264.7 20 49 33 25 360.0
21 56 17 15 600.0 21 56 34 27 333.3  
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LTQ-Orbitrap in both ESI+ve and ESI-ve mode (follwoing HUSER-MET serum 
protocol), the Orbitrap was operated to minimise sample fragmentation so that we 
hope that the masses we detect originate from whole intact metabolites.   
 
Non-polar samples  
Non-polar samples (chloroform phase of the extract) were diluted to an appropriate 
level and were analysed directly. The samples rather than being subjected to UPLC, 
were directly infused into the Thermo LTQ Orbitrap operated in ESI-ve mode , since 
the samples are not diluted by LC eluents, this gives nice rich profiles of triglycerides, 
phospholipids and fatty acids. 
Paired samples (i.e. same participant pre and post exercise) were separated in 
consecutive runs of the calibrated equipment. Control experiments demonstrated a 
correlation of z of such paired experiments.  
 Data processing: Because no internal standard was used data normalisation was 
indicated to allow the comparison of relative signals resulting from the count of peak 
signals in mass spectrometry. Peaks with signals below 12.5 x the standard deviations 
of blank samples were set to zero. Data were normalized to the median peak ratio as 
described (Wang et al., 2003). In brief, a reference profile was constructed for pre- and 
post-exercise samples from the median of values for each peak. Subsequently, for each 
sample profile the fold difference of each peak versus the respective peak of the 
reference profile was estimated, values with a denominator of "0" were removed and 
the mean fold difference of all peaks was determined. This value was used as 
normalization factor to adjust the signals of each experimental sample. Then the 
revealed normalized values were related to the mean of pre-exercise signals from the 
respective training cohort.  
 Metabolites for non-polar mass spectral features giving rise to the peaks of 
interest (Tables 15-17) were putatively identified by submitting the accurate mass 
information to the LipidMaps database (http://www.lipidmaps.org/). 
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Chapter 3 
 
 
 
 
 
Exercise Alters the Human Muscle 
Metabolome 
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3.1. Introduction 
 
 High intensity exercise greatly increases energy expenditure and metabolic rate 
must increase to provide the ATP necessary for continuation of muscle contraction.  
Oxygen consumption can increase by more than 10-fold, from resting values of around 
0.3-0.5 L/min to values in excess of 3-5 L/min at maximal oxygen uptake. During 
prolonged low-to-moderate intensity exercise, it is lipid oxidation that provides the 
majority of the ATP, particularly in endurance trained people, but as exercise intensity 
increases to levels beyond 60% VO2max, lipid oxidation decreases and the reliance on 
glucose as substrate increases (Venables et al., 2005).  These substrates can be sourced 
locally from muscle TAG and glycogen stores for lipid and glucose, respectively.  
They can also be supplied to the contracting skeletal muscles from adipose tissue and 
liver glycogen reserves from the circulatory system (Frayn, 2003).  
 With recent advances in technology and metabolomics it has become evident 
that numerous complex signalling and molecular events occur in response to exercise 
and many of these can be observed in blood serum (Yan et al., 2009; Lehmann et al., 
2010; Lewis et al., 2010). These metabolic changes are undoubtedly necessary to 
effectively meet the challenge associated with the metabolic disturbance of intense, 
prolonged physical activity. As regular endurance exercise can lead to extensive 
phenotypic changes to skeletal muscle and other body systems, the precise response, is 
likely to differ between untrained and endurance trained individuals. The general 
endurance-training adaptations that occur within skeletal muscle have been well 
characterised, and include increased lipid oxidation; volume density of 
intramyocellular lipids and mitochondrial enzymes. There are also adaptations that 
occur within the cardiovascular system, such as increased capillarisation; blood 
volume and stroke volume (Rosler et al., 1986; Braun, 1991; Convertino, 1991), and 
hypertrophy of the cardiac muscle itself. These adaptations result in altered metabolic 
profile during exercise (i.e. higher lipid oxidation) and enable physical activity to be 
sustained at higher power output for longer durations. With extensive aerobic 
conditioning (training) skeletal muscles can improve their capacity for fat oxidation 
{Ramos-Jimenez, 2008}. Increases in volume density of intramyocellular lipids, and 
components of the respiratory pathway [extending from muscle organelles (i.e. 
mitochondrial volume density) to cardiovascular parameters (i.e. capillary density, 
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stroke volume)] all contribute to these ameliorations in endurance trained participants 
(reviewed in Keins, 2006). At the whole-body level this manifests in increased 
maximal oxygen uptake with a concomitantly reduced respired expiratory ratio (RER) 
at a given exercise intensity (Ramos-Jimenez, 2008). RER is an indirect method (gas 
analysis at the mouth) commonly used to estimate the respiratory quotient (RQ), 
which is the ratio of oxygen consumed to carbon dioxide expired. In steady state 
RER=RQ. However, as RQ reflects the usage/removal of oxygen and carbon dioxide 
respectively at the cellular level, during maximal exertion external respiration 
(measured during RER) will not match cellular respiration. Put another way, as RQ is 
measured at the local level, changes in buffer systems of the upstream elements of 
CO2 and O2 transport in the vascular distort the equilibrium.  
 Metabolomic studies have identified significant differences between trained 
and untrained individuals in the changes that occur in response to an acute exercise 
bout. For example, it is possible to differentiate key intermediates of glucose, lipid and 
amino acid metabolism following a bout of exercise and identify differences in these 
responses between trained and untrained individuals (Yan et al., 2009; Lewis et al., 
2010).  The metabolomic approach further identified differences between people of 
different skill levels and training status of the athletes, indicating that the subtle 
differences between trained and highly trained people can be detected. These 
metabolic differences were evident despite there being no notable differences between 
groups in the traditional biochemical markers of exercise, such as haemoglobin, 
testosterone, and creatine kinase (Yan et al., 2009; Lewis et al., 2010).  
 In the present study, it was hypothesised that a metabolomic approach would 
reveal changes in novel lipid species after an exhaustive bout of endurance exercise in 
SKM. It was further hypothesised that such changes would differ between untrained 
and endurance-trained individuals.  
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3.2. Methods 
 
3.2.1 Experimental Design  
 
 The study design was intended to identify novel physiological differences 
within the muscle and cardiovascular systems between endurance trained and 
untrained people.  
 
There were many tests involved, requiring an absolute minimum of eight visits. Please 
refer to Figure 34 for an overview of the tests and order they were conducted per 
participant. Due to the complex nature of the study, which is studying the potential 
 
 
Figure 34. Outline and flow of tests used in study 
Extra tests required no effort on participants part and could be conducted at any visit where indicated. 
The visits in the grey shaded area (visits 1 to 4) must be done in that order, visits 7 and 8 could come 
before 5 and 6. 
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interaction of many systems levels within a whole-organism (human) it was necessary 
to collect data from these different systems. Below is a description of why each test 
was chosen, problems encounted and development of tests: 
 
Rationale for tests  
 
Single-legged exercise was used to 1) maximally tax aerobic energy metabolism in 
contracting muscle without the central limiting factors imposed by the cardiovascular 
system that affects exercise of multiple body segments, 2) to allow the collection of a 
muscle biopsy from the non-exercising leg thus reducing the acute interference of this 
intervention on exercise performance and muscle metabolites. There were two 
different one-legged endurance tests: the main one being the acute one-legged exercise 
test where muscle biopsies are taken (visit 4 – the key visit). In order to ensure each 
participant exercised at the same relative intensity their one-legged Pmax would need 
to be calculated (visits 2 and 3). The steady state peak power output of 60% was 
chosen based (one-legged exercise bout – visit 4) research produced by Jamie McPhee 
and conversations with him – as this was a very novel area (McPhee et al., 2010). The 
60% intensity has also been piloted on volunteers (not any of the participants) and was 
deemed to be the maximum power output that could be reasonably maintained by one-
leg but would also be great enough to challenge the working muscle. To ensure the 
local muscle would be maximally stressed a ramp was introduced at the end of the 20 
minutes of steady state one-leg exertion. Previous studies have shown that during two-
legged exercise the training intensity experienced by the local musculature differs 
from person to person (McPhee et al., 2009; McPhee et al., 2010). The single-legged 
acute exercise test (visit four) was performed early in the morning after participants 
had fasted over-night, to control for any dietary effects and to impose an additional 
challenge to metabolic control, as metabolism during moderate exercise is mainly 
driven by lipid oxidation in the fasted state (De Bock et al., 2005).  
  A single-legged force test was also performed as were were interested to see is there 
were force differences between the participants who were trained and untrained.     
 A whole body DEXA scan was performed to assess body composition (mainly 
body fat percentage) and magnetic resonance imaging (MRI) was used to estimate 
quadriceps mucle volume. Evidence suggests that those people who regularly perform 
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physical activity (especially of the endurance type) will have reduced body fat and 
increased muscle mass – especially in the quadriceps – in essence these tests should 
confirm our conclusions about the training status of the participants. The order of the 
first four visits is vitally important – as we want each participant to do as little 
additional exercise as possible. Although very small the two extra two-legged VO2max 
tests may start having an exercise effect on the untrained participants. Also, it’s 
notoriously difficult to get participants to give muscle biopsies due to the invasive 
nature. There were a number of tests performed that were of interest to the 
participants, namely: VO2max, DEXA (body fat %) and serum blood measures. The 
most important visit for the study was the mucle biopsies – to keep participants 
motivation up we ensured those tests they were interested in came after the one that 
was key to our research. Also, participants were not told of there results from each test 
until all tests were completed, again to ensure they completed all tests. 
 The two-legged maximal oxygen uptake (VO2max) cycling test was used to 
assess general whole-body aerobic fitness and is a well established measure – plus is 
was used to corroborate whether a participant was deem endurance trained or 
untrained. Blood samples were obtained before and after the two-legged cycling test to 
assess the effect of exercise on serum metabolites. Muscle biopsies were taken before 
and on completion of the single-legged exercise test (visit four), at 30 minutes and 
eight hours. We chose these two times because 30 minutes was the quickest time that a 
muscle biopsy could be taken following cessation of the exercise bout, .e.g. it takes 
about 10 minutes for the participant to get off the bike, compose themself and then lie 
down on the physio plinth, then it takes about 10-15 mintues for the doctor to prepare 
the area on the leg for the muscle biopsy to be taken (area to be cleaned, marked, and 
aneathestic to work). Eight hours was the time chosen for the last muscle biopsy as 
this is the time-point where important gene transcripts, relating to energy metabolism, 
have previously been identified as being up-/down-regulated (Flueck & Hoppeler 
2003; Booth & Neufer 2005) – this muscle biopsy was not being used for metabolomic 
analysis. By utilising a one-legged exercise paradigm we could be more confident that 
all participants in these studies were performing work at similar relative intensities of 
their localised peak aerobic capacity (McPhee et al., 2009).  
Main serum metabolites (glucose, triglyceride, high- and low-density lipoproteins, 
total cholesterol and ketones), and the entire collection of non-polar metabolites, were 
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assessed in m. vastas lateralis. Capillary density and fibre types were also analysed to 
ascertain if these important local factors were significantly altered between the two 
cohorts.  
  
3.2.2 Participants 
 
 Twenty healthy males (with no known medical contraindications) aged 19 – 38 
participated in this study. Females were excluded due to potential differences in 
energy metabolism (e.g. greater usage of lipids during endurance exercise), plus we 
would have needed to controlled for each females menstral cycle, which was deemd to 
logistically difficult. Exclusion criteria included smoking, long-term ill health, female, 
and not within the study age range (18 – 39).  Participants were deemed to be trained if 
they had a VO2max >50ml/min/kg unless they deemed themselves unfit and sedentary 
or had indicated, by questionnaire and orally, the only activity they did was walking. 
This was the case of two of the untrained participants who had a VO2max > 
50ml/min/kg. The number of participants is on the lower side, when studying a gene 
variant. However, these numbers have been deemed acceptable for studies of a similar 
invasive nature (e.g. muscle biopsies, blood, maximal tests) in many other studies. 
Plus, the detailed analysis of many linked system levels allows for a finer resolution.    
 
The methodology is listed below. A full description of study methodology can be found 
in the methods chapter (2). 
 
3.2.3 List of all Tests/Measures (see methods chapter for description) 
 
One-legged cycling peak power/oxygen uptake test (VO2peak/Pmax test)  
Two-legged cycling oxygen uptake VO2max 
Quadriceps muscle volume (MRI scan) 
Body fat percentage (DEXA scan) 
Acute cycling endurance test 
Serum metabolite measures 
Muscle biopsies 
Capillary density determination 
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Fibre type percentage determination 
Metabolome Profiling 
Respiratory exchange Ratio  
 
3.2.4 Statistics  
 
 Two kinds of statistical designs were used to assess the data: 
A paired test to assess pre. vs post exercise effects on physiological and biochemical 
parameters and unpaired test to compare differences between the untrained and trained 
cohort. 
Paired tests: Individual parameters characterising metabolites with exercise were 
assessed with a repeated ANOVA (STATISTICA) and a post-hoc test of Fisher. This 
latter test is also a T-test. 
 Due to the multi-factorial nature of the metabolome data general effects on the 
metabolite peaks were assessed with a repeated ANOVA followed up with 
significance analysis of microarrays (SAM). This was necessary to account for the 
strong influence of the multiple tests on a type I error. Unpaired T-Tests were applied 
to assess differences in anatomical and physiological values between the trained vs. 
untrained cohort (MS-Excel, Kildare, IRL). To reiterate errors of multiple 
comparisons were taken care of with SAM for microarray and metabolomic data 
which controls false discorvery rate. 
 
3.3. Results 
 
 Endurance trained and untrained individuals were of similar age, height and 
body mass.  Although there was no significant difference between trained and 
untrained individuals in BMI, the DEXA scan revealed that endurance trained 
participants tended to have lower body fat percentage (P=0.06) (Table 11).  The MRI 
images of the thigh muscles shown in Figure 35 for trained (left) and untrained (right) 
individuals revealed that endurance trained participants tended to have higher muscle 
volume (Table 12 and 14). When each of the four quadriceps muscles was analysed 
only the vastus intermedius muscle volume was significantly different between the 
trained and untrained participants (Table 14, P=0.02).  The percentage of Type I 
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muscle fibre and capillary number did not differ significantly between the trained and 
untrained participants (Table 13).  
Endurance trained participants had significantly higher aerobic fitness, as indicated by 
higher VO2max, higher local muscle VO2peak and higher power output during both 
two-legged and single-legged exercise (Table 11). There was no significant difference 
between trained and untrained individuals in RER at any point during the two-leg 
cycling maximal oxygen uptake test, with the exception of the final 15 seconds, where 
the untrained participants had a higher RER (1.04 vs. 1.12; P=0.02; Figure 36). 
 
 
 
 
 
 
 
 
 
 
Table 11. Anthropometry of the trained and untrained cohort. 
 
  Training Status  
  Trained (n=11) Untrained (n = 9)  P 
Age (years) 27.3 (19:38) 24.8 (19:34) 0.39 
Body Mass (Kg) 79.6 (69:99) 74.8 (60:99) 0.32 
Height (M) 1.83 (1.77:1.94) 1.79 (1.37:1.91) 0.22 
BMI (Kg/M
2
) 23.7 (21.0:29.6) 23.3 (18.5:30.9) 0.78 
Body Fat (%) 14.8 (6.1:28.0) 21.0 (10.7:32.1) 0.06 
     
The data is displayed as mean (range), Body Fat (%) demonstrated a trend for being different between the 
trained and untrained cohort, as highlighted by underlining 
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Table 13. Mean and extreme values for three muscle parameters in the two cohorts. 
                          Training Status  
      Trained (n=11) Untrained (n = 9)     P 
Capillary density (mm
-2
) 300 (246:345) 283 (207:352) 0.35 
Fibre type I (%)* 44.5 (22.0:63.0) 37.9 (27.2:52.6) 0.25 
Quadriceps volume (cm
3
) 2348 (1802:2949) 1957 (1419:2468) 0.04 
         
The data is displayed as mean (range). *n=8, untrained. Only quadriceps volume is significantly 
different between cohorts, as underlined 
 
    
 
 
Table 12. Parameters of aerobic fitness in the trained and untrained cohorts. 
    Training Status   
           Trained (n=11)          Untrained (n = 9)          P  
VO2max (ml/min/Kg): 2-leg 60.3 (50.1:70.1) 48.2 (43.2:57.6) 0.0001 
VO2peak (ml/min/Kg): 1-leg 48.4 (42.1:56.0) 42.3 (34.2:48.9) 0.01 
VO2max (ml/min): 2-leg 4774 (3848:5319) 3564 (3115:4639) 0.00005 
VO2peak (ml/min): 1-leg 3845 (3148:4719) 3128 (2937:4093) 0.00003 
Pmax (W): 2-leg 369 (290:450) 267 (230:340) 0.00005 
Pmax (W): 1-leg 234 (190:275) 168 (140:220) 0.007 
Pmax (W/Kg): 2-leg 4.64 (3.92:5.42) 3.58 (3.31:4.00) 0.00001 
Pmax (W/Kg): 1-leg 2.95 (2.57:3.41) 2.26 (2.00:2.75) 0.00002 
         
The data is displayed as mean (range). All parameters of aerobic fitness are significantly different 
between the untrained and trained cohorts, as underlined 
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Table 14. Quadriceps mucle volume of untrained and trained participants. 
 
 
 
 
Untrained 
    Quadriceps Volume (mm
3
) Total 
Volume 
(mm
3
) 
 RF VL VM VI 
 225 467 352 375 1419 
 285 530 404 447 1666 
 258 643 548 521 1970 
 326 569 503 695 2093 
 320 740 530 693 2283 
 370 625 616 679 2290 
 279 570 400 502 1751 
 237 521 401 513 1672 
 377 828 561 702 2468 
 297.4 610.3 479.4 569.7 1956.9 Mean 
18.21 37.97 30.62 41.41 117.54 Se 
      
Trained 
   
 Quadriceps Volume (mm
3
) Total 
Volume 
(mm
3
) 
 RF VL VM VI 
 316 681 542 594 2133 
 326 670 494 625 2115 
 287 671 571 678 2207 
 386 817 700 765 2668 
 292 523 402 585 1802 
 358 748 801 1029 2936 
 530 888 649 852 2919 
 270 619 554 710 2153 
 332 591 447 546 1916 
 406 894 722 927 2949 
 290 525 453 761 2029 
 344.8 693.4 575.9 733.8 2347.9 Mean 
22.56 39.43 38.50 45.99 130.74 Se 
0.13 0.15 0.07 0.02 0.04 P 
      RF: rectus fermoras, VL: vastus lateralis, VM: vastus medialis, VI: vastus intermedius. Underlined 
denotes significantly different between trained and untrained (unpaired T-test). 
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Figure 36. RER at the start and end of a single bout of two-legged aerobic exercise 
*P=0.02 vs untrained. RER values are means of 15 seconds taken at the: start of exercise (2 mins), 
and at the end (at maximal volition, just before cessation of exercise bout – 15 seconds left). Data 
are expressed as mean ±     SEM, trained n=10, untrained n=8.   Untrained          Trained. Both 
trained and untrained cohorts had an RER at the end of exercise, which was significantly different, 
P<0.0000001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35. Local body fat (surrounding quadriceps muscles) differences between a trained and 
untrained participant 
Both images are taken at approximately the same point along the quadricep muscle – 
approximately at the location where the vastus lateralis muscle starts to appear (its origin) as 
highlighted by the red circle. This is figure is displayed for illustrative purposes to highlight the 
physiological (clear) differences between someone who regularly exercises and someon who does 
not 
Trained participant, with a body fat 
percentage of ~ 6% 
 
 
 
Untrained participant, with a body fat 
percentage of ~ 32% 
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Blood samples were taken at the beginning and the end of the two-legged cycling 
VO2max test and were measured for serum concentrations of lipids, ketones and 
glucose metabolites. Serum LDL was significantly higher in trained participants in the 
fasted state at rest and following the two-legged VO2max test (P=0.04 and P=0.06, 
respectively). None of the other measured metabolites differed between trained and 
untrained participants in the rested state.  From the measured metabolites, only glucose 
concentration showed a significant change after exercise in the trained individuals. 
Untrained participants showed no exercise-induced change in any of the measured 
metabolites (Table 15). 
Table 15. Serum metabolites pre- and post-exercise (two-legged) in trained and untrained cohorts. 
                                                  T             UT         Pre-Ex   Post-Ex 
 T UT       Pre vs. Post                 T vs. UT 
(mmol/l) 
Pre-
Exercise 
Post-  
Exercise 
Pre-
Exercise 
Post- 
Exercise  
     P       P                  P            P 
Glucose 
3.92 
(3.2:4.9) 
4.92    
(3.5:7.3) 
4.1  
(3.3:5.4) 
4.56   
(3.0:6.9) 
0.03 0.43 0.54 0.57 
Total Chol 
3.94 
(3.27:5.37) 
4.11 
(3.38:6.02) 
3.58 
(3.07:4.19) 
3.53 
(3.01:4.19) 
0.59 0.82 0.16 0.09 
HDL 
1.00 
(0.70:175) 
1.33  
(0.81:4.0) 
1.00 
(0.65:1.61) 
1.04 
(0.65:1.71) 
0.31 0.24 0.97 0.43 
LDL 
2.82 
(2.24:3.89) 
2.67 
(2.06:3.12) 
2.39 
(1.88:2.83) 
2.29 
(1.83:2.76) 
0.47 0.53 0.04 0.06 
TAG 
0.61 
(0.57:0.80) 
0.61 
(0.57:0.75) 
0.95 
(0.57:2.72) 
0.99 
(0.57:2.65) 
0.89 0.90 0.12 0.21 
Ketones 
0.58 
(0.32:0.89) 
0.48 
(0.34:0.58) 
0.55 
(0.19:0.90) 
0.49 
(0.28:0.72) 
0.38 0.33 0.76 0.91 
 
 
The data is displayed as mean (range). Glucose levels pre vs. post in trained  and LDL levels Pre-
Ex in trained vs. untrained were significantly different as, as underlined.  
T: Trained, UT: Untrained, Pre-Ex: Pre-exercise, Post-Ex:Post-Exercise, Total Chol: Total 
Cholesterol, HDL: High Density Lipoprotein, LDL: Low Density Lipoprotein, TAG: 
Triacylglyceride. n=8 UT cohort (for all measures), n=10 Glucose and HDL, n=9 Total Chol, n=8 
Ketones, n=6 LDL and TAG. 
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Figure 37. Metabolite reference profiles (of three different classes) 
Line graph visualizing the reference profiles for the peaks identified with mass 
spectroscopy in the polar and non-polar fraction of vastus lateralis muscle prior to 
endurance exercise. Please note the units are dimensionless – reflect intensity of 
signal (the signal represents the signal intensity of the different ions of a given m/z 
ratio. It is related to Volts but this is not absolute and depends on instrument 
calibration. To take care of this signals were related to reference profiles, which 
are shown in these graphs – they reflect the median of ‘signal intensity’ for each 
m/z data point. DIMS, direct injection mass spectroscopy (MS) (polar fraction); 
LCMS_ESI+, liquid chromatography MS in positive electrospray ionisation mode 
(LCMS_pos) (non-polar fraction); LCMS_ESI-, liquid chromatography MS in 
negative electrospray ionisation mode (LCMS_neg) (non-polar fraction). 
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There was no significant difference between trained and untrained participants in the 
non-polar (Figure 38) or the polar (Figure 39) metabolites in the rested and fasted 
state.  Both groups showed significant increases in the non-polar and the polar 
metabolites following the single-leg exercise bout, but the increase that occurred, in 
non-polar metabolites, in the endurance trained individuals was significantly higher 
than the increase seen in the untrained participants (P=0.0004; Figure 38). The 
opposite was seen in the polar metabolites, where untrained individuals had 
significantly higher increases in polar (positive and negative) metabolites than 
endurance trained individuals (P<0.00001; Figure 39) 
 
 
Figure 38. Interaction effect of an acute exercise bout and training state on non-polar metabolites 
*P=0.0004, repeated ANOVA mean fold change post-exercise: trained vs. untrained. Vertical bars 
denote 0.95 confidence intervals. Normalised data to pre-exercise (T & UT) = 1.0 
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Figure 39. Interaction effect of exercise and training state on polar metabolites 
 
*P<0.00001, repeated ANOVA mean fold change post-exercise: trained vs. untrained. Vertical bars 
denote 0.95 confidence intervals. . Normalised data to pre-exercise (T & UT) = 1.0 
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Identification of the metabolites that caused the peak in the results trace:  The specific 
polar metabolites that caused the peak in the results trace have not yet been identified, 
but preliminary studies have been conducted to identify the non-polar metabolites. 
SAM identified six metabolite peaks in the non-polar fraction of muscle extracts that 
were significantly different between trained and untrained participants in the rested, 
fasted state (Table 16). In the untrained participants, there were four non-polar 
metabolites that increased after single-leg endurance exercise (Table 17).  
In trained participants there were 76 metabolites increased following the bout of 
single-legged endurance exercise (Table 17). The results are shown in tables 16-18 
with the altered DIMS peaks and their putative identification. Metabolites are grouped 
(putatively) by main- and then sub-class (in alphabetical order).   
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3.4. Discussion  
 
 The main purpose of this study was to examine the response of lipid species to 
an acute bout of endurance-type exercise and to compare the responses between 
sedentary and endurance trained individuals. The major novel findings were that 
trained and untrained individuals both showed significant exercise-related increases in 
non-polar lipid metabolites within the musculature, but the observed increases were 
much greater in trained individuals. There were also significant differences in polar 
metabolite responses following an acute exercise bout, but no preliminary 
identification has occurred on these to date (further elaboration is not possible as no 
further analysis was performed due to no more financial or technical resources 
remaining.  
 Overall results reveal the complex substrate and energetic response to exercise 
and suggest that through exercise training it is possible to up regulate lipid metabolic 
responses. It should be noted that the non-polar metabolites have only been tentatively 
identified, therefore the following text should be read with this firmly in mind.  
 The endurance-trained individuals in this study had higher aerobic capacity 
compared with the untrained participants and had lower body fat and larger leg 
muscles, which are all probable adaptations to their exercise training regimens. During 
the two-legged exercise bout, we did not observe differences between trained and 
untrained participants in the RER at submaximal exercise intensities, but it is pointed 
out that the ramped incremental protocol utilised in the present study is not appropriate 
to examine fuel utilisation (reflected in the steady-state RER) because participants 
never reach a steady state. Thus, although not demonstrated in this study, it is widely 
known that endurance trained individuals have higher rates of fat oxidation and 
mitochondrial density (Gollnick et al., 1973; Hoppeler et al., 1985).  It is possible that 
the marked increase in 76 lipid species seen in the musculature of trained participants 
as well as higher circulating LDL following exercise is related to an enhanced 
localised fatty acid oxidation and overall lipid metabolism. 
 The lipid species have been tentatively identified (putative ID - main class, sub 
class). Many were glycerophospholipids – Table 18. These are primarily membrane 
components but they can also produce “lipid mediators that not only transduce signals 
from the cell surface to interior, but also modulate intracellular metabolism, ion 
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transport, and gene expression” (Mathews et al., 2000; Farooqui, 2009). These same 
compounds are involved in fatty acid metabolism, especially TAG and cholesterol 
transport (Mathews et al., 2000). Interestingly the physiologically potent compound 
Platelet Activating Factor (PAF-1) has the same structure as the compound 1-alkyl,2-
acylglycerophosphocholines Ttable 18) (Mathews et al., 2000). This compound has 
many important physiological effects including stimulation of blood platelet 
aggregation, reduction of blood pressure and stimulation of glycogenolysis (Mathews 
et al., 2000). Diradylglycerols were also significantly increased in trained participants 
following a single exercise bout.  They are thought to stimulate phospholipase A2 
(itself a key enzyme involved in the inflammatory/signalling pathway and importantly 
involved in hydrolysis of glycerphospholipids (Mallat et al., 2010)), and is a key 
intracellular messenger involved in the mediation of agonist-induced vascular smooth 
muscle cell contraction (Hui et al., 1992). Eicosanoids were also increased after 
training.  They are important signalling molecules, controlling inflammation and are 
derived from DAG’s and phospholipids. Prostaglandins, a subclass of eicosanoids, 
have been shown to be involved in vaso-constriction/-dilatation and angiogenesis 
(Lord et al., 2007). The unsaturated fatty acid docosahexaenoic acid (DHA) up-
regulates fatty acid oxidation in skeletal muscle (and increases total glycogen storage) 
(Clarke, 2001), and is an activating ligand for many transcriptional factors controlling 
beta-oxidation (Clarke, 2001). DAG, TAG, fatty acids, cholesterol esters, and 
gangliosides are further examples of tentative lipid species, which are important in 
lipid metabolism. These data suggest that trained participants demonstrate a clear up-
regulation of lipid species, which supports the general view of a greater reliance on 
lipid metabolism in conditioned working muscle.  
 Our observations of altered skeletal muscle lipid species following exercise, 
reported above, were made after the participants completed a bout of intense single-
legged endurance exercise. Although two-legged exercise is more conventional and 
better reflects usual physical activities in daily life, it has been shown that the leg 
muscles of different people can receive different exercise intensity during moderate 
intensity conventional endurance exercise (McPhee, 2009).  Single-leg exercise was 
therefore chosen to ensure that the exercise stimulus received by the working muscles 
was similar in all participants, irrespective of differences in training status, stature or 
other physiological variables such as cardiac output. The single-leg exercise bout was 
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set at 60% Pmax and continued for 20 minutes. At this exercise intensity it is expected 
that fat oxidation would be at or close to maximum, but glucose metabolism would 
also be concomitantly high. The RER during single-leg exercise of both trained and 
untrained subjects reached a steady state at around 0.89, indicating that a combination 
of fat and glucose was being utilised. But, it is pointed out that the RER during single-
leg work does not provide a true representation of the metabolism of the exercising leg 
because the gas exchange was measured at the pulmonary level where it had been 
diluted and influenced by metabolism in other parts of the body. 
 
To the author’s knowledge this study is the first time metabolites have been 
(tentatively) identified in skeletal muscle in untrained, trained; at rest and following a 
single-legged bout of endurance exercise. Previous work investigated serum 
metabolites (Yan et al., 2009; Lehmann et al., 2010; Lewis et al., 2010), their profile 
at rest, post exercise and in trained individuals. However, our results here, measured 
from the non-polar fraction of skeletal muscle do suggest that there may be important 
metabolites related to energy metabolism (especially lipid), which are differently 
regulated in trained populations. Interestingly, these do not belong to the conventional 
metabolites/pathways. This is in agreement with Yan et al. (2009), who found no 
differences in “normal” biochemical parameters associated with training. 
 It remains a possibility that a different metabolic response of lipid species 
could be observed following two-legged endurance exercise and/or exercise of longer 
duration, where it is known that fat oxidation contributes a relatively greater fraction 
of the overall energy utilisation. 
 
3.5. Conclusion 
 
 Endurance trained and untrained individuals did not differ significantly for 
their skeletal muscle lipid species when in a fasted, rested state. However, following a 
bout of high-intensity single-leg endurance exercise, the trained individuals’ 
upregulated 76 lipid species whereas the untrained individuals upregulated only 4. 
These results suggest that trained individuals display a much greater ability to up-
regulate lipid pathways during endurance exercise. A major theme in the affected 
metabolite classes concern lipid mediators involved in signal transduction as initiated 
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in the plasma membrane (i.e. glycerophospholipids). It also appears that the affected 
pathways are not part of metabolic substrate pathway that fuel contraction but rather 
plasma membrane associated. This may indicate signalling? 
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Chapter 4 
 
 
 
 
 
 
Does the ACE I/Dp Genotype Modify 
Plasticity of Skeletal Muscle in Untrained 
and Trained British Citizens? 
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4.1. Introduction: molecular and metabolite responses to muscle whole-body  
work  
 
 Exercise phenotypes and the implication of muscle plasticity to adjustments 
with training. New UK physical activity guidelines were produced in July 2011 by the 
four home countries’ Chief Medical Officers: Start Active, Stay Active (CMO, 2011). 
This document laid out key recommendations that highlighted the importance of 
regular exercise for health: at least 150 minutes per week, mixed modalities of 
exercise, e.g. endurance and resistance, and stressed the importance of intensity – 
specifically stating vigorous type exercise. Finally there was a recommendation that 
sedentary type behaviour (watching TV, sitting, reading etc) should also be reduced, 
and that this in itself is a health risk, even in those meeting physical activity 
recommendations.  The link between sedentary behaviour being detrimental to long-
term health is not new to those in the field of exercise physiology and health (Booth et 
al., 2002; Hu et al., 2003; Lees & Booth, 2004) (see section 1.1.3, Table 3). But, this 
important point has been now been recognised in guidelines intended for the general 
public.  
 Regular exercise has many benefits (see section 1.1.3), of which there are three 
basic exercise or training patterns that can be followed: endurance, strength or a 
combination of these (as recommended by the new UK physical activity guidelines: 
CMO, 2011). The type of exercise has a profound effect on physiological adaptations, 
especially adaptations of muscle (see Figure 2).  
Endurance type training is associated with increases in whole-body oxygen uptake 
capacity and aerobic fitness through local and systemic related metabolic and local 
changes especially processes of energy metabolism. With the most notable adaptations 
being: increases in mitochondrial (and related enzymes) and capillary density 
(Gollnick et al., 1972; Costill et al., 1976; Spurway & Wackerhage, 2006) – occurring 
preferentially in slow oxidative fibres (Rossiter et al., 2005) – plasma volume and 
myoglobin content (Astrand, 2003; Spurway & Wackerhage, 2006), TCA enzymes 
(Jones, 2004), heart size (left ventricular hypertrophy) and stroke volume (Gledhill et 
al., 1994; Moore & Palmer, 1999; Astrand, 2003).  
Strength type training is associated with stimulation of signalling pathways specific to 
the hypertrophic response (Spiering et al., 2008) and subsequent protein synthesis 
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(providing adequate nutrition) leading to increased fibre size (hypertrophy) (Astrand, 
2003; Jones, 2004; Atherton et al., 2005; Spurway & Wackerhage, 2006). Although it 
is important to note that physiological and structural adaptations are exercise specific, 
it is possible to observe both increases in capillarity and mitochondrial density in 
highly glycolytic muscle – if the exercise type mainly stimulates these fibres, such as 
interval sprint training (Gute et al., 1994; Glowacki et al., 2004). Concurrent exercise 
training (endurance and strength) was first thought to interfere, where strength training 
gains were prevented by endurance training (Hickson, 1980). However, since then 
studies have both supported (Craig, 1991; Hennessy, 1994; Bell et al., 2000) and 
refuted this theory (Sale et al., 1990; Wood et al., 2001; McCarthy et al., 2002).  
 From chapter two we provided evidence that adjustments in skeletal muscle, 
recruited during exercise, play an important role for fine-tuning in metabolic fitness 
with endurance training. In this chapter we will provide evidence that a specific 
genetic polymorphism modifies the implicated biochemical process in skeletal muscle. 
  
The rest of this chapter will focus on the related effects of endurance training/exercise. 
 
Gene expression reflects remodelling of muscle: Molecular biology has produced a 
highly resolved picture on the sequential time course and breadth of adaptation to 
external stressors. With the advent of technologies like microarrays the expression of 
hundreds (if not thousands) of different genes have been studied in skeletal muscle 
(Cameron-Smith, 2002; Keller et al., 2011). Sections 1.1.3, 1.1.4 and 1.1.5 provide 
further detail on genes/gene expression and exercise. In addition some of the more 
studied transcript level adjustments, during recovery from endurance exercise, are 
briefly mentioned here, especially those involved in energy metabolism and vascular 
remodelling. 
 ATP provides the energy for muscle contraction, therefore anything that affects 
its availability or levels will have profound effects. It is the splitting of the high energy 
phosphate bonds to liberate Pi from the ATP molecule that provides the energy to 
drive muscle contraction.  This then leaves ADP, which can be further broken down to 
AMP.  As rates of ATP turnover are increased with increasing intensity of exercise, so 
the concentration of the intermediates ADP and AMP are also increased. AMP can be 
thought of as the cells energy sensor, involved in stimulating the activity of a key 
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phosphorylation enzyme: 5’adenosine monophosphate activated protein kinase 
(AMPK) (Hardie & Sakamoto, 2006). AMPK plays a key role in activation of fatty 
acid metabolism (Winder et al., 2000), especially involving the activation of a key 
mitochondrial biogenesis regulator, PPAR-γ coactivator-1α (PGC-1α) (Wu et al., 
1999), but also stimulates the expression of GLUT-4 receptors and the translocation of 
GLUT-4 to the cell membrane to enhance the take-up of glucose into the cell (Holmes 
et al., 2005).  AMPK is not the only signalling molecule activated as a consequence of 
muscle contraction.  It is now appreciated that muscle contraction produces very many 
stimuli that have been shown to activate a variety of signalling processes, from 
substrate intermediates, to calcium, hypoxia, mechanical stretch-activated proteins, 
CO2 and so on (Booth, 1996; Fluck & Hoppeler, 2003). Other genes whose expression 
levels are of interest following endurance exercise (some well studied, some less so) 
include: lipoprotein lipase (LPL – lipid metabolism, (Pilegaard et al., 2000)), vascular 
endothelial growth factor (VEFG – angiogenesis (Richardson et al., 1999)), 
cytochrome c oxidase subunit I/IV (COX-I/IV – components of the respiratory chain 
in mitochondria, (Hood, 2001)), mitochondrial transcription factor A (Tfam – involved 
in mitochondrial biogenesis, (Hood, 2001)), hypoxia inducible factor 1 (HIF-1, 
transcription factor responding to low oxygen levels, and which regulates the 
expression of other genes involved in energy metabolism and angiogenesis, (Semenza, 
2000). Expression in skeletal muscle of less well studied genes includes: tenascin C 
(TnC, mechano-regulated extracellular matrix protein associated with remodelling, 
(Fluck et al., 2008)), bradykinin receptor type 2 (BK2, mediates most of the 
physiological effects of the bradykinin, which is an important indirect vasodilatory 
factor (Figueroa et al., 2001)), high molecular weight kininogen (HMWK, the 
precursor to Bradykinin (Offermanns, 2008), angiotensin converting enzyme (ACE, a 
key regulatory enzyme which produces the body’s major vasoconstrictory peptide 
angiotensin 2 – Ang2, (Sturrock et al., 2004)), and angiotensin converting enzyme 
type one receptor (AT1R, main Ang2 binding receptor eliciting the classical actions of 
the RAS, (Baker & Kumar, 2006; Fyhrquist & Saijonmaa, 2008).   
In search of master regulators of muscle phenotype: Based on screening of 25,000 
possible factors encoded in the human genome a few distinct candidates for main 
genetic influences evolve from association of polymorphisms with fitness (Wolfarth, 
2001). Chapter one section 1.1.5 provides more detail, especially Tables 6 and 7, with 
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linked text. One of these polymorphisms is the angiotensin converting enzyme 
insertion/deletion polymorphism (ACE I/Dp). It is the presence of an Alu insertion 
sequence (I-allele) and its association with elevated endurance performance and its 
trainability that has generated much interest over the last 20 years. See section 1.2.1 
for an overview of the ACE I/Dp. 
Mechanism of ACE action: The mechanism of ACE action on exercise phenotype is 
not known. Current investigations favour a role of its product, Ang2, as it has been 
shown to regulate local energy metabolism, angiogenesis, and is needed for optimal 
over-loaded skeletal muscle hypertrophy, via AT1R receptor (Figure 40) (Rattigan et 
al., 1996; Gordon et al., 2001; Henriksen et al., 2001; Henriksen & Jacob, 2003; 
Dietze & Henriksen, 2008).  
However, there are reports for an opposing role of Ang2 on anti-angiogenesis via 
AT2R (Munzenmaier & Greene, 1996). Conversely ACE also acts via breakdown of 
the vasodilators, the kinins (Drexler & Hornig, 1999) (Figure 41). The contribution of 
either of the possible ACE affected pathways and particularly to ACE modulated 
exercise phenotype has not been resolved: “Much of the mechanisms underlying this 
(ACE I/Dp importance as a single factor in the determinant of sporting performance) 
remain unexplored despite 12 years of research” (Puthucheary et al., 2011). 
 
 
 
Figure 40. Effects of angiotensin 2 on muscle performance 
Abbreviations: FGF, fibroblast growth factor; TGF-β, tumour growth factor-beta, PDGF, platelet 
derived growth factor (Jones & Woods 2003) 
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It has been shown that altered control of gene expression in stressed muscle provides 
an indication of those mechanisms which are involved in signalling processes (Gracey 
et al., 2004). If ACE controls globally the aerobic phenotype one would expect to see 
some evidence for this at the level of muscle structure and transcript expression (as 
distinct messengers encode factors that regulate metabolism and make up functional 
elements). 
Muscle’s metabolite response: As already highlighted in the introductory chapter 
(section 1.1.4) measuring gene expression, in isolation of other factors, can lead to 
misleading conclusions, as protein expression is not necessarily affected (Mata et al., 
2005). By using the same metabolomic approach highlighted in chapter two we were 
able to compare and contrast the influence, if any, of the ACE I/Dp on global polar 
and non-polar metabolites at rest, following an acute exercise test, and between 
training states – in the local muscle. 
   
We hypothesized: that the ACE I/Dp modifies the muscle phenotype and its metabolic 
response to endurance exercise and that these effects would be modulated by training.   
 
Figure 41. Hypothetical illustration of ACE signalling 
Figure visualizing the hypothesized points of ACE signalling action, which were assessed at the level of 
transcript expression 
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4.2. Methods 
 
4.2.1. Experimental Design 
 
 The above hypothesis was tested by assessing the effect of the absence or 
presence of the ACE I-allele on muscle anatomy and the response of muscle 
metabolites and gene expression to a bout of endurance exercise.  Towards this end we 
assessed to which extent elements of Ang2 signalling processes (TnC, AT1R, AT2R, 
ACE, LPL, BK2R, HWMK, COX-IV, GLUT-4, Figure 41) show different transcript 
expression in skeletal muscle, at rest and in recovery from exercise, due to the absence 
of ACE I-allele.   
 The study design was intended to expose the relation of the local muscle and 
system metabolic response, with a single bout of one legged endurance exercise (see 
2.2.1 for rationale of using one legged testing) on a bicycle, to the ACE I/Dp and the 
interaction with training status and its major product Ang2. The same participants as 
reported in chapter two were assessed but grouped based on genotyping for the ACE I-
allele. The experimenter was blinded to each participants ACE I/Dp genotype until all 
tests and experiments had been completed. Figure 42 illustrates the blinding protocol.  
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Rationale for tests  
 
Rationale for the tests is basically the same as in chapter 3 (section 3.2.1). The 
rationale for choosing the single transcripts of interest is explained above (see Figure 
41) and the sequences outlined below in Table 19.  
 
 
 
 
 
 
        
Figure 42. ACE I/Dp genotype blinding protocol 
  DoS: Director of StudiesProtocol and overview of how the author performed the ACE I/Dp genotyping 
without knowing which sample belonged to which participant. Blinding refers to the fact that the principle 
investigator was never informed of the ACE I/Dp genotype of each sample until after all tests/experiments 
had been completed. The four letter codes (e.g. NZXS) refer to the code generated by the person that 
anonymises (blinds) the samples 
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4.2.2. Participants 
 
 Twenty healthy males (with no known medical problems) aged 19 – 38 
participated in this study. Exclusion criteria included smoking, long-term ill-health, 
female, and not within the study age range (18 – 39). Participants all gave their written 
informed consent before undertaking any testing. The study and all tests were 
approved by the ethics committee of Manchester Metropolitan University. 
 Participants were deemed to be trained if they had a VO2max >50ml/min/kg 
unless they deemed themselves unfit and sedentary or had indicated, by questionnaire 
and orally, the only activity they did was walking. This was the case of two of the 
untrained participants who had a VO2max > 50ml/min/kg. 
 
The methodology is listed below. A full description of study methodology can be found 
in the methods chapter (2).  
 
4.2.3. List of all Tests/Measures (see methods chapter for description) 
 
Same tests/measures in section 3.2.3. 
In addition the following tests were carried out relevant to this study: 
ACE I/Dp genotyping 
ACE I/Dp related transcript analysis 
Table 19. mRNA primer sequences used for real-time PCR. 
 
All transcripts were detected with the exception of AT2R, BK2R and HMWK. 
 
 111 
4.2.4. Statistics 
 
 An unpaired test (Student’s T-test) was used to compare ACE I/Dp genotype 
physiological and local muscle differences. 
 A three way ANOVA was run to expose effects of the repeated factor, post 
versus pre exercise, and its interaction with the “ACE -allele” and “training state” 
using Statistica 9.1 using post-hoc test of Fisher (Statsoft, Tulsa, USA). ACE I/Dp 
genotype effects at rest and its interaction with training were assessed with a two-way 
ANOVA. 
 
4.3. Results 
 
 ACE I/Dp dependent exercise phenotype and interaction with training state: 20 
prticipants were investigated for ACE genotype dependent physiological variables of 
exercise capacity. The Hardy-Weinburg Equilibrium (HWE), which tells us about the 
relataive frequencies of alleles (and variability/stability from generation to generation), 
has been shown to be consistently met in studies investigating the ACE I/Dp 
(Montgomery et al., 1998; Hagberg, et al., 2002). However, low number of samples 
(participants) is often quoted for not being able to calculate the HWE – our study 
sample number was low (n=20), therefore it was not possible to calculate whether the 
HWE was met. However, when all participants (n = 60) who were genotyped were 
taken into consideration (II 13.3 %: ID 66.7%: DD 20.0%) the HWE was satisfied.  
Table 20 lists the ACE I-allele dependent participant characteristics. 
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There were no significant interactions between ‘ACE I/Dp genotype’ and ‘training 
status’ (including age) on any of the assessed physiological variables of exercise 
performance (2-way ANOVA for factors 'presence of the ACE I-allele' x 'training 
status').  
 
Table 20. Participant characteristics grouped by ACE I/Dp genotype. 
ACE IDp genotype 
   DD (n = 11)         ID + II (n = 9)          P 
Age (years)  25.2 (19:36) 27.3 (21:38) 0.46 
Body mass (Kg)  75.5 (60:93) 79.8 (65:99) 0.38 
Height (M)  1.81 (1.67:194) 1.81 (1.77:1.91) 0.97 
BMI (Kg/M
2
)  23.0 (18.5:27.6) 24.3 (20.3:31) 0.37 
Body fat (%)  17.4 (8.8:29.4) 17.8 (6.1:32) 0.90 
VO2max (ml/min/Kg): 2-leg 54.5 (43.2:70.1) 55.3 (46.9:66) 0.83 
VO2peak (ml/min/Kg): 1-leg 44.8 (34.2:52.2) 46.6 (41.2:56.0) 0.49 
VO2max (ml/min): 2-leg 4101.7 (3217:5319) 4385.1 (3115:5288) 0.44 
VO2peak (ml/min): 1-leg 3377.1 (2397:4719) 3700.7 (2677:4616) 0.26 
Pmax (W): 2-leg 301.4 (230:410) 348.9 (250:450) 0.11 
Pmax (W): 1-leg 193.6 (140:260) 217.2 (145:275) 0.22 
Pmax (W/Kg): 2-leg 
Pmax (W/Kg): 1-leg 
3.98 (3.31:4.67) 4.40 (3.43:5.42) 0.16 
2.56 (2.00:3.40) 2.73 (2.22:3.41) 0.39 
RER: 2-leg (start of exercise)
a
 0.81 (0.71:0.87) 0.79 (0.72:0.86) 0.32 
RER: 2-leg (end of exercise)
a
 1.09 (0.96:1.17) 1.00 (0.99:1.18) 0.42 
RER: 1-leg (start of exercise)
a
 0.78 (0.67:0.90) 0.75 (0.65:0.83) 0.39 
RER: 1-leg (end of exercise)
a
 1.06 (0.92:1.22) 0.98 (0.99:1.15) 0.67 
 
There were no significant differences at the physiological level between the genotypes.  Assessed by 
unpaired Student’s T-Test. aDD n=8, aII/ID = 8 
a
DD n = 8, II/ID n = 8 
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ACE dependent muscle phenotype: There was a significant effect of the presence of 
the ACE I-allele on muscle capillarity. Participants with the ACE I-allele showed  
 
greater capillary density in the vastus lateralis muscle than those without the I-allele 
(p=0.04). The training state did not demonstrate a significant interaction with this 
genotype difference (p=0.25). 
ACE I/Dp dependent muscle metabolite response: We assessed whether the ACE-
dependent difference in muscle capillarity would be reflected by an altered response of 
metabolites in serum and at the level of the recruited vastus lateralis muscle. From the 
panel of selected serum metabolites of glucose and lipid metabolism, which were 
measured immediately after the exercise, LDL concentration demonstrated a 
significant interaction effect of the ‘exercise response’ x ‘ACE I-allele’ x ’training 
state’ (p=0.03).  
Post hoc testing resolved that LDL was significantly reduced in trained participants 
without the I-allele (p=0.04).   
 
 
Table 21. Participant muscle characteristics grouped by ACE I/Dp genotype. 
  ACE I/Dp genotype 
    DD (n = 11)                                ID + II (n = 9) P 
Quadriceps volume (cm
3
) 2075.1 (1419:2919) 2290.3 (1672:2949) 0.29 
Capillary density (mm
-2
) 277.3 (207:345) 311.4 (282:352) 0.04 
Type I fibre (%)
a
  41.81 (34.80:52.60) 41.5 (38.0:63.0) 0.96 
                 
Capillary density (mm
-2
) significantly different greater in genotype with the I-
allele (P=0.04, assessed by unpaired Student’s T-test).  aDD n = 10 
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We assessed the local changes of polar and non-polar metabolites in vastus lateralis 
muscle 30 minutes after single leg exercise with mass spectrometry. There was an 
interaction effect, between ‘ACE I-allele‘ x ‘post exercise response’ (P=0.009) and 
between ‘ACE I-allele‘ x ‘post exercise response’ x ‘training state’ (P=0.0002), for 
non-polar metabolites (Figure 43). Post hoc tests showed that the selective increase in 
non-polar metabolites in ACE-DD genotypes in untrained participants is lost in trained 
participants as both genotypes demonstrate an increase.  
 Similar observations were made for the exercise induced changes in polar 
metabolites assessed with LCMS in positive (LCMS_ESI+, Figure 45) and negative 
(LCMS_ESI-, Figure 44) mode, although using LCMS_ESI+ this interaction was not 
significant. 
 Interestingly, the genotype effects on the exercise response of muscle 
metabolites in the untrained state were all lost in trained participants (Figure 45).  
 
Figure 43. Interaction effect of ACE I/Dp genotype and training status on the exercise response of 
non-polar metabolites 
*P=0.001, Repeated ANOVA, vs. pre exercise without the I-allele. **P=0.001, Repeated ANOVA, 
vs. post-exercise with the I-allele. 
$
P=0.001, Repeated ANOVA, vs. pre exercise with or without the 
I-allele. Vertical bars denote 0.95 confidence intervals.  
Normalised data to pre-exercise (T & UT) = 1.0 
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Figure 44. Interaction effect of ACE I/Dp genotype and training status on the exercise response of 
polar metabolites (LCMS_ESI-). 
*P<0.05, Repeated ANOVA, vs. with I-allele post exercise. **P<0.001, Repeated ANOVA, vs. pre- 
exercise with I-allele. 
$
P<0.001, Repeated ANOVA, vs. with I-allele pre-exercise. Vertical bars 
denote 0.95 confidence intervals.  
Normalised data to pre-exercise (T & UT) = 1.0 
  
 
 
 
Figure 45. Interaction effect of ACE I/Dp genotype and training status on the exercise response of 
polar metabolites (LCMS_ESI+) 
*P<0.001, Repeated ANOVA, vs. pre-exercise with the I-allele. **P<0.001, Repeated ANOVA, vs. 
pre-exercise without the I-allele. 
#
P<0.001, Repeated ANOVA, vs. pre-exercise with the I-alelle. 
$
P<0.001, Repeated ANOVA, vs. pre-exercise with the I-allele. 
†
P<0.05, Repeated ANOVA, vs. 
exercise without the I-allele. Vertical bars denote 0.95 confidence intervals.  
Normalised data to pre-exercise (T & UT) = 1.0 
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ACE I/Dp dependent muscle gene response:  We analyzed the effect of the ACE I/Dp 
genotype on combined transcript expression in vastus lateralis muscle using reverse-
transcriptase polymerase chain reactions (rt-PCR). A number of gene transcripts for 
factors of Ang2 signalling (AT1, AT2, BKR2, HMWK, Tn-C) and (ACE dependent 
factors) involved in substrate import from the capillaries (Glut-4, LPL) and oxidative 
metabolism (COX-4) were selected. All were detected except AT2, BKR2 and 
HMWK – it’s possible they were not present or below the dection limit. 
 There was a general interaction between “ACE I/Dp genotype” x “training 
state” on expression of the selected transcripts at rest (P=0.02, Figure 46). 
In untrained participants there was a significant interaction effect between 'ACE 
genotype' and the response to exercise when all transcripts were assessed combined 
(P=0.05). This interaction effect did not reach the level of statistical significance in 
trained participants (P=0.184).   
 A detailed inspection of the ACE I/Dp genotype identified single transcripts 
that were modified (Figures 47, 48). Significant effects for single gene transcripts 
involved higher ACE mRNA level in vastus lateralis muscle of untrained participants 
without the ACE I-allele, and a significant reduction eight hours post exercise (Figure 
 
Figure 46. Interaction of ACE I/Dp genotype and training status of combined muscle transcripts 
P=0.02, Two-way ANOVA, ACE I/Dp genotype x training state, combined muscle transcripts: ACE, AT1R, 
TnC, GLUT-4, LPL, COX-4. Vertical bars denote 0.95 confidence intervals.  
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47). Also, LPL mRNA was reduced in untrained participants without the ACE I-allele 
eight hours post exercise (Figure 47). Both these differences were lost in the trained 
state (Figure 48). 
 
 
TnC mRNA also showed elevated expression in genotypes with the I-allele in trained 
participants only (p=0.02, Figure 48), but this difference was lost eight hours post 
exercise. The changes in transcript expression eight hours into recovery demonstrated 
a general interaction effect with the ‘presence of the ACE I-allele’ and training state 
(p=0.04). When the ACE I/Dp genotype dependent effect was assessed for each 
transcript only for COX-4 was this interaction preserved (p=0.07).  
 There was a generally elevated level of transcript levels in untrained ACE I/Dp 
genotypes without the I-allele pre-exercise (p=0.03). This was lost post-exercise.  
                                                
 
 
 
 
Figure 47. Pre- and post-exercise effects for each muscle transcript between ACE I/Dp genotypes in 
untrained participants. 
Transcripts [per 28s rRNA], untrained cohort.  
+
: 0.05< p <0.10vs. pre other genotype, 
++
: p< 0.05 vs. pre other genotype, 
*
: 0.05< p <0.10vs. pre same 
genotype, 
**: p< 0.05 vs. pre same genotype. MANOVA for the repeated factor ‘time respective to 
exercise’ (i.e. pre vs. 8 h post) with a post hoc test of Fisher. Mean and standard error of muscle transcript 
levels pre and post exercise. 
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4.4 Discussion 
 
 The insertion polymorphism in intron 16 of the ACE gene has firmly been 
related to endurance performance and the training effect of exercise (Montgomery et 
al., 1998; Williams et al., 2000). The contribution of a muscle mediated mechanism to 
this phenomenon is not understood (Puthucheary et al., 2011). We show that this ACE 
I/Dp influences both the molecular and metabolite response to an acute bout of 
exercise, and that local delivery vessels are altered. Plus, we identified that the ACE 
I/Dp modulates muscle metabolites, non-polar and polar differently, as a consequence 
of the environmental stimulus of regular endurance exercise (trained state). There was 
a blunting of muscle polar metabolites in the trained population (Figures 44, 45). 
However, the blunting of non-polar muscle metabolites was over-ridden in the trained 
population with the I-allele, mirroring the trained population without the I-allele 
(Figure 43). Thus, the environmental stimulus of regular exercise (trained population) 
                                
 
Figure 48. Pre- and post-exercise effects for each muscle transcript between ACE I/Dp genotypes in 
trained participants 
Transcripts [per 28s rRNA], trained cohort.  
+
: 0.05< p <0.10vs. pre other genotype, 
*
: 0.05< p <0.10vs. pre same genotype. MANOVA for the 
repeated factor ‘time respective to exercise’ (i.e. pre vs. 8 h post) with a post hoc test of Fisher. Mean and 
standard error of muscle transcript levels pre and post exercise. 
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over-rides the ACE I/Dp effects on muscle metabolite metabolism during recovery 
from an acute bout of endurance exercise.   
 As our study was limited by a cross-titudinal design there is uncertainty 
whether the interaction of training and ACE I/Dp on the metabolome and transcript 
levels is explained by a direct effect of the repeated exercise. Thus, the general ACE 
I/Dp dependent regulation of transcript expression of factors involved in Ang2-
dependent signal processes, and key parameters involved in import of carbohydrate 
and lipid factors at rest and following endurance exercise is of interest (Figures 47 and 
48). There is support for a role of the environmental stimulus of exercise over-riding 
the genetic influence of the Alu insertion sequence in the ACE gene, due to the 
inversion of the ACE I-allele dependent exercise response.  Due to absent interaction 
effects of exercise and ACE I/Dp on single transcripts it is not possible to draw 
definite conclusions on ACE I/Dp control of the Ang2/RAS system. Bearing this in 
mind it is of interest to note the ACE I/Dp genotype effect on the two transcripts, ACE 
and TnC.  The higher ACE mRNA levels in ACE DD genotypes hints for the 
existence of a local ACE I/Dp modulated RAS system in skeletal muscle which 
expression is regulated by training. Equally it also suggests a role for TnC as 
downstream effector of ACE as indicated previously in cell culture (Hahn et al., 
1995).  
By contrast, our data does not support that altered expressional regulation of receptors 
downstream of ACE, Ang2 or BK signalling (i.e. BK2R, AT1R and AT2R) is 
involved in muscle's adaptation to endurance training. In fact, the undetected 
amplification of AT2R and main kinin receptor (BK2R) transcripts using RT-PCR 
with indicate a possible minor contribution of this system to ACE effects in the studied 
muscle. 
Our metabolomic scan identified a general effect of the ACE I/Dp on exercise-induced 
changes in metabolite levels in both polar and non-polar fractions of the exercised 
vastus lateralis muscle (Figures 43, 44, and 45). This implies that the ACE I/Dp 
influences variability in muscle’s metabolic response to exercise. A number of factors 
which warrant further exploration could account for this. One, possibly major 
contributor, is a net effect on blood vessels (perfusing muscle) capacity to vasodilate 
and therefore downstream effect on angiogenesis. This contention of a possibly altered 
perfusion is in line with the significant difference in capillary density in vastus 
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lateralis between ACE I/Dp genotypes, and the supply dependent muscle metabolome 
after a workout.  
 Interestingly, the ACE I/Dp dependent change in the polar fraction were 
completely blunted in trained participants (Figures 44, 45). These findings imply an 
important fraction of the ACE I/Dp genotype effect on metabolite flux is modified 
dependent on whether participants regularly perform physical activity. This finding 
suggests that regular exercise overrides to some extent the genetic inhibition of 
biological processes downstream of ACE which is evident at a muscle level at rest.   
 
4.5. Conclusion 
 
  From this small study, it appears that an Alu insertion sequence is possibly 
influencing different system level responses to an acute exercise bout. An aerobic 
phenotype would favour greater vascular space (capillary density) at the local working 
muscle to deliver and remove oxygen/carbon dioxide and energy substrates, which 
was evidenced in participants with the Alu insertion sequence. Participants without the 
insertion sequence (ACE DD) demonstrated: reduced capillary density, a greater 
reliance on local lipid metabolism (increased non-polar metabolites pre and post 
exercise) in the untrained state, and had reduced levels of LDL following an acute 
exercise bout in the trained state.  
 These results tentatively suggest that this Alu insertion sequence, in an 
important regulator of a key gene (ACE), which controls a major vasoconstrictory 
peptide (Ang2), favours the development of an aerobic muscle phenotype.  
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Stability of the ACE modulated muscle 
phenotype between populations with a 
specific ACE variant 
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5.1. Introduction  
 
 Endothelial cells play a vital role in substrate delivery to the working muscle, 
interacting and responding to local changes (Clifford & Hellsten, 2004). A key 
function of the endothelial cells is their role in altering blood flow by 
dilation/constriction. The ACE I/Dp may be involved in regulating substrate supply to 
working muscle, therefore it will influence the conditioning of metabolic fitness by 
endurance exercise. As we, and others, have shown in the previous chapter this 
involves capillary supply lines in muscle as one of the most plastic structures 
(Hudlicka et al., 1992). Whilst the literature is not conclusive there is evidence that 
reduced ACE activity is associated with a greater vascular space (Dietze & Henriksen, 
2008), increased glucose usage (Dietze & Henriksen, 2008; Jayasooriya et al., 2008), 
and a more reactive vasodilatory capacity (Brown et al., 1998b). This relationship is 
replicated with ACEi’s and in the presence of the insertion sequence – ACE II/ID 
(Buikema et al., 1996; Brown & Vaughan, 1998a; Brown et al., 1998b; Butler et al., 
1999; Arcaro et al., 2001; Henriksen & Jacob, 2003). Whilst ACE is found circulating 
free in plasma, the majority is (Danser et al., 2007) is anchored to endothelial cells 
(Figure 26 B). An often overlooked effect of increased ACE activity (when the Alu 
insertion sequence is missing) is not only an amplified production and/or conversion 
of Ang1 to Ang2, but also an increased degradation of BK (a potent dilatory factor) 
(Brown et al., 1998b; Murphey et al., 2000). Much of the literature on ACE I/Dp and 
human performance looks into the effects of the Alu insertion sequence and trainability 
or increased/decreased frequency in differently trained populations versus untrained 
controls (Montgomery et al., 1998; Myerson et al., 1999; Rankinen et al., 2000b; 
Hagberg et al., 2002; Scanavini et al., 2002; Hruskovicova et al., 2006; Pescatello et 
al., 2006; Thompson et al., 2006). Due to the plethora of factors influencing human 
performance it is not surprising to find much controversy, on the ACE I/Dp, in the 
literature. The influence (if it really exists) of the ACE I/Dp will likely be small but 
potentially significant due to the key end products it effects: Ang2 and BK. Studies 
have demonstrated that Ang2 increases with exercise (Staessen et al., 1987; Miura et 
al., 1994; Woods et al., 2004). However, sustained exercise (over 3 minutes) over-
rides constriction (Murrant & Sarelius, 2000). Therefore can training over-ride any 
influence of the ACE I/Dp, and if so at what system level? We found in chapter three 
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that training state ‘inverted’ ACE I/Dp dependence, but whether this was due to 
repeated endurance type exercise per se or the natural habitat of the participants is not 
known.  
 A potentially important factor contributing to the ACE I/Dp controversies is 
the consistency of its influence between different ethnic groups (Scott et al., 2005; 
Payne et al., 2007; Woods, 2009).  Therefore the role played by the genetic 
background and habitual factors probably interacts with other genes x environment on 
the ACE-related phenotype. These interactions are not related to ethnic differences in 
the ACE I/Dp allele frequencies, per se (see introduction – Figure 31).  
 
We hypothesised: that the exercise induced pathway of ACE related muscle signalling 
is preserved, in different populations, as this environmental stimulus reflects a 
dominant perturbation of the Ang2 signalling pathway.  
 However, steady state differences in physiological variables relating to the trait 
of metabolic fitness between genotypes of the ACE I-allele may not necessarily be 
preserved between populations (see section 1.2.6 for a brief explanation of differences 
in the ACE I/Dp and ethnicities). This was tested by comparing a Swiss and British 
population – even though both populations are caucasion, their culture, habitat 
(altitude) and ancestry is different – (over ten’s of thousands of years and beyond).  
   
5.2 Methods 
  
5.2.1. Experimental Design 
 
 Using an integrative approach two cohorts of healthy, male Caucasians were 
investigated: Swiss and British cohorts. Both cohorts were analysed for the ACE I/Dp 
genotype, and their gene expression response and organelle content, in relation to 
energy substrate usage and pathways, in recruited vastus lateralis muscle at rest. This 
muscle tissue was chosen due to its important recruitment during the exercise tests on 
the bicycle (Krustrup et al., 2004b).  
 In addition a subset of the Swiss cohort was also assessed following an 
endurance training regime, and the British cohort was split into trained and untrained 
subsets.  Whole body aerobic capacity was also assessed.  
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Rationale for tests 
 
Rationales for tests (for the British cohort) is the same as chapter 3 (section 3.2.1). As 
the Swiss data came from study data already analysed (see 5.2.2.) the only extra test 
required was the ACE I/Dp genotyping.  This analysis was carried out in collaboration 
with Prof. Hans Hoppeler from the University of Berne. The author’s role in this 
specific part of the study was limited to the ACE I/Dp genotyping of each sample, 
which was performed using preserved skeletal muscle material (see chapter 2 – 
methods, and 5.2.3. below).  
 
5.2.2. Participants 
  
 Age, height, body mass, and percent body fat were recorded for all participants 
in both the Swiss and British cohorts.  
The Swiss cohort comprised two not systematically trained, Swiss populations (males) 
from the Canton of Berne (Switzerland), from two studies which underwent an 
endurance program composed of 6 weeks of bicycle exercise or 6 months of jogging 
as described were included in the analysis (Suter et al., 1995; Schmutz et al., 2006; 
Schmutz et al., 2010). The investigations were conducted with permission of the 
Ethics Committee of Bern, Switzerland, in compliance with the Helsinki Convention 
for Research on human participants. 
The British cohort comprised 9 untrained and 11 trained males from the Manchester 
area of the UK (see section 3.2.2).  The study and all tests were approved by the ethics 
committee of Manchester Metropolitan University. 
 Participants were deemed to be trained if they had a VO2max >50ml/min/kg 
unless they deemed themselves unfit and sedentary or had indicated, by questionnaire 
and orally, the only activity they did was walking. This was the case of two of the 
untrained participants who had a VO2max > 50ml/min/kg. 
 
The methodology is listed below. A full description of study methodology can be found 
in the methods chapter (2). 
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5.2.3. List of all Tests/Measures (see methods chapter for description) 
 
British Population (Author’s own research/data) 
 
All tests/measures have already been covered in section 3.2.3 and 4.2.3. 
 
Swiss Population (Berne Uinversity research/data) 
 
Additional tests/measures done for the Swiss population, which is already published 
(Suter et al., 1995; Schmutz et al., 2006) 
Genotyping: For both cohorts, DNA isolation was performed from pooled 
cryosections of approximately 10 mg tissue of m. vastus lateralis following a 
commercially available protocol (Qiagen DNeasy Blood and Tissue Handbook, 
07/2006, cat. no. 69504). 
ACE genotyping was carried out with Polymerase chain reaction (PCR) as described 
by Evans et al., (1994) (Evans et al., 1994). The primers cor responded to those 
established previously for the identification of the ACE-I/D genotype (for details see 
Genebank number X62855): 
Detection of the 66 bp amplicon specific for the I-allele in intron 16 of the ACE gene 
was achieved by a combination of ACE2 (5’-tgggattacaggcgtgatacag-3’) and ACE3 
(5’-atttcagagctggaataaaatt-3’) primers. ACE1 (5’-catcctttctcccatttctc-3’) and ACE3 
(5’-atttcagagctggaataaaatt-3’) primers were applied to detect the 83 bp amplicon 
specific to the absence of the insertion sequence (i.e. the D-allele).  
Whole body aerobic capacity: Maximal oxygen uptake, peak power output and whole 
body respiration (from respiration exchange ratio) was determined with 
ergospirometry in an incremental endurance test on a stationary bicycle ergometer 
(Ergoline 800S, Jaeger, Ergoline 800S, Ergoline GmbH, Bitz) using a Cortex system 
(k4b2) as described (Suter et al., 1995; Schmutz et al., 2006).  
Endurance exercise: Participants from cohort one carried out a single bout of 
endurance exercise. Muscle biopsies were collected from vastus lateralis muscle for 
the purpose of profiling the transcript response into recovery from exercise as reported 
(Schmutz et al., 2006). The resting biopsy was collected two weeks before exercise. 
Thereafter participants carried out a single bout of two-legged endurance exercise at 
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65% peak power output after an overnight fast with collection of biopsies 1, 3, 8 and 
24 hours in alternating order from new incision sites in the left or right leg as reported 
(Schmutz et al., 2010).  
 
Participants from cohort two completed a 6-month endurance exercise training 
program comprising home-based jogging of 120 min/wk at 75% VO2max for which 
adjustments in muscle structure and whole body aerobic capacity had been described 
(Suter et al., 1995). The biopsies of cohort two were collected pre and post endurance 
training with Bergstroem needles. 
Muscle structure: Quantitative alterations in muscle ultrastructure were evaluated with 
established morphometrical technique from glutaraldehyde fixed muscle biopsies 
(Schmutz et al., 2006). In brief, this comprised the assessment of volume densities of 
myofibrils, total mitochondria, subsarcolemmal mitochondria, intramyocellular lipids, 
residual organelles and capillaries. Additionally muscle fibre cross section, capillary-
to-fibre ratio, and fibre types were estimated (Suter et al., 1995).  
Transcript profiling: Level alteration of gene transcripts for major function of skeletal 
muscle pre and 8 hours post exercise in the untrained and trained state in the subjects 
were evaluated in total RNA with validated low-density Atlas® cDNA arrays (BD 
Biosciences, Allschwil, Switzerland; (Schmutz et al., 2006). This time point was 
chosen as it refers to the peak response of transcript expression in untrained subjects 
(Schmutz et al., 2010). The array platform (GPL 1935 at Gene Omnibus, 
http://www.ncbi.nlm.nih.gov/geo) covered 231 transcripts from the major gene 
ontologies (GO) underlying muscle energy and protein metabolism, fibre structure and 
angiogenesis. Microarray data series were deposited under accession codes GSE 
13623 and GSE 2479, respectively, at GEO.  
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5.2.4. Statistics 
 
 Physiological and structural variables were assessed with Student’s t-test. A 
repeated ANOVA was applied to compare ‘pre vs. post’ effects of exercise or training 
between genotypes ‘with ACE I-allele’ (ACE-ID/ACE-II) and ‘without ACE I-allele’ 
(ACE-DD) for the measured variables (serum metabolites, ultrastructural variables) 
using Statistica 9 (Statsoft).  
Gene expression: Microarray data were background corrected as described (Schmutz 
et al., 2010). Subsequently, the background-corrected signals were related to the total 
count of transcript signal per array to reveal normalized values. Significant 
adjustments in muscle transcript expression following a single bout of endurance 
exercise and training, between ACE genotypes with or without the I-allele were 
evaluated from normalized values using a Significance Analysis of Microarrays test 
(SAM) running as applet in Excel software (Tusher et al., 2001). Default settings for 
two class paired data with post hoc T-tests were used during the calculation. The 
largest delta value, with the smallest significant false discovery rate (FDR, denoted as 
q-values), was set to calculate all differently expressed genes.  
 
 
5.3. Results  
 
 ACE I/Dp difference in oxygen dependent pathways: British versus Swiss 
population: We assessed whether ACE I/Dp differences of oxygen delivery and 
utilisation (maximal oxygen usage: VO2max, maximum power output: Pmax, capillary 
density: CD, and oxidative fibre type: Type I), seen in the British population (previous 
chapter, section 3.3), were preserved in a population of untrained Swiss males. 
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Table 22. Physiological characteristics of both cohorts: Swiss and British 
 
Swiss Cohort ACE I/Dp genotype 
  DD (n = 10) ID + II (n = 10) P  
Age (years)  30.5 (±2.7)  32.8 (±2.4)  0.53 
Height (M)  1.76 (±2.1) 1.76 (±2.6) 0.91 
Body Mass (Kg)  71.6 (±2.5) 79.6 (±5.1)  0.15 
BMI (Kg/M
2
) 23.0 (±0.5) 25.4 (±1.5)  0.11 
       
       
British Cohort ACE I/Dp genotype 
  DD (n = 11) ID + II (n = 9) P 
Age (years) 25.2 (±1.7) 27.3 (±2.3) 0.46 
Height (M) 1.81 (±0.02) 1.81 (±0.02) 0.97 
Body Mass (Kg) 75.5 (±2.7) 79.8 (±4.0) 0.38 
BMI (Kg/M
2
) 23.0 (±0.8) 24.3 (±1.2) 0.37 
 
Numbers represent mean (SE±). Unpaired Students T-Test. 
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Figure 50. Capillary density, without and with the I-allele, in British and Swiss populations 
*p=0.10. **p=0.04. Swiss n=10 with, and n = 10 without I-allele; British n = 11 with, and n = 9 without 
I-allele. Unpaired Students T-Test. (Error bars ± SEM). Swiss population biopsies taken with 
chonchotome – mid point of vastus lateralis; British population biopsies taken with fine-needle mid point 
of vastus lateralis. 
  
Figure 49. Maximal oxygen uptake and power output, without and with the I-allele, in British and Swiss 
populations 
Vertical bars denote 0.95 confidence intervals. 
Effect of ACE I/Dp genotype x population (VO2max and Pmax). 
VO2max x ACE I/Dp genotype x population: p=0.15 (Repeated ANOVA). Pmax x ACE I/Dp genotype x 
population: p=0.05 (Repeated ANOVA). 
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Figure 52. Type I muscle fibre differences, in British and Swiss populations without the I-allele.  
*p=0.02. Unpaired Students T-Test. Error bars ± SEM. 
 
Figure 51. Type I muscle fibre differences, in British and Swiss populations (not separated by ACE I/Dp) 
*p=0.06. Unpaired Students T-Test. Error bars ± SEM. 
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We explored whether exercise, which controls the pathway of oxygen utilisation and 
the product of the ACE gene (Ang2), is a factor in explaining these differences. 
Therefore we sought to uncover whether the ACE I/Dp genotype dependent muscle 
response of transcript expression, seen in the British cohort during recovery from a 
bout of endurance exercise (see chapter three), is preserved in Swiss participants of 
this study. The previously investigated factors of Ang2 signalling (ATR1, ATR2, 
BKR1, HWMK, TnC) and ACE dependent factors involved in substrate delivery from 
capillary (GLUT-4 and LPL) and oxidative metabolism (COX-4) were analysed in a 
previously published set of microarray data (Schmutz et al., 2006; Schmutz et al., 
2010).  
 There was a trend, in the British cohort, for a larger increase in expression of 
(all) transcripts in the vastus lateralis muscle eight hours post exercise, in participants 
with the I-allele   (p=0.07, ANOVA) (Figure 53). This trend for a larger increase of 
(all) transcripts was reproduced in the Swiss (p=0.06, ANOVA) (Figure 53). 
 
Figure 53. Fold changes in combined gene transcripts (pre- versus post-exercise) in untrained British 
and Swiss cohorts, split by ACE I/Dp genotype (please note scales not identical) 
British cohort: p=0.07, Swiss cohort: p=0.06 
Effect of ACE I/Dp genotype (ACE ID/ID versus ACE DD) x population (British: left figure, Swiss: 
right figure) on transcript fold change (eight hours post- exercise versus pre-exercise). Vertical bars 
denote 0.95 confidence intervals. 
British cohort data assessed from 28S related RT-PCR data with an ANOVA. 
Swiss cohort data assessed from background corrected microarray data with an ANOVA. 
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At the single transcript level the ACE I/Dp genotype dependent fold-change in 
untrained participants of only one factor, TnC, was statistically comparable between 
the UK and Swiss cohorts.  
 
A subset of the Swiss population underwent an endurance training programme (Suter 
et al., 1995; Schmutz et al., 2006), and this significantly increased muscle capillarity 
in participants without the I-allele. Conversely, increases in intramyocellular (IMCL) 
lipids were inhibited in participants without the I-allele (Figure 54). 
 
  
5.4. Discussion 
 
The influence of the ACE I/Dp in two different populations (Swiss and British) 
were compared, at rest, at different system levels (physiological, ultra-structural and 
molecular). The Swiss cohort was also assessed following an endurance training 
regime. 
 
Figure 54. Local muscle changes in the Swiss cohort following an endurance training programme 
Bar graph of mean +SE of fold changes in muscle parameters and VO2max in ACE I/Dp genotypes after 
an endurance training programme. N=10 with out I-allele, 9 with I-allele. *p<0.05 for post vs. pres 
changes (paired T-test). #p<0.05 for fold changes between ACE I/Dp genotypes (repeated ANOVA) 
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 Acute endurance exercise produces ACE dependent changes in substrate 
utilisation pathways to working muscle, of which capillary density and local lipid 
storage are influenced differently, following endurance training (only studied in the 
Swiss cohort).  
 The ACE I/Dp differences between the Swiss and British cohorts could 
possibly be explained by differences in physiological factors. The I-allele appears to 
be interacting differently dependent on population, as oxygen consumption and power 
output vary (Figure 49). This would suggest that other factors (environmental and 
physiological) are over-riding any influence of the ACE I/Dp. Further evidence of this 
is highlighted in capillary density between populations. There is a significant increase 
in capillary density in participants without the I-allele in the Swiss cohort, however the 
opposite is found (trend) in the British cohort (Figure 50). Evidence generally points 
towards increased capillarity in fibres with a high oxidative capacity, such as the type I 
fibres (Andersen & Henriksson, 1977; Laughlin & Roseguini, 2008), but ultimately 
capillaries will develop, regardless of fibre type, should demand necessitate (Egginton 
& Gaffney, 2010). Therefore you may expect to see a significant difference in 
capillarity between cohorts if one cohort had more type I fibres, as in the case here: the 
Swiss cohort displayed a trend for increased type I fibres, which became significant in 
the Swiss versus British cohort without the I-allele (Figure 52). Another study has 
investigated the association of fibre type and ACE I/Dp, but found a significant 
increase in type I fibres in the presence of the I-allele (Zhang et al., 2003), which is the 
opposite of what we found. However, there was no association with ACE I/Dp and 
capillarity. Was this opposite effect down to differences in ethnicity, as Asian 
populations have been shown to have an increased frequency of the I-allele (Figure 31, 
(Salem & Batzer, 2009)). Although there is not a significant difference between 
VO2max and ACE I/Dp, as seen is some earlier studies (Hagberg et al., 2002; Zhao et 
al., 2003), the association of increased percentage of type I fibres without the I-allele 
is in conflict with the majority of evidence that points towards the I-allele being 
associated with an endurance phenotype (Gayagay et al., 1998; Montgomery et al., 
1998; Myerson et al., 1999; Williams et al., 2000; Collins et al., 2004; Hruskovicova 
et al., 2006). What is interesting are the different adaptations following an endurance 
training regime (Swiss cohort). In participants without the I-allele capillary density is 
significantly increased, whilst intramyocellular lipids (IMCL) are inhibited (Figure 
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54). Despite this inverted ACE I/Dp genotype dependence between Swiss and UK 
populations the gene expression response to exercise is preserved (Figure 53).   
 
5.5. Conclusion 
 
 Ethnicity and the ‘blurring’ of differing training states (e.g. whether a 
population is endurance or strength trained) are possibly two key variables that 
contribute towards the controversy seen within the literature surround human 
performance and the ACE I/Dp (Woods, 2009). 
 In this study with male Swiss and British participants we saw evidence for a 
possible role of ethnicity as an explanation for differences in ACE I/Dp dependent 
metabolic performance between Caucasian populations.  It was however interesting to 
note that important gene transcripts involved in angiogenesis and substrate utilisation 
were unaffected. The fact that capillarity and IMCL were oppositely regulated, post 
endurance training in Swiss participants, supports the view that the ACE I/Dp is a 
compensatory reaction to  overcome limitations  in blood flow related metabolic 
supply to skeletal muscle during or post exercise. 
 As the numbers were low in the Swiss endurance training population these 
conclusions must be treated with caution – as sampling errors could possibly account 
for the differences seen.  
 Together with the observations that metabolite responses were lost in trained 
versus untrained British participants (chapter three), here we showed that the 
environmental stimulus in a different population again over-rode the influences (at 
different system levels) of the ACE I/Dp.   
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6. Epilogue: Studying the whole-organism  
 
 On the face of things the number of chapters presented in this thesis are fewer 
than would normally be expected for a PhD. However, the very nature of the research 
where many system levels are investigated in concert dictates that results need to be 
presented together. Results could have been separated (e.g. one-legged exercise, gene 
expression, metabolomics, physiology, capillarity), thus increasing the number of 
chapters, but the impact and related inter-connectivity of the different systems would 
have been lost – or at best harder to follow.  
 I would also like to present and comment on additional experiments/analysis 
that were performed during my research, but due to a combination of time and 
financial constraints I was not able to complete and include in my thesis. 
 
Overall findings from research 
 
Chapter 3 
To really understand what is driving/limiting energy metabolism (and link it to whole-
body metabolism) at the local working muscle it is vital that the muscle is maximally 
stressed (relatively). Traditional exercise analytical research and methodology (e.g. 
two-legged VO2max) may not be appropriate to identify local muscle differences 
between trained and untrained populations. Although only tentatively identified, it was 
clear that the trained population was able to utilise both non-polar and polar 
metabolites much more efficiently than untrained – as highlighted by the metabolomic 
analysis 
 
Chapter 4 
Building on chapter 3, chapter 4 sets out to test the influence, if any, of a well studied 
performance genetic variation (ACE I/Dp) in these two populations (trained and 
untrained) at several system levels. Despite no difference in physiological measures 
there were significant specific gene expressional differences in ACE I/Dp untrained 
pre- versus post-exercise bout (Figure 47), which were lost in trained (Figure 48). 
There were also clear differences in the metabolite response (polar, and non-polar) in 
ACE I/Dp untrained pre- versus post-exercise bout, which again were lost in the 
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trained state (Figures 43, 44 and 45). These results highlight that the strong stimulus of 
exercise can over-ride any genetical inhibition that may exist – even if small.  
 
Chapter 5 
Ethnicity is often quoted as a confounding factor in interpreting results from ACE 
I/Dp studies. Again building on chapter 4, we showed that a different population 
(albeit still Caucasian – but distinctly different in origin) – Swiss, whilst having some 
different physiological measures (Pmax, capillary density: Figures 49 and 50 
respectively) has similar gene expressional differences at rest (Figure 53). However, 
following an endurance exercise programme (Swiss only) capillary density and IMCL 
were differently regulated depending on ACE I/Dp (Figure 54).  
 From these three studies it is evident that there are 1) novel polar and non-polar 
metabolites, which are differently regulated/expressed in trained populations versus 
untrained, 2) ACE I/Dp gene expression and metabolite differences in untrained, 
which are lost in trained populations, and 3) ACE I/Dp may influence capillary supply 
lines and energy stores following an endurance training programme. 
 
Additional discussion, results and methodological developments (not included in 
main research chapters)        
 
The fascination and study of regular physical activity and health (or disease 
prevention) is not a new phenomena, see Fgure 55. But during the last century and 
certainly within the last 25 years there has been an ever increasing focus on why 
regular physical activity confers so many potentially protective health benefits (see 
Table 4,  and Figure 21). One area of research that has generated much interest, with 
regard to health (and sporting performance – the two are closely linked) over the past 
20 years is genetics. 
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If we all (humans) have the same DNA, which in turn instruct the production of the 
same specialist cells and organs, then why do we all not enjoy the same quality of life 
(QOL) and live to a ripe old age free from debilitating diseases and/or early death? 
The answer is a simple one: because DNA is just like the letters and words on this 
page, they are inert and only have a meaning (or produce a result) once read and 
translated (DNA---RNA---Protein). Leaving aside the monogenic diseases, such as 
muscular dystrophy and Huntington’s disease, diseases (especially those related to 
lifestyle – chronic diseases related to the cardiovascular system/metabolism) are the 
result of an interaction between many genes and the environment over many decades – 
leaving aside any epigenetic influences, which is a new area only just begingin to be 
explored.  
 
 
Figure 55 – Physical activity research through the ages 
The aim of the figure is to provide some examples of key milestones related to physical activity research 
and related milestones through the ages. 
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“There are no biological functions that rely on the coding provided by a single gene” 
(Noble, 2008).  
 
Despite the avalanche of positive health benefits, the importance of physical activity in 
the prevention and treatment of disease is under-valued and poorly communicated. 
Possibly one of the fundamental reasons regarding this “lack of interest” is the paucity 
of concrete evidence that details exactly how it confers health benefits (Coffey & 
Hawley, 2007). One way for this to change is to design and perform studies that 
provide an insight into detailed changes/adaptations encompassing many system levels 
within the body – from molecules to movement.    For example, studies investigating 
the contractile properties of single muscle fibres in vitro and then inferring what their 
findings mean at a whole body level can be misleading due to redundancy and 
cooperativity in biological systems. Single muscle fibres don’t act in isolation; they 
are part of a living, moving, and complex organism.  
 Only by attempting to uncover pathways that show how the body, as a whole, 
responds and benefits at inter-connected levels can we really begin to unravel the 
mysteries behind the health benefits of physical activity – and this will provide strong 
evidence, which will be difficult to ignore.  It is time to stop “looking” for associations 
and start identifying (or at least attempting) molecular mechanisms that result in the 
myriad of health benefits resulting from regular PA.  This view is succinctly 
encapsulated by Hamilton and Booth in a review in 2000: “Because so many potential 
physiological and biochemical signals change during exercise, it will be an important 
challenge in the next century to move beyond ‘correlation studies’ and to identify 
responsible mechanisms” (Hamilton & Booth, 2000). 
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The integrative style of the research is illustrated in Figure 56 below: 
 
Angiotensin 2 
 
Angiotensin 2 (Ang2) as already alluded is the key effector molecule of the RAS and 
it is often quoted that ACE levels have no correlation with Ang2 levels – this is 
something I believe to be untrue. Again whilst ACE I/Dp demonstrates a strong 
correlation with ACE levels (DD>ID>II) most evidence suggests this correlation does 
not exist with Ang2 levels. As already highlighted (chapter 1, section 1.2.3) Ang2 is a 
very challenging peptide to accurately measure. During my research I spent a good 
proportion trying to accurately quantify Ang2, with minimal success, and if there was 
any correlation with the ACE I/Dp and/or pre- and post-exercise changes. Whilst I was 
not able to successfully complete this analysis (due to cost and time constraints) I was 
able to set-up a reliable technique (Figure 57). 
 
 
 
Figure 56. Integrative style of study depicting how different levels are linked 
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Figure 57. Standard curve – SPI BIO angiotensin 2 assay kit 
 
Subsequent analysis on new participants from a separate study by Msc Michael 
Brogioli  that followed up on the relationship between ACE I/Dp, Ang2 and exercise 
in humans has provided new evidence to support my theory that Ang2 levels depend 
on the ACE I/Dp (Figure 58). 
 
At rest (Figure 58 illustrates) Ang2 serum levels were 134% higher (+ p=0.08) higher 
in ACE I/Dp genotypes without the I allele. 
 
Figure 58. Angiotensin 2 levels pre- and post exercise in ACE I/Dp genotypes 
n=2, without I allele; n=8 with I allele, +p=0.08. Unpublished data by MSc student Michael Brogioli. 
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Methodolical problems 
 
There are many problems in quantifying levels of Ang2 (accurately and repeatedly – 
constistently) below is a brief synopsis of what the more important ones were (in order 
of occurance) and some suggestions for overcoming: 
 Mixing of all sufficient inhibitor cocktail ingredients (see SPI-BIO, 
Angiotensin II kit, A05880) – and ensuring they all fully dissolve 
 Venous blood sampling: As the half-life of Ang2 is reported to be very short 
(possibly as short as 30 seconds) consistent sampling is vital as it is not always 
possible to withdraw 4 ml (minimum really needed to perform assay) very 
quickly due to variation in viscosity of participant’s blood. It would also be 
very prudent to ensure each participant is adequately hydrated and they are in 
the supine position (to reduce risk of fainting) 
 Another key step is the extraction protocol (extraction of Ang2 peptides) – of 
which the evapouration step can be troublesome. If you choose to evapourate 
under a stream of dry nitrogen ensure you use a large enough (deep) glass test 
tube and do not exert too much pressure as the fluid will likely spill over the 
edge. Leaving to evapourate overnight is also an option – but one that may take 
longer than one night 
 For the final step (enzymatic reaction) which involves reading the plate (colour 
development) I suggest taking readings at pre-determined times following 
incubation, e.g. 5, 10, 20, 40, 80 to see what time produces optimal colour 
development and readings 
 Finally, it would be ideal to get more than one sample from each participant, 
and one post an exercise bout (immediately) as Ang2 levels have been shown 
to increase with exercise. It is possible that you may not detect any Ang2 in 
some participants as the levels are below the sensitivity of the kit (less than 1 
pg/ml) - hence taking more than one sample and/or taking a sample post 
exercise 
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Energy substrate usage 
 
I mentioned evidence that suggested ACE inhibitors offer additional benefits other 
than merely reducing blood pressure (short-term benefits) (chapter 1, section 1.2.4). A 
key possible benefit being that ACE inhibitors increase the volume of the perfused 
vasculature by reducing vasoconstriction and hence increasing the ability of substrates 
to be metabolised by the working muscle. This has implications for people with 
diabetes, especially. Again, in new participants following on from my work amateur 
marathon runners had venous blood samples taken pre- and post-race. They were also 
ACE I/Dp genotyped and serum glucose was significantly elevated in marathon racers 
without the I allele versus those with the I allele (7.6 vs. 4.4 mM, n=4 vs. 12; 
p=0.0001, Student’s T-test).  
 
Whilst both the above findings come from small numbers, and the data is not accepted 
as a publication in a peer reviewed journal they do add some support to the fact that 
Ang2 levels do correlate with ACE I/Dp, and the higher levels of Ang2 (at rest) 
possibly offer an explanation as to why serum glucose levels are higher post race in 
ACE DD genotypes – they are not able to dispose of as efficiently to the contracting 
muscle due to a reduced vascular compartment/service area. This suggestion fits in 
well with the observations in chapter 5, where endurance training increased the 
capillary density in ACE DD genotypes only. Genotypes with the ACE insertion 
sequence (I) can more efficiently expand the blood vessel service area (enhancing 
glucose disposal) thus reducing shear stress and associated angiongenesis and new 
blood vessel development. 
 
Carbohydrate and gene expression – GenMAPP 
 
The data presented in chapter 5 included only a small number of key transcripts related 
to RAS and energy metabolism. The visualization of significantly changed transcripts 
from the larger microarray data set with GenMAPP  illustrates that CHO metabolism 
(at a transcript level) is further increased in participants without the I allele (Figure 
59). This could suggest a greater up-regulation of glucose pathways (at a transcript 
level) in ACE genotypes without the I-allele. It could be argued that the reduced 
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vascular capacity to expand blood vessels results in increased blood glucose levels (as 
described above). This then requires an up-regulation of glucose pathways to enable 
disposal of excess circulating glucose – hence related CHO transcript expression 
(especially glucose transporters – into muscle cells).  This would be in agreement with 
the higher levels of glucose described above.  
 
 
 
 
 
 
 
 
 
 
 
Figure 59. Gene expression of CHO metabolism transcripts: without I allele fold change difference, 
relative to with I allele 
n=7, without I allele; n=5 with I allele 
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Limitations 
 
A major limitation of my research was the combining of trained and untrained 
participants – a necessary concession to increase numbers. And then the resulting low 
numbers when trying to analyse the two cohorts separately. Originally we had hoped 
to accept only ACE I/Dp homozygotes (II or DD) but the low number of II’s, together 
with the interesting results from the Swiss data, meant we accepted the heterozygote 
genotype too.  
 Another major limitation was the metabolomic data analysis. Due to no 
previous published work on metabolite analysis in human skelelal muscle techniques 
had to be set up, which proved very time consuming and problematic. After the 
technique was established the mass spectrum and peaks needed interpretating and 
unknown metabolites needed identifying – this again requires extensive resources and 
expertise. Some tentative non-polar metabolite identification was possible, but the 
equally interesting polar metabolite analysis and identification has yet to commence. 
Arguably the most novel and interesting part of the whole research is proved the most 
problematic – something that I hope will be resolved in the near future, but alas too 
late for inclusion in my thesis. 
 
Concluding remarks 
 
With such low numbers, especially when investigating a widely studied gene 
polymorphism, there will be much scepticism as to chance playing its part or even the 
experimenters own bias.  
 If it was not clear in the methods I would like to reiterate the fact that all tests 
and measures (including any potentially affected data analysis) were done blind – the 
main experimenter (author) did not know the ACE I/Dp genotype of any participant 
until the measure of molecular, cellular, anatomical and physiological parameters was 
complete.  Any one part of the research taken in isolation (RT-PCR, microarray, MRI, 
DEXA, capillary density, gas measures, force, muscle metabolites, serum 
metabolites), especially in such a small population, would provide very little new 
evidence – especially regarding the potential influence of the ACE I/Dp. However, 
when examining the data together it becomes more interesting (challenging to 
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understand and explain too) and hopefully offers a new insight into why integrative 
style research is needed – especially when studying complex whole-organisms and 
trying to understand how exercise (acute and long-term) influence muscle to produce 
beneficial health adaptations. 
 
Future research and devopments 
 
The ACE I/Dp most interesting function is the possible influence it has, not on ACE 
levels, but on Ang2 – as this is the really interesting and effector molecule of the RAS. 
Therefore directing research towards identifying if there is truly a correlation between 
ACE I/Dp and Ang2 levels – at different time points (and within individuals) is 
crucial. Also, again it would be very interesting to ascertain if there are any 
correlations between BK levels (and or receptors – proteins not just gene expression) 
and the ACE I/Dp as there is very little research directed along this pathway, which is 
surprising given its potent vasodilory properties and the fact that many of the 
beneficial affects of ACEi’s may be due to the potentiation of this molecule rather than 
the reduction of Ang2 production. Plus, BK levels my also be naturally higher in 
participants with the insersion sequence (ACE levels certainly are). Again keeping on 
the theme of identifying components of the RAS and ACE I/Dp it would be of great 
interest to see if it was not simply the levels per se of ACE or Ang2 that were 
important but the efficiency of the conversion from Ang1 to Ang2, which has been 
demonstrated to be different between ACE I/Dp (genotype without I allele more 
efficient). There is some evidence produced, but generating more would certainly be 
of great benefit. 
 Whilst it is known that lipid pathways are regulated differently in trained 
populations of which important proteins/enzymes have been identified, what is not 
known is why are some processes both beneficial and detrimental, e.g. both type II 
diabetics and endurance trained populations have greater IMCL stores, but this is 
deleterious in type II diabetics but beneficial in trained populations. Investigating one 
or a few metabolites at once can prove very time consuming, but analysing 10’s if not 
100’s at once by using a metabolomic approach can be very efficient – providing 
systems are in place to robustly identify subsequent metabolites. This approach may 
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shed new light onto already existing evidence and more importantly identify new 
metabolites – those yet to have been explicitly implicated in energetic pathways. 
Finally, using a more integrative style of research (when studying whole-organisms) 
would be of real benefit as it allows the usage of smaller numbers – something that is 
often quoted as not sufficient when investigating genetic components.  
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Appendix 
 
Appendix 1: Ethics 
 
Ethics Committe Reference Number: 2007.11.04 
 
Application for Ethical Approval for the Use of Humans in Research 
 
1. Name of responsible investigators.   
 
David Vaughan (PhD student) 
Professor Martin Flueck (Director of Studies) 
Dave Tomlinson (Advisor) 
Professor Joern Rittweger (GMC Registered) 
Dr Hans Degens (Advisor) 
Professor Marco Narici (Advisor) 
Professor Roy Goodacre (Collaborator – University of Manchester) 
Dr William Allwood (Collaborator – University of Manchester) 
 
2. Title of investigation:  “Systems Biology of Human Strength and Fitness” 
(changed later to “Integrative Phyiology of Human Aerobic Fitness and the Influence 
of the ACE I/Dp Genotype”) 
 
3. This is a PhD programme research project. 
 
4. The full details have been appended.  
 
5. Brief description (500 words maximum) and purpose of the investigation.   
 
Metabolic diseases and frailty pose a significant health risk of which skeletal muscle 
(SKM) is an important component.  We know that SKM is very adaptable in respect of 
use and disuse but that the extent of the adaptation varies between people and must 
reflect their underlying genetic background.  However the details of the interaction 
between genes and environment are poorly understood.  
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Rationale 
 
The response of the SKM phenotype to a stimulus such as exercise is mediated by the 
activation of gene-dependent signalling pathways (Booth and Neufer 2005, Flueck and 
Hoppeler 2003). This signalling is specific to the type of exercise and can be 
demonstrated as changes in mRNA over time following stimulus. These changes in 
gene expression are translated into protein, which results in mechanical and metabolic 
adaptations in SKM.  Over time, and with repetition, the exercise stimulus results in a 
cumulative adaptation of SKM (Flueck 2006). 
 
This project aims to demonstrate the involvement of gene-dependent pathways in an 
exercise-specific SKM adaptation by monitoring changes in relation to angiotensin 2 
(Ang 2) activity, which is thought to be a master factor of SKM signalling for strength 
and fitness.  The extent of the adaptation to the exercise stimulus will be contrasted in 
participants with high and low Ang 2 activity as a consequence of polymorphisms in 
the gene producing Ang 2 (ACE I/D gene polymorphism – see Sayed-Tabatabaei et al 
2006 for a review).  There are two-fold higher Ang2 levels in serum for ACE DD 
compared to ACE II genotype (Rigat et al., 1990; Mondorf et al., 1998; Bloem et al., 
1996). 
 
General Hypothesis 
 
Angiotensin 2 governs the balance between physiological angiogenesis (broadly, 
endurance adaptations) and myogenesis (mainly, strength adaptations) to an acute bout 
of exercise.  
 
Specific hypotheses 
 
In sedentary but healthy males we expect to see after an acute bout of endurance or 
strength exercise:  
 
1. Participants with the ACE II genotype (less Ang2 levels) will demonstrate a 
pronounced up-regulation of genes associated with capillarity and muscle 
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mitochondrial content in comparison with those with the ACE DD as a result of 
endurance type exercise. 
 
2. The ACE DD genotype (higher Ang2 levels) will show a greater myogenic 
response compared to participants with the ACE II genotype in response to resistance 
exercise. 
 
Parts 1 and 2 of the proposed study respectively address these two hypotheses. 
 
Experimental design: please see figure 1, which shows when each test / procedure will 
be performed and also how they fit together in the study as a whole.  
 
6.  (a) How will the participants be recruited? 
 
Participants will be recruited from MMU and/or  local offices/clubs/organisations by 
means of posters, emails, flyers and letters.  
 
(b) Provide details on the number and type of participants likely to be involved? 
 
We will select 9 ACE-II and 9 ACE-DD homozygotes for part one (endurance 
exercise acute bout), and this will be repeated in part two (strength exercise acute 
bout).  
 
(c) What inclusion and exclusion criteria will be employed in the selection of 
participants? 
 
The participants should be healthy, not taking any medication, non-diabetic, male, 18 
– 39 years of age, BMI between 20 and 30 kg/m2. They should not undertake regular 
exercise (>1 hours/week). Maximal oxygen uptake (2max) should therefore not be 
above 50ml O2/min/kg.  Eligibility for participation will be assessed by a lifestyle 
questionnaire adapted from Ware and Sherbourne 1992, Howley and Franks (2003) 
and via an online test (similar/adapted to one described by George et al., 1997).     
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The General Health Departmental Questionnaire will be used as an additional 
screening tool immediately before participation of exercise.  Participants will not be 
allowed to exercise if they have a cold, flu or fever at the time of testing, or are 
suffering with musculo-skeletal problems.  
 
(d) What criteria have been employed to determine the number of participants for the 
study? 
 
Assuming all participants will complete part one and part two of the study these 
numbers will provide nine biological replicates per given genotype and acute exercise 
intervention (endurance and strength). These numbers have been proven to be large 
enough in previous studies to detect exercise effects of genotype-dependent transcripts 
with the proposed molecular techniques (Schmutz et al., 2006, Fluck 2006, Pilegaard 
et al., 2000, Klossner et al., 2007). This is supported by prospective power analysis on 
the expected transcript level changes, which indicates a prospective sample size of 6-8 
to reach significance for the anticipated genotype effect (Erdfelder et al., 1996). 
 
7. Likely duration of the project and location of study 
 
Parts one and two, should each take one year to complete (please see figure 1 for a 
study outline). 
Briefly, the functional tests should be completed within 8 weeks.  Every participant 
will  be asked to attend for testing on 4/5 separate days (with the option of possibly 
another 2 separate days), each visit will last no longer than half a day, except for the 
final visit, which will be a whole day.  It is envisaged that each participant will 
complete all tests within 8 weeks.   
The exercise interventions will be conducted in the IRM laboratories at Alsager and/or 
Manchester.   
 
Location of study** 
 
New physiology laboratory and data collection area: DEXA scan and appropriate 
exercise tests.  
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Active lifespan laboratory: Magnetic Resonance Imaging (MRI), muscle 
function/strength tests. 
Old physiology lab: Acute endurance and strength training bouts, anthropometric 
measurements (height, weight and waist circumference), blood sampling (finger prick 
and venous), heart rate, blood pressure, pre-test medical questionnaire completion, 
muscle biopsies.    
 
The University of Manchester: Analysis of metabolites in both venous and finger prick 
blood and muscle biopsies in compliance with the Human Tissue Act 2004. 
 
**Test locations will obviously change upon moving to Manchester  
 
8. Specify the particular procedures that involve human participants. 
 
Tests and procedures 
 
The following tests/procedures will be performed by Mr David Vaughan (PhD 
student) with help from professor Martin Flueck (especially for molecular tests) and 
Mr Dave Tomlinson (for physiological measures).  The one exception is with regard to 
taking muscle biopsies, which will be performed by professor Joern Rittweger. 
 
Lifestyle questionnaire: This will be used as a screening tool, to assess potential 
participant’s suitability for inclusion in the study, including motivation, attitude and 
nutrition.  An online test will also be used to estimate each particip ant’s VO2max (see 
appendix II). See appendix I, which is an example copy of the questionnaire.  
 
Rapid screen 
 
Anthropometric measurements: Weight, height, BMI, waist circumference; all 
measured with participants wearing T-shirt and shorts.  
Resting heart rate and blood pressure:  Measured with a Polar heart rate monitor (or 
similar device – yet to be determined) and automatic blood pressure machine (exact 
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make and model to be determined).  Participants will be sitting and rested for at least 
10 minutes before measurements are taken. 
Mucosal mouth swab: A cotton bud will be used to collect cells lining the inner cheek 
of each participant.  This sample will then be analysed to determine the ACE 
genotype.  
 
Based on the above results, suitable participants will be invited to take part in the 
study.  
 
Dietary analysis: Each selected participant will have a thorough dietary analysis.  To 
be performed by DV – registered dietitian. 
Blood samples, venous and finger prick:  20ml venous blood samples will be collected 
before the dietary intervention, and at the same time points as the muscle biopsies 
(immediately pre-test) and at three time points after the acute exercise bout (see 
appendix II).  The metabolites and proteins of interest are given in Tables 2 and 4.  
Ang2 levels will be measured in finger prick samples taken before, once during and 
immediately after the exercise bout. All blood sampling will be performed by a 
qualified phlebotomist(s) – MF, DV and DT are to attend an appropriate course on 
February 21st 2008.      
Magnetic resonance imaging (MRI) and ultrasound:  These will be used to determine 
the quadriceps muscle volume.  Using four MRI scans, with each scan being 16cm in 
length, starting from the distal lateral condyle to the proximal end of the greater 
trochanter of the femur.  Standard scanning procedures will be employed. For 
ultrasound see appendix II. 
Maximal voluntary isometric strength:  This will be determined at optimal knee angle 
using the Cybex.  
DEXA scan:  Body composition will be determined with a whole body DEXA scan. 
Muscle biopsies:  This procedure is required to be able to analyse transcripts, proteins, 
and metabolites of interest.  Genes are up/down-regulated at different time points 
following a bout of exercise.  Based on previous work by MF, 4 important time points 
have been identified; pre-exercise (control), 30 minutes and 3 hours post exercise 
(these 3 biopsies will be with the fine needle), plus a final biopsy at 8 hours, which 
will be taken with a conchotome – this larger sample is needed for histochemical 
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determination of fibre type composition and fibre size.  See appendix II for a detailed 
explanation and reasoning.  All muscle biopsies will be performed by Professor Joern 
Rittweger (GMC registered)    
 
Depending on which part of the study (part 1 or 2) the participants are doing they will 
perform the following tests. 
 
Part 1: Response to an endurance exercise stimulus.  
 
One-legged cycling oxygen uptake (VO2peak test):  Participants will perform an 
incremental exercise test on a cycle ergometer, but using just one leg. The result will 
be used to set the workload for the single leg endurance-training stimulus (see below).  
 
One-legged cycling (acute endurance stimulus):  One leg exercise will be used to 
remove the variability that exists in two-leg exercise as a consequence of differences 
in cardiac output. Participants will exercise one-legged at a constant exercise intensity 
of 60% peak power for 25 minutes after which the power will be increased by 5W 
every 30 seconds until volitional exhaustion. 
Two-legged cycling oxygen uptake (VO2max test):  A conventional progressive 
exercise test will be conducted on a cycle ergometer approximately two weeks after 
participants have completed the acute exercise test.  These results will be used to 
further characterise the participants and replace the estimates made in the preliminary 
screen.   
 
Part 2: Response to a resistance exercise stimulus. 
 
Maximal single repetition (1RM):  1RM will be determined using a conventional leg 
extension work station.  Participants will make one contraction a minute, starting at 
about 60% of their estimated 1RM and the load will be progressively increased until 
they can no longer fully extend the knee. The result will be used to set the workload 
for the single leg strength exercise stimulus (see below).    
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One-legged extension (acute strength exercise stimulus):  Using the same workstation 
on which the 1RM was determined, participants will perform 10 repetitions, and 3 sets 
at 75% of their 1RM.  
  
Molecular tests 
 
All these techniques are selected to determine the contribution of gene-dependent 
pathways. 
 
Please refer to Tables 1 – 4 for a definitive list of transcripts, proteins and metabolites 
to be analysed, and see appendix II. 
 
We have already established a technique for ACE genotyping using mucosal samples 
(See Figure 2) 
 
ACE genotyping: Mucosal cells will be removed from a participant’s inner cheek with 
a cotton ear bud.  ACE II and DD will be identified by real-time polymerase chain 
reaction (RT-PCR), using specific ACE II / DD primers.  To avoid miss-genotyping 
the products of the initial RT-PCR will be run through another RT-PCR test with 
either ACE II or DD specific primers and may also be run through a gel.   
 
Transcript profiling: This is required to identify those transcripts of interest, which 
may be up regulated by exercise (gene expression).  A technique will be employed, 
which “converts” the products of gene expression (mRNA) to cDNA, by using an 
enzyme called reverse transcriptase.  The cDNA can then be identified and quantified 
using RT-PCR. 
 
Analysis of metabolites: It is necessary to measure levels of key metabolites (both 
locally – in the muscle, and systemically – in the blood), e.g. Ang 2, glucose, 
triglycerides, etc.  Obviously Ang 2 is of key interest, as we expect to see significantly 
different levels between the two ACE genotypes.  Other relevant metabolites (refer to 
Tables 1 to 4) will be analysed (exact number will depend on exercise test and time, 
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with preference being given to those of high importance) as we expect to find 
significant differences in response to exercise with the different ACE genotypes. 
 
Metabolic Profiling: To be carried out by the University of Manchester.  This will be 
an important addition to the study, which will allow key metabolites (refer to Table 4) 
to be identified and possibly quantified.  This will provide us with further information, 
which will help us build up a metabolic profile, in response to the stimulus of exercise. 
 
Previous work performed and published by MF has shown that 20mg of muscle biopsy 
obtained with the fine needle is sufficient for the three molecular tests described 
above. 
 
Cellular diagnostics: This is required to identify fibre types, fibre-to-capillary ratio, 
and capillaries per muscle area.  A larger “normal” size muscle biopsy is required for 
these molecular tests. 
 
9. Are any novel procedures involved in this study?  If so, full details must be 
attached. 
 
The only procedure that is new is the fine needle muscle biopsy (details attached), 
which is intended to be less traumatic than the conventional biopsy technique. 
 
10. Clearly state all substances or materials to be administered or applied.  State 
their potential hazards, if any, and the precautions to be taken. 
 
Muscle biopsies: Professor Joern Rittweger (GMC registered) will perform all muscle 
biopsy procedures.  Participants will first be asked if they have ever had an adverse 
reaction to a local anaesthetic; if not local anaesthetic (2% Lignocaine) will be 
infiltrated under the skin.  In the case of an adverse reaction (such as reddening or a 
weal mark) no further Lignocaine will be administered and the condition of the 
participant will be monitored for general change in colour, heart rate and blood 
pressure, over the following 30-60 min.  In the case of a severe reaction emergency 
medical help will be summoned.  The well being of the participants will be monitored 
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continuously.  A defibrillation set will be available in the same building of the MMU 
Alsager Campus, in the extremely unlikely event of a severe reaction occurring with 
the anaesthetic.      
 
Blood venous and finger prick samples: There is a small risk of infection when taking 
blood but every precaution will be taken to minimise this risk, with the use of sterile 
equipment.  The blood samples will be drawn by qualified phlebotomists when taking 
venous samples.   
 
11. State the degree of discomfort in terms of apprehension, pain, stress and 
disturbance in terms of alternation to routine. 
 
The majority of the tests and procedures should be without stress for all participants.  
The exercise tests will entail a degree of effort and fatigue but this will not be 
excessive or prolonged and is something that the participants will be able to assess 
when volunteering and giving consent.  Participants will be constantly monitored 
before, during and after all tests and will be made aware that they may withdraw from 
the test/study at any time.  The venous blood sample may cause a very brief slight 
discomfort for some participants.  The muscle biopsies may cause discomfort to some 
participants (usually the injecting of anaesthetic is the only painful part), but 
everything will be done to keep participants relaxed and address any concerns they 
may have, and to provide aftercare advice and information.  Please see appendix III for 
a more detailed explanation. 
 
12. State your experience or that of the supervisor or other investigators in this 
type of investigation. 
 
Prof. Martin Flueck has experience in similarly invasive exercise studies with a similar 
population in humans (Schmutz et al., 2006, Klossner et al., 2007) and has expertise in  
2peak testing, molecular diagnostics and biochemical tests.  Professor Joern Rittweger 
is experienced in performing invasive muscle biopsies, including fine needle biopsies.  
Prof. Roy Goodacre and Dr William Allwood are experts in the field of metabolomics 
(Hollywood et al., 2006).  Dr Hans Degens has experience of muscle histochemistry 
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and capillary measures.  Prof. Marco Narici has experience in strength training design 
and analysis.  Mr Dave Tomlinson has experience of physiological and functional 
measures and Mr David Vaughan (registered dietitian) has experience of nutrition, diet 
analysis, questionnaire design and lifestyle assessment.  
 
13. How and where is the data to be stored? 
 
Will the data be securely stored?  Where?   
 
All paper hard copies of questionnaires and tests will be kept locked away in a filing 
cabinet. 
 
All electronic data will be stored on a server and/or on a mobile hardware device (to 
be securely locked away – e.g. external hardware drive and USB stick), in a password 
protected file.  The participants’ names will be coded in compliance with the Data 
Protection Act 1998. We will only work with the ‘blinded’ data (i.e. will obviously 
know the names of participants but will not know their exact genotype – only that they 
are either homozygous II or DD) and save the ‘key’ relating code to names in a safe 
place. To achieve this, a person external to the main investigations will be responsible 
for coding the data (Professor David Jones).  
 
Will information which could identify participants be coded? Yes 
Will the data be destroyed at the end of the study? No.   
 
The data will be archived in compliance with the guidelines for good laboratory 
practice.  Files of raw data shall be kept at a secure place for approximately 5-10 years 
after the review of planned publications has been completed. This will enable any 
future meta-analysis, should there be any relevant need. 
  
Appendix II 
 
Lifestyle questionnaire: Each participant will be asked to complete a detailed, 
validated questionnaire (adapted from Ware and Sherbourne 1992, and Howley and 
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Franks 2003) to assess their anthropometrics, lifestyle, physical activity/exercise 
levels, current and past medical health, general quality of life and dietary habits, which 
will allow us to assess the participants suitability for study inclusion. The theory 
behind the completion of this questionnaire is to try (as much as possible) and select 
participants who will be best able to complete the whole study.  This questionnaire 
may prove unsuccessful therefore, we may modify/simply scrap it if it fails to identify 
enough suitable participants and simply pick those that meet the minimum 
requirements (are male, aged 18 – 39 years of age and are sedentary), providing there 
are no health issues. 
 
Non-exercise test for VO2max: A ‘dry’ assessment of general fitness will be used to 
estimate the participants VO2max.  This will be achieved via online access to 
http://www.brianmac.co.uk/vo2maxnd.htm.  We will perform one/two VO2max tests 
(approximately two weeks after the participants have completed the exercise test).  
This is to reduce the risk that the VO2max test may actually reduce the affect of the 
single acute exercise test and/or give them an extra push or incentive to become more 
physically active between starting the study and taking the exercise test, we are trying 
to minimize any “noise”. 
 
Anthropometric measures:  
 
Height, weight, BMI (body mass index), WHR (waist-to-hip ratio) measurement to 
compare against BMI.  These are all very simple, straight forward measurements that 
are non-invasive. 
 
Resting heart rate and blood pressure:  Sphygmomanometry will be used for the static 
measure of mean arterial pressure.  A suitable automated blood pressure measuring 
device (yet to be determined), validated and recommended by the British Hypertension 
Society (O’Brien et al., 2001(a)) will be used.  Protocol for use will be followed as 
recommended by O’Brien et al., 2001(b). 
 
Mucosal mouth swab: There must be no cuts or ulcers in mouth, the mouth must be 
cleaned (e.g. swilled out with water – several times) immediately before sample 
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collection.  Participants will also be asked to refrain from drinking (other that water) 
and eating one-hour before sample collection.  Sample collection is simple and pain 
free, it involves collection of cells from the mucosal lining inside of the cheeks by 
simply twirling/rubbing an ear bud against the inner cheek wall.  This technique has 
already proved successful, as we have recently identified the different polymorphisms 
of the ACE insertion/deletion sequence by using this method (refer to Figure 2).    
 
Dietary analysis: Each subject will have their dietary habits analysed, which may 
include an interview, analysis of a four-day food diary and/or analysis of photographs 
of all food consumed, if they have a mobile phone with suitable photographic 
capabilities (jpeg-pictures at 640 x 480 pixel resolution, with a file size of 62 kb).  
Participants may also be supplied with electronic scales and be asked to keep all food 
wrapping if they have do not possess a suitable phone/camera.  All dietary analysis is 
to be performed by DV.   
 
Blood samples, venous and finger prick:  Following a 12 hour overnight fast, one 20 
ml blood sample will be drawn from a forearm vein (in the first meeting – see figure 
1).  Blood samples will also be taken during the acute exercise bout; pre-test (and 
possibly during the exercise bout – finger prick only) and post test, at the same time 
points as the muscle biopsies.  All blood samples will be collected into pre-chilled, 
pre-marked (for sample identification) tubes.  All venous blood samples will be taken 
by a qualified phlebotomist.  Finger-prick blood samples will be taken using 
disposable lancets.  An electronic blood-monitoring device will also be used to 
measure certain metabolites (test strips and capability permitting – refer to Table 2).  
All blood samples will be analysed for small key metabolites by colleagues at 
Manchester University (refer to Table 4).  
 
Magnetic resonance imaging (MRI) and Ultrasound: These will be used to measure 
muscle volume and architecture of the quadriceps femoris muscle group (VL, VI, VM 
and RF), at rest, which will allow calculation of physiological cross sectional area 
(PCSA).  The volume will be calculated from three to four scans of the thigh (each 
scanning region will be 16cm in length).  Scans will be carried out using a 0.2 T 
magnetic resonance imaging (MRI) scanner (Esaote Biomedica, Genoa, Italy) 
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following the Manchester Metropolitan University safety guidelines from the safety 
document for ESAOTE 0.2 Tesla MRI system E-Scan.  Participants will be scanned in 
the supine position.   
 Muscle architecture of the quadriceps femoris muscle group will be analyzed 
using real-time Bmode ultrasonography (ATL-HDI 3000, Bothwell, USA).  A 7.5 
MHz linear array probe will be placed in the central region corresponding with 50 % 
of each muscle length, over the mid-sagittal axis of the muscle-tendon complex after 
identifying and marking the vertical axis of the muscle.  An eco-absorptive marker 
will be placed over the centre of the measurement site for each individual muscle to 
provide a reference marker for muscle architecture measurements. Probe placements 
will be recorded on an acetate paper sheet to ensure the repeatability of the 
measurement site in the subsequent testing session if needed.   
 
Maximal voluntary strength- static contractions: Measurements of maximum voluntary 
contraction torque (MVCs) will be made using a Cybex dynamometer (Cybex Norm, 
Cybex International, New York, NY, USA).  Seat adjustments, body position and joint 
angle will be optimised for each participant and kept constant throughout the trial.  At 
least three MVCs, each lasting 2-4 seconds, will be performed with a rest-interval of 1 
min. This will be carried out twice, once for familiarization and again for actual 
measurements.  Both legs will be tested.  EMG signals from the hamstrings will be 
recorded with bipolar silver chloride surface electrodes (20 mm interelectrode 
distance). EMG activity will also be recorded from the Biceps Femoris muscle during 
the MVC. Before placing the EMG electrodes, skin impedance will be reduced below 
5 kHz by standard preparation including shaving, gentle abrasion and cleaning with an 
alcohol-based tissue pad. The electrodes will be placed along the sagittal axis over the 
muscle belly, with the reference electrodes on the tibial condyle. Raw EMG signal will 
be rectified and averaged (Acknowledge, Biopac System Inc.).  To convert the EMG 
measures of the hamstrings into a torque, participants will be asked to make a maximal 
knee flexion during which the EMG will be recorded.  
 
DEXA scan: This measure will be performed to assess body fat composition.  Body 
composition in terms of percent body fat, lean body mass and bone mineral content 
can be assessed by dual energy x-ray absorptiometry (DEXA) with a Lunar Prodigy 
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Advance (GE Healthcare, Waukesha, Wisconsin, USA). This shall be done in whole 
body mode. The scanning takes approximately five minutes and is without any 
inconvenience.  However, there is a theoretical risk involved by the radiation imposed. 
In reality, that risk is rather low, as total body equivalent dosage is expected to be 0.4 
microSievert. This could be compared to the background radiation of more than 2000 
microSievert per year, or to the additional radiation of 10 microSievert per hour of air 
flight. 
 
One-legged cycling oxygen uptake test (VO2peak test):  Participants will complete two 
incremental exercise tests (VO2peak tests) to the limit of tolerance for one-legged 
cycling exercise (Davies & Sargeant 1975) on the electrically braked cycle ergometer.  
These two tests will be separated by at least 72 hours.  Following a two minute warm-
up period at 40W, cycling with one leg, the external work rate will be increased by a 
further 10W every minute.  A pedal frequency of 70 rev.min-1 will be maintained 
throughout the exercise period.  The test will be terminated when the pedal rate falls 
consistently below 60 rev.min-1.  Pulmonary gas exchange will be measured breath-
by-breath (Cosmed K4b2, Italy) and VO2peak and peak power will be determined 
using standard techniques.  Heart rate will be monitored throughout with a Polar heart 
rate monitor (exact device(s) yet to be determined, probably - Polar Electro, Kempele, 
Finland).  Saddle and handlebar positions will be adjusted for each participant and the 
positions recorded to allow accurate replication of the test conditions in the acute 
endurance test (see below). 
Immediately following termination of the test, the participants will be encouraged to 
perform an active recovery by cycling at a very low external work load using two legs.  
This should reduce sensations of local muscle fatigue and light-headedness. 
 
One-legged cycling (acute endurance test):  Each participant will have their peak 
power calculated from the one-legged cycling oxygen uptake tests (described above) 
and will exercise at 60% this peak power for 25 minutes, followed by an external work 
rate increase of 5W every 30 seconds until volitional exhaustion.  Staessen et al (1987) 
demonstrated that exercise at 60% of peak aerobic two-leg exercise capacity elevates 
Ang 2 levels in serum by ca. 60%.  Pulmonary gas exchange will be measured breath-
by-breath (Oxycon alpha, Jaeger, Germany) and VO2peak and peak power will be 
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determined using standard techniques.  Heart rate will be monitored throughout with a 
suitable device (possibly a Polar Accurex plus monitor).  Saddle and handlebar 
positions will be set to previous settings, as recorded in earlier tests.   
 
Maximal single repetition (1RM): The dynamic strength of the knee flexor muscles 
will be assessed by determining the maximum weight with which a participant can 
perform one unilateral standard leg extension or leg press exercise (Technogym, 
Gambettola, Italy). The 1RM protocol will be modified from Baechle et al. (2000) and 
will commence with a warm-up of three repetitions against weights at ~50% of the 
participant’s predicted 1RM. After 60 seconds of rest, the weight will be increased to 
90% of the estimated 1RM. Following 60 seconds of rest, the weight will be increased 
to 100% for a 1RM attempt. Thereafter, successful attempts will be followed by 
further addition of weights to determine the 1RM in three to five attempts. This 
procedure will be performed prior to the one-legged knee extension exercise session 
(detailed below). 
 
One-legged knee extension:  Participants will be asked to perform, on a weight-lifting 
machine (Technogym), 3 sets of 10 knee extensions at a load corresponding to 75% of 
the 1RM. The amount of work (Joules) performed in each lift will be equal to m.g.h, 
where m=lifted mass (kg), g=acceleration of gravity (9.81 m.s-2) and h= vertical 
displacement (metre) of the mass measured with a linear position cable potentiometer. 
Hence the mechanical power developed in each lift will be equal to: (m.g.h) / t, where 
t = time in second.  Therefore, the instantaneous power output will be given by 
m.g.dh/dt.  A rest of 60 s will separate each series of 10 lifts.  
 
Two-legged cycling oxygen uptake (VO2max test):  Each participant will complete 
two incremental exercise tests to the limit of tolerance for two-legged exercise on an 
electrically braked cycle ergometer approximately two weeks after the acute exercise 
test.  Each test will be separated by at least 24 hours.  Following a four-minute warm-
up period at 40W, the external work rate will be increased by a further 20W every 
minute until volitional exhaustion.  A pedal frequency of 80 rev.min-1 will be 
maintained throughout the exercise period.  The test will be terminated when the pedal 
rate falls consistently below 70 rev.min-1.  Pulmonary gas exchange will be measured 
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breath-by-breath (Cosmed K4b2, Italy) and the gas exchange threshold and  
2max/peak will be determined using standard techniques.  Heart rate will be monitored 
throughout with a suitable device (possibly a Polar Accurex plus monitor).  Saddle and 
handlebar positions will be adjusted for each participant and the positions recorded to 
allow accurate replication in each test.  Immediately following termination of the test, 
the participants will be encouraged perform an active recovery by cycling at a very 
low external workload.  This should reduce sensations of local muscle fatigue and 
light-headedness. 
 
Fine-needle biopsy procedure: A very small (~ 20 mg) biopsy will be taken from the 
VL muscle of the quadriceps between the upper third and the lower two thirds of the 
distance between the knee and the head of the femur.  The micro-biopsy will be 
performed with a spring-loaded and reusable instrument; the Onecut Disposable 
biopsy (14 Gauge x 150 mm, product code ONE-141502, UK BIOPSY Ltd, Great 
Britain).  Participants will first be asked if they have ever had an adverse reaction to a 
local anaesthetic; if not local anaesthetic (2% Lignocaine) will be infiltrated under the 
skin.  After the skin has been shaved and sterilized an incision in the skin will be made 
to reduce resistance and allow successful sampling with the needle from the VL 
muscle.  A muscle sample will then be obtained by the activation of a trigger button, 
which unloads a spring and activates the needle to collect a piece of muscle.  We 
estimate that 20mg of muscle sample will be sufficient for all molecular and 
biochemical tests, and in a study by Hayot et al., 2005, using the fine-needle biopsy 
technique, muscle sample average weight was approximately 32mg.  The muscle 
sample will be placed on weighing boat, rapidly weighed and immediately frozen in 
liquid nitrogen and stored at – 80oC for later analysis.  Once any bleeding has stopped 
the tiny needle hole will be covered and closed with Steristrip(S), a sterile plaster and 
appropriate dressing. Professor Joern Rittweger will perform all muscle biopsies.   
 
Muscle biopsies will be later analysed (to identify and quantify transcripts and 
proteins), using reverse transcription, real-time polymerase chain reaction, gel-
electrophoresis and Western blot, and possibly other techniques as required. 
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“Normal” muscle biopsy:  The procedure for the last muscle biopsy will be exactly as 
described above (fine-needle), with the difference being that a chonchotome (instead 
of the fine needle) will be used to extract a larger sample (~ 200mg).  This method is 
currently the preferred method of muscle biopsy sampling at MMU, and Prof. Joern 
Rettweger has extensive experience in this.  
  
Muscle biopsy: The time points are based upon published human work of MF to allow 
differentiation of the ACE- and exercise-dependent course of the different waves of 
the molecular response (Booth and Neufer 2005; Schmutz et al., 2006, and refer to 
Figure 3 below). Fine needle biopsies are chosen (for the first 3 samples) since they 
provide sufficient biological material (see Schmutz et al 2006; Klossner et al., 2006) 
but are less invasive than the conchotome for repeated sampling. 
 
Pre: This measure is the reference for the determination of the molecular exercise 
response of each individual from the repeated biopsy measures after the single 
exercise.  To be taken from the non-exercised leg. 
 
30-60 minutes: At this time mechanical signalling and the first wave of downstream 
gene expression (c-jun pathway) is increased (Puntschart et al., 1998, Klossner et al., 
2007). These changes are under control of ANG2-FAK pathway (Mehta and 
Griendling 2007), which evolves a major topic in control of the muscle phenotype 
(Fluck et al., 2007). 
 
3 hours: This is the earliest time when myogenic factor expression is increased after 
strength type exercise (Klossner et al., 2007).  
 
8 hours: Metabolic transcript expression is increased after endurance type concentric 
exercise (Schmutz et al., 2006). This time-point allows us to distinguish from the 
response after eccentric type exercise. A conchotome sample will be collected to allow 
the orientation of muscle fibres for capillary density measures per fibre area. 
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Molecular tests   
 
Please refer to Tables 1 to 4 for a definitive list of transcripts and metabolites to be 
analysed (time permitting) 
 
ACE genotyping: This procedure has been adapted from published protocols (please 
refer to Badenhop et al., 1995 and Evans et al., 1994, plus Figure 2 for further details).  
We have already established a successful technique from mucosal samples.  
 
Transcript profiling: Total RNA will be isolated from 25 μm cryosections of the 
muscle biopsies and quantified as described previously (Schmutz, Fluck 2006). 1 μg 
RNA will be reverse transcribed and subjected to real-time polymerase chain reaction 
(RT-PCR) for selected transcripts. cDNA will be quantified. Dependent on the 
primers, reactions will be run with Sybr Green or Taqman master mix (Applied 
Biosystems) on a Biorad DNA machine controlled by the MJ Opticon Monitor 
software (Biorad). 40 standard cycles (1 min 95ºC, 1 min 60ºC) will be performed 
after a hot start on same amounts of RNA. Primers will be used as established (Zoll et 
al., 2006) or designed with primer express software (Applied Biosystems) and 
synthesized at Sigma, Genosys. RNAs to be compared will be run in a design allowing 
referencing. Signals will be expressed per input amount of cDNA. Alternatively, 
 
Figure 1 (Ethics) 
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signals will be related to the internal reference 18S RNA which will be run as a 
multiplex reaction in the same well (attention saturation effects). 
 
Analysis of metabolites: This methodology will be established from existing protocols 
for selected metabolites in blood and muscle samples. For finger-prick blood samples 
the tests will be established for angiotensin 2, glucose and triglycerides. Angiotensin 2 
concentration will be measured with a sandwich assay (Fildes et al., 2005). In brief, 
100 μL of blood will be collected with a large finger-prick (or if this isn’t possible 
then a venous blood sample will be taken). 11 μL of 0.1 M sodium citrate will rapidly 
be added as an anticoagulant (or alternatively heparanised tubes may be used). 
Samples will then be centrifuged at 2000 rpm for 10 minutes. The plasma will then be 
removed and assayed with the Sandwich Elisa (AssayMax Human Angiotensin II 
ELISA Kit). The undiluted sample will be stored at -20ºC or below for up to 3 months. 
Glucose and (bound) triglycerides will be measured from the collected sample with a 
specific instrument and test strips.  
 Optionally, the suitability of test-strips for the measurement of diacylglycerol, 
lactate, Beta-hydroxy-butyrate, pyruvate and acetoacetate will be evaluated. Also 
optionally, ACE activity will be assayed with a commercial spectrophotometric ACE 
assay system (SIGMA Diagnostics®, St Louis, USA). In this regard see Barceló et al 
2001. 
 The suitability of the above techniques for angiotensin 2, glucose (glycogen) 
and triglycerides on muscle extracts will be validated. The measure of triglycerides 
and glycogen is important and might have to be achieved via other means (see Essén-
Gustavsson and Tesch, 1990). 
 
Metabolomic profiling: This analysis will request additional ethical approval by the 
University of Manchester as it is to be carried out on biopsy samples at the 
metabolomic unit of Professor Royston Goodacre by Dr. William Allwood.  In brief, 
20 mg of frozen muscle sample will be cryo-sectioned at 25 μm and transported to 
Manchester. Muscle components will be extracted with a modified Fiehn protocol and 
separated for polar and non-polar metabolites. For an overview see Hollywood et al 
2006. 
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Cellular diagnostics: Microanatomy of muscle: Cross-sections will be prepared at 12 
μm from the biopsies and stained with monoclonal antibodies specific for fast (My-32) 
or slow type myosin heavy chain (MAB1628) (Schmutz et al 2006) with the 
modification that fluorescent antibodies will be used (Molecular probes). In addition, 
capillaries will be double stained with rabbit anti Ulex europaeus agglutinin I lectin on 
the same section, essentially as described by Qu et al., 1997. 
Fibres will be typed according to the expression of fast and slow myosin types into 
slow, fast and hybrid population. Staining will be visualized using a confocal 
microscope (Leica SP5). Signals will be recorded from different, non-overlapping 
fields for evaluation of mean and fibre type-specific ‘capillary-to-fibre ratio’ and 
‘capillaries per muscle area’. Percentage and mean cross-sectional area of each fibre 
type will be determined by stereological counting of all fibres from the assembled 
microscopic field of the biopsy cross-sections. 
  
Appendix III 
 
Participants will encounter disruption to their normal routine caused by the scheduled 
testing and procedures.  The one-legged and two legged VO2peak tests, and strength 
and endurance tests are hard work and some participants may feel light-headed after 
these tests.  A sufficient low intensity cycling cool-down period will be implemented 
to avoid this as much as possible (with the VO2peak test), and a chair will also be 
available should the participant feel light-headed following the cool-down period. 
 The majority of testing procedures should be without stress for the participants.  
Taking a venous blood sample is a minor procedure with minimal discomfort and 
participants will be supine to minimise any danger of fainting.   
 The procedures for muscle imaging (MRI, ultrasound and DEXA scan) are 
without sensation and are without known health-risks. 
 The muscle biopsies are not particularly painful; however, it is an invasive 
procedure which some people find unpleasant.  The most painful part is the initial 
injection of local anaesthetic, which stings but this lasts only a few moments and after 
that the sensations are mainly ones of pressure as the fine-needle is inserted through 
the skin and the muscle sample removed.  There may be some bleeding and bruising 
around the biopsy site, which may remain tender for a day or so.  The sensation is 
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similar to that of a bruise.  The wound has to be kept dry and clean for about four days 
while the skin heals but there have been no reports of any complications.  Should 
complications occur, such as signs of infection, the participant will be advised to seek 
immediate medical assistance from his local general practitioner or the nearest hospital 
and to keep us informed. 
  
Appendix IV  
 
Informed Consent Form (to be retained by the investigator and participant) 
Participant:   
 
Name: Sex: Male  
 
Date of Birth:       
 
Principal Investigators: Prof Martin Flueck and Mr David Vaughan   
 
Collaborators: Prof Joern Rittweger, Prof Marco Narici, Mr Dave Tomlinson, Dr Hans 
Degens, Prof Roy Goodacre and Dr William Allwood  
 
Ethics Committee Approval Number: 
 
Project Title: “Systems Biology of Human Strength and Fitness” 
 
Purpose of study and brief description of procedures.  
(Not a legal explanation but a simple statement) 
 
 Athletic ability is related to metabolic fitness, which assessed during exercise 
is a good predictor of health and morbidity as it is a complete task that exposes the 
functionality of the whole body system.    
  We will be taking a holistic approach, by looking at the structure of 
skeletal muscle (including fat, types of muscle fibres, cellular components and 
capillary network) and how it responds to exercise – both endurance and strength.  
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This will entail screening for a known, possible “fitness gene” that may play a role in 
how skeletal muscle responds to exercise. 
  Why do some people and families seem more prone to particular 
diseases, e.g. heart disease, diabetes, certain cancers, osteoporosis, etc?  Whilst 
environment factors undoubtedly play a role, the genes we have certainly impact 
greatly upon our chances of leading a healthy life.  This and future research will 
hopefully influence clinical treatment, by uncovering the signalling pathways that are 
up-regulated by exercise.  Ultimately, we would like to influence how people are 
treated.   
  It is quite feasible that in the future people would receive personalised 
health plans, to not only prevent disease, but to also help recovery from them.  This 
would include specific exercises and nutrition based on their genotype.  This type of 
treatment would be a more natural approach than the current situation where 
medication is widely used to help manage diseases, rather than addressing the root of 
the problem.   
  If you decide to take part you will receive invaluable information and 
feedback on a whole host of import parameters such as, breath-by-breath gas analysis 
(related to fitness), body composition (including body fat percentage of different fibre 
types), blood analysis of factors related to cardiovascular (heart disease) health, and a 
detailed analysis of your diet together with expert advice on how to improve it (from a 
registered dietitian), should you want to.   
  
The study will be conducted in several stages: 
 
 You are free to refuse any test and withdraw from the study at anytime, for no 
reason, even after signing up.   
 
 Explanation of tests and procedures 
 
 There will be a minimum of 5 visits, of which 4 will last up to ½ a day (4 
hours), one visit lasting a whole day (9 – 10 hours).   
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Lifestyle questionnaire:  This is used as a screening tool to assess potential 
participants’ suitability for the study, we do not know the response we are going to 
get, and if it’s large this will help us to be more selective.  This will take 
approximately 15 minutes. 
 
 
Mucosa sample:  A small sample of cells from your inner cheek will be collected with 
an ear bud.  This is completely painless.  Please don’t eat or drink (except water) any 
food an hour before and your mouth should also be free from any gum disease, ulcers 
and cuts.  This will take approximately 5 minutes to complete. 
 
Anthropometric measures:  Height, weight, resting heart rate and blood pressure (both 
analysed using a Sphygmomanometer).  These will take approximately 45 minutes to 
complete. 
 
Dietary assessment: You will be asked to either fill in a food diary for 4 days 
(including the weekend) and/or (if you have a suitable mobile) take pictures of 
everything you eat and drink.  You will be given guidance on portion sizes and how to 
record the information if you choose to complete a food diary.  Further clarification 
may also be sought by means of an informal chat regarding your dietary intake.  After 
analysis of your diet a suitable personalised nutrition plan will be formulated for you, 
which will be based on healthy eating guidelines.  You will be asked to follow this for 
3 weeks.  You won’t be asked to eat any foods that you don’t normally eat, but you 
will be asked to adhere as strictly as possible to your personalised nutrition plan.  This 
is a very important part of the study, basically we are trying to “normalise” all 
participants nutritional intake so that any change that we find after the exercise tests 
(in the blood and muscle) can be attributed to the exercise and not to some component 
of your diet, e.g. certain foods and compounds within them are known to 
increase/decrease gene expression. 
 
Assessment of muscle size: The size of your quadriceps (thigh) muscles will be 
determined using magnetic resonance imaging (MRI) and ultrasound. This is a 
painless method of producing high quality images of tissues and all you have to do is 
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lie still for 30 minutes (not continuously – in bouts of approximately 5 minute 
periods).  The only constraint is that you should have no metal on, or inside you, as the 
machine uses high magnetic fields to generate the images.  We will check that you do 
not have any metal before you enter the machine.  There is no pain or discomfort 
involved and the measurement takes about 45 minutes in total including setting up.   
 
Maximal strength test: Maximal voluntary strength of the Vastus Lateralis (VL) 
muscle (right and left leg) will be made using a piece of gym equipment that looks like 
a leg (hamstring) curl machine – called a Cybex dynamometer.  This entails you 
contracting your thigh/quadriceps muscle as hard as you can for approximately three 
seconds.  This will be performed three times on each leg.  This test is completely 
painless (apart from your effort when contracting your muscle).  These measurements 
will take approximately 60 minutes, most of which involves the actual setting up of 
the equipment to an individual’s dimensions. 
 
DEXA scan: We will be measuring substances involved in exercise metabolism, and 
fat plays an important role in this, hence we want to accurately measure body fat 
percentage.  Body composition in terms of percent body fat, lean body mass and bone 
mineral content can be assessed by dual energy x-ray absorptiometry (DEXA).  The 
amount of radiation emitted (and therefore risk) is very low – as the total body 
equivalent dosage is approximately 50 times less than a 2 ½ hour air flight. There is no 
pain or discomfort involved and the measurement takes about 15 minutes in total, 
including setting up. 
 
One-legged cycling oxygen uptake (VO2peak test):  This involves sitting on an 
exercise bike and cycling with one leg.  You will start off with the resistance set 
relatively low and then every 30 seconds the resistance will be increased until you 
cannot cycle any more.  While you are doing this we would like you to breath through 
a mouthpiece so we can measure the amount of oxygen you are using.  We will also 
measure your heart rate using a monitor fitted around your chest.  We would like to do 
this test twice.  The exercise itself takes about 30 - 40 minutes but you should allow 
about 75 minutes in total for setting up the test, adjusting the cycle for you and for 
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warming up and cooling down afterwards.  The test is not unpleasant but for the last 
part you will be working hard and will feel hot and breathless.  
   
One-legged cycling (acute endurance test):  This test is very similar to the above test 
except a bit longer.  Based on the results from the above test you will exercise at a 
constant intensity (using one-leg) for 25 minutes and then the resistance will be 
increased every 30 seconds until you cannot cycle any more.  While you are doing this 
we would like you to breath through a mouthpiece so we can measure the amount of 
oxygen you are using.  We will also measure your heart rate using a monitor fitted 
around your chest.  Before starting this test you will have a cannula inserted into a 
vein in your arm (to enable blood sampling at various time points) and a small sample 
of muscle taken from your non-exercising leg.  Upon finishing the test, you will then 
have two very small muscle samples and one small sample taken from your exercised 
leg at three separate time points – 30 minutes, 3 hours and 8 hours post test (together 
with blood samples at similar time points).  Please see below for a more detailed 
description of these procedures.  You will be required to stay on the campus during 
this time.  We will provide entertainment (you will be able to watch a DVD, surf the 
web, listen to music, watch TV etc) and food/fluid during this period.  The test is not 
unpleasant but for the last part you will be working hard and will feel hot and 
breathless.   
 
Two-legged cycling oxygen uptake (VO2max test):  This involves sitting on an 
exercise bike and cycling with two legs.  You will start off with the resistance set 
relatively low and then every minute the resistance will be increased until you cannot 
cycle any more.  While you are doing this we would like you to breath through a 
mouthpiece so we can measure the amount of oxygen you are using.  We will also 
measure your heart rate using a monitor fitted around your chest.  We would like to do 
this test twice.  The exercise itself takes about 30 - 40 minutes but you should allow 
about 75 minutes in total for setting up the test, adjusting the cycle for you and for 
warming up and cooling down afterwards.  The test is not unpleasant but for the last 
part you will be working hard and will feel hot and breathless.  
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The following two tests (maximal single repetition and one-legged knee extension) are 
not applicable to participants in part one of the study.     
 
Maximal single repetition (1RM):  This test is for calculating the maximum weight 
you can lift (by one-legged knee extension) once.  We need to know this to work out 
what weight you will lift in the acute strength exercise test (see below).  The test is not 
unpleasant, but you may feel breathless and your leg will ache towards the end of each 
set.  You will not be performing this test if you are participating in part one of the 
study, as we are looking at the affect of endurance exercise. 
 
One-legged knee extension (acute strength test): This test is performed sitting down, 
with your back straight and one foot “hooked” under a padded lever.  With you leg in 
a bent position, you will contract your quadriceps muscle and pull your leg towards 
and up.  This will be performed against resistance (weights).  You will be asked to lift 
75% of your 1RM weight 10 times, have a 1 minute rest then repeat this twice more.  
The test is not unpleasant, but you may feel breathless and your leg will ache towards 
the end of each set.  Before starting this test you will have a small sample of muscle 
taken from your non-exercising leg.  Upon finishing the test, you will then have two 
small muscle samples and one “normal” size sample taken from your exercised leg at 
three separate time points – 30 minutes, 3 hours and 8 hours post test (together with 
blood samples at similar time points).  Please see below for a more detailed 
description of these procedures.  You will be required to stay on the campus during 
this time.  We will provide entertainment (you will be able to watch a DVD, surf the 
web, listen to music, watch TV etc) and food/fluid during this period.  The test is not 
unpleasant but your leg will ache and you may feel hot and breathless towards the end 
of each set. 
   
Blood samples (finger prick and venous):  Physiological and metabolic changes occur 
after exercise, which mainly occur in the muscle.  We would like to analyse and 
compare metabolites produced in the blood after exercise with changes in muscle 
samples.  To do this we need blood samples.  Where we can we will use finger prick 
blood samples, otherwise we will use a vein in your forearm.   A small blood sample 
(5ml) will be taken from a vein in your forearm (at several different time points during 
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the acute exercise bout).  This is not a painful procedure but some people are a little 
squeamish about blood and may faint.  With the exception of the blood sample taken 
whilst exercising you will be seated whilst the blood samples are collected.  This is 
because sometimes people become a little squeamish and may faint.  Occasionally 
there is a little bruising.  Qualified personnel will take the blood sample.  Pressure will 
be applied for approximately one-minute and a small plaster will be placed over the 
area.   
 As mentioned above we would like to take blood samples during the acute bout 
of exercise and after completion.  Blood will be collected at three time points post-
exercise (at the same time-points as muscle samples), which will allow us to analyse 
certain metabolites, of which glucose and triacylglerides will be included.  The blood 
will immediately be placed in special tubes for later analysis.   
 
Muscle sample (biopsies): Most of the changes with exercise are reflected by 
physiological and metabolic changes in the working muscle.  To look at these factors 
we need to have a small sample of your thigh muscle, the sample is taken using a 
procedure known as a “muscle biopsy”.  The biopsy procedure consists of 
anaesthetising the skin, making a very small incision in the skin and inserting a fine-
needle (for three of the samples, and then a “tweezer-like” device to extract a larger 
sample - still only ~ 10th of a gram - for the larger sample), which will take a very 
small sample of muscle, approximately 20mg (50th of a gram).  Probably the most 
painful part (if you feel anything) is the injection of local anaesthetic, which may sting 
for about 10 seconds.  Thereafter the sensations are of pressure in your muscle.  The 
preparation time, cleaning the skin, injecting the anaesthetic (and waiting for it to 
work), takes about 15 minutes, whilst the actual biopsy is all over in about a second.  
Afterwards, the very small incision in the skin is closed with Steristrips, and a plaster 
and a sterile dressing taped over the site.  You need to keep the site dry for about four 
days to allow the cut to heal.  When the anaesthetic wears off you may feel the biopsy 
site to be rather tender and there may be some bruising.  But in general a muscle 
biopsy is very well tolerated and there have been lots of studies where participants 
have had biopsies in the middle of races and then carried on.  The muscle itself 
recovers rapidly and the biopsy will have no effect on your muscle strength.  The 
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biopsy will be taken by a qualified doctor who is very experienced in this type of 
procedure.  Each whole procedure will take approximately 20 minutes.  
  
 You should not have a biopsy if you have ever had an adverse reaction to a 
local anaesthetic (such as when having dental treatment) or if you have a tendency to 
bleed excessively.  After the biopsy you should keep an eye on the cut and check it is 
healing properly.  In the unlikely event that it becomes red and inflamed you should 
immediately see your GP and keep us informed. 
 
 Muscle biopsy and blood storage:  Both your blood and muscle samples will be 
anonymously labelled/coded and stored at –80oC, which will enable us to perform 
tests of importance for this study, like: genetic analysis, muscle fibre type 
identification, and metabolite analysis.  We will only be analysing genes and 
metabolites, which are of interest and have previously been identified in other studies, 
which may be relevant in metabolic fitness. 
 
I have read and understood the nature of the tests and procedures, including the blood 
samples and muscle biopsies (and storage, and subsequent analysis) and what they 
involve.  I give my consent to taking part in the study but realise that I can withdraw 
from the study at any time without having to give an explanation. 
 
Signed………………………………………  Date………………………… 
 
Name (Print)……………………………….. 
 
Witnessed…………………………………… 
 
 Name (Print)……………………………….. 
 
 If you have any questions about the study as a whole or about individual tests 
or procedures, now or at any time in the future, please contact David Vaughan (0161-
2475457) or Professor Marin Flueck (0161-2475417). 
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 All data obtained will be treated as strictly confidential.  You will also have the 
option to receive specific advice regarding nutrition and exercise based on our 
findings.  We are more than happy to talk to you about any results and what they may 
imply.  At the end of the study we will compile a short report for all the participants to 
keep you informed about the contribution you will have made to advancing 
knowledge. 
 
Thank you for your interest and help. 
 
Participant Statement:   
 
 I fully understand what is involved in taking part in this study. Any questions I 
have about the study, or my participation in it, have been answered to my satisfaction. 
I understand that I do not have to take part and that I may decide to withdraw from the 
study at any point without prejudice. I have had my attention drawn to the document 
'Ethical Regulations for the Use of Humans in Research'. My concerns regarding this 
study have been answered and such further concerns as I have during the time of the 
study will be responded to. It has been made clear to me that, should I feel that these 
Regulations are being infringed or that my interests are otherwise being ignored, 
neglected or denied, I should inform the Chair of the Ethics Committee of the 
Department of Exercise and Sport Science, Manchester Metropolitan University, 
Hassall Road, Alsager, Cheshire, ST7 2HL who will undertake to investigate my 
complaint. 
 
Signed .................................... Date ............................. 
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Appendix 2: Publications, Proceedings and Communications 
 
Publications: 
 
Martin Flueck, David Vaughan, and Hakan Westerblad. Linking genes with exercise: 
where is the cut-off? European Journal of Applied Physiology (2010): 110; 1095-
1098. 
Abstract: Studies on gene-phenotype associations are a popular theme in exercise 
physiology. This editorial follows up on the current limitations in this quest with 
regard to the identification of mechanistically important relationshipds. 
 
Manuscripts submitted and in preparation: 
 
David Vaughan, Felicitas A Huber-Abel, Franziska Graber, Hans Hoppeler, and 
Martin Flueck, The Angiotensin Converting Enzyme Insertion/Deletion Polymorphism 
Alters the Response of Muscle Energy Supply Lines to Exercise - submitted to the 
European Journal of Applied Physiology 
 
Conference proceedings: 
 
Michael Brogioli, David Vaughan, Wouter Eilers, Sarah Waldron, Martin Flück, 
Glucose oxidation during endurance work is reduced in ACE genotypes lacking the I-
allele, 
4
. Congress of the Sportwissenschaftliche Gesellschaft der Schweiz (2012), 
Eigenössische Hochschule für Sport, Magglingen, Switzerland. 
Introduction: Oxidation of blood borne nutrients carbohydrate and triglyceride 
importantly drive endurance performance
1
. The vasoconstrictor angiotensin 2 may 
play an important role in the underlying metabolic control. This is indicated by the 
improved glucose disposal with pharmacological inhibition of angiotensin 2 
production by angiotensin converting enzyme (ACE; 
4
) and elevated serum 
angiotensin 2 levels post exercise
3
. We hypothesized that modulated nutrient supply 
explains the reduced endurance performance in subjects with genetically enhanced 
levels of the major vasoconstrictor angiotensin 2 due to the presence of a silencer 
region (the I-allele) in the ACE gene
2
. 
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Methods: Amateur endurance runners were screened for the I-allele with polymerase 
chain reaction in mucosal samples. Serum glucose and triglycerides were measured 
using a cardiocheck (brand) in venous blood samples before and immediately after a 
Marathon race in Chester (UK). A subset of subjects reported to the laboratory for the 
apprehended investigation of serum glucose and triglycerides in relation to serum 
angiotensin 2 (ELISA, Sp-Bio) and respiration exchange ratio (Cortex system) during 
an exhaustive single leg endurance test on a stationary bicycle ergometer. The protocol 
consisted in 25 minute at 60% peak power output followed by an increase of the 
intensity until exhaustion. 
Results: Serum glucose but not triglyceride concentration after the Marathon was 
significantly higher in ACE genotypes lacking the I-allele vs. those with the I-allele 
(7.6 vs. 4.4 mM, n=4 vs. 12; p=0.0001, T-test). No difference between the race time of 
ACE genotypes lacking the I-allele vs. those with the I- allele was found (214 vs. 201 
min, p=0.703, n=5 vs. 13, T-Test). When we raised the threshold of running time, no 
athletes that ran under 3 hours showed a genotypes lacking the ACE I-allele (p=0.03, 
sign test, n=5). Fold changes in glucose concentration after 30 minutes single leg 
bicycle exercise were also higher in ACE genotypes lacking the I-allele (1.19 vs. 1.06, 
p=0.07, n=2 vs. 6, T-test) which demonstrated elevated angiotensin 2 levels at rest. 
The changes in glucose correlated to average respiration exchange ratio (r=0.70; 
p=0.08; n=7) and changes in serum angiotensin 2 (r=-0.846; p=0.008; n=8) at the end 
of the exhaustive ergometer exercise. 
Discussion/Conclusion: Altered genetic drive in the producer of the major 
vasoconstrictor, angiotensin 2, explains 50% of the variability in glucose oxidation 
with endurance work and appears to be a handicap to achieve competitive race time 
during an extensive run. The findings imply that ACE genotypes lacking that the I-
allele show inhibited uptake of blood borne substrates in working muscle. 
 
References: 
1 Rose, A. J., & Richter, E. A. (2005). Skeletal muscle glucose uptake during exercise: 
how is it regulated. Physiology, 20, 260–270. 
2 Rigat, B., Hubert, C., Alhenc-Gelas, F., Cambien, F., Corvol, P., & Soubrier, F. 
(1990). An insertion/deletion polymorphism in the angiotensin I-converting enzyme 
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gene accounting for half the variance of serum enzyme levels. The journal of clinical 
investigation, 86, 1343–1346. 
3 Staessen, J., Fagard, R., Hespel, P., Lijnen, P., Vanhees, L., & Amery, A. (1987). 
Plasma renin system during exercise in normal men. Journal of applied physiology, 
63, 188–194. 
4 Henriksen, E.J., JACOB, S. (2003), Modulation of Metabolic Control by 
Angiotensin Converting Enzyme (ACE) Inhibition, Journal of Cell Physiol 196: 171–
179. 
 
The FASEB Journal. 2011;25:862.5 
Angiotensin Converting Enzyme Exerts System Control Over Fuel Handling In 
Skeletal Muscle 
Martin Flueck1, David Vaughan1, William Allwood2, Hans Hoppeler3, Felicitas 
Huber-Abel3, Joern Rittweger1, Warwick Dunn2, Steven O’Hagen2 and Royston 
Goodacre2 
1 Institute for Biomedical Research into Human Movement and Health, Manchester 
Metropolitan University, Manchester, United Kingdom 
2 Manchester Interdisciplinary Biocentre, University of Manchester, Manchester, 
United Kingdom 
3 Department of Anatomy, University of Berne, Berne, Switzerland 
 
Using a genetical metabolomics approach we assessed whether altered energy supply 
in locomoter muscle underlies the elevated aerobic performance of human genotypes 
containing a silencer region (I-allele) of the major regulatory enzyme of 
vasoconstriction, angiotensin converting enzyme (ACE). 
 
Extensor muscle, m. vastus lateralis, of ACE-II/ID genotypes holding the I-allele 
demonstrated a trend for elevated capillarity compared to ACE-DD counterparts 
lacking the I-allele (311.0 vs. 279.7 mm-2, n=20, p=0.10). In untrained subjects, 
maximal oxygen uptake during bicycle exercise was lower in ACE-DD genotypes 
(44.9 vs. 47.8 ml O2/min/kg). Exhaustive aerobic exercise selectively reduced low 
density lipoproteins in serum of ACE-II/ID genotypes (–14%) but was spared in ACE-
DD (+6%, p=0.25). By contrast, non-polar metabolites in exercised muscle, 
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comprising tentatively identified LDL-derived glycerophosphocholine species, were 
depleted in ACE-DD genotypes (q=2.8%; statistical analysis of microarrays). The 
interaction effect of exercise and genotype on lipidic muscle metabolites was 
maintained in trained subjects (p=0.03, ANOVA). The observations indicate that 
elevated import of serum lipids into exercised muscle underlies the enhanced aerobic 
exercise performance of I-allelic genotypes for this major checkpoint of vascular 
perfusion. 
 
Poster Communications 
 
University of Manchester (2010) Proc Physiol Soc 19, PC175 
Angiotensin converting enzyme exerts system control over fuel handling in exercising 
skeletal muscle 
 
D. Vaughan1, W. Allwood2, H. Hoppeler3, F. Huber-Abel3, W. Dunn2, S. O'Hagen2, 
R. Goodacre2, M. Flueck1 
 
1. IRM, Manchester Metropolitan University, Manchester, United Kingdom. 2. 
Manchester Interdisciplinary Biocentre, University of Manchester, Manchester, United 
Kingdom. 3. Department of Anatomy, University of Berne, Berne, Switzerland. 
 
Blood-borne nutrient supply is critical to fuel muscle contraction and limits exercise 
performance. A silencer region (I-allele) within intron 16 of the gene for the major 
regulatory enzyme of vasoconstriction, angiotensin converting enzyme (ACE), is 
implicated in phenotypic variation of human performance and its trainability. The 
muscular mechanisms contributing to ACE-modulated exercise performance is not 
known. We hypothesized that modified substrate supply and aerobic metabolism in 
skeletal muscle underlies the modulation of maximal aerobic exercise performance by 
the genetic silencing of ACE expression. This was exposed using a genetical-
metabolomics approach. Human subjects, who gave informed consent, were recruited 
to characterize ACE-dependence in muscle makeup and muscle’s metabolic response 
to exercise. Aerobic performance was assessed by ergospirometry. Muscle biopsies 
were collected (under lidocaine as local anaesthetic), from the major extensor muscle 
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vastus lateralis, before and 30 min after a bout of maximal aerobic exercise at a 
standardized intensity on an ergometer (Jaeger). Biopsies of untrained healthy subjects 
(n=20) were subjected to transcript profiling and ultra-structural analysis, carried out 
as described (Schmutz et al 2010). Muscle metabolites of untrained (n=10) and trained 
(n=10) subjects were extracted from cryo-sectioned samples into a polar (methanol) 
and non-polar (chloroform) phase and assessed by liquid chromatography - mass 
spectrometry (LC-MS) and direct infusion mass spectrometry (DIMS), respectively, as 
described in (Dunn et al 2008; Brown et al 2009). ACE-DD genotypes demonstrated 
elevated muscle capillarity (+17.8%; p<0.05) and increased expression (assessed by 
significance analysis of microarray - SAM) of transcripts related to vascular 
remodelling and lipid metabolism compared to ACE-II/ACE-ID genotypes (q-value = 
2.39; fold change 1.01 - 2.08). Oxidation of lipid substrates (as assessed by respiration 
exchange ratio; -30%; p=0.30, ANOVA) and levels of non-polar, but not polar, 
metabolites were reduced with exercise in the ACE-DD genotype lacking the I-allele 
(-33%, p=0.06, repeated ANOVA). The selective depletion of the non-polar metabolite 
class was preserved in trained subjects (-34%, p=0.03). Serum LDL was selectively 
reduced (-14%, p=0.03) in the genotypes with the I-allele. The observations 
demonstrate a clear difference in whole-body substrate utilisation between the 
investigated ACE-genotypes during maximal endurance exercise, which relates to 
muscle metabolite levels. A mismatch between vascular delivery and myocellular 
turnover of non-polar metabolites upon exercise is suggested to underlie the different 
trainability of genotypes for the major checkpoint of vascular perfusion, ACE 
(Montgomery et al 1998). 
 
University of Dublin (2009) Proc Physiol Soc 15, C34 
 
Aerobic Fitness in Humans is Under System Control by The Angiotensin 2 Pathway 
David Vaughan, Hans Hoppeler and Martin Flueck. IRM, Manchester Metropolitan 
University, Manchester, England. 
Background: Blood supply is critical to fuel muscle contraction and limits exercise 
performance. The presence of a silencer sequence in intron 16 (insertion, I) in the ACE 
(angiotensin converting enzyme) gene, which is the enzyme that converts the 
vasoconstrictor angiotensin (Ang) into its active form Ang2, has been associated with 
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enhanced endurance capacity (Montgomery et al., 1998 and Scanavini et al., 2002).  
However, conflicting evidence exists on the association of ACE genotypes with regard 
to the presence (or absence) of the I sequence and human performance (Rankinen et al. 
2000, Amir et al., 2007 and Zhao et al., 2003). 
Hypothesis: Adaptations of capillary supply lines in muscle contribute and explain the 
altered endurance phenotype in ACE genotypes, with an ACE insertion, due to 
reduced ACE gene expression in muscle.    
Methods: Participants were untrained healthy medical students (n=12) recruited from 
the University of Berne.  Aerobic performance was measured and muscle biopsies 
collected, under local anaesthetic (lidocaine), from the Vastus lateralis muscle.  Ultra-
structure and gene expression were quantified in biopsies with morphometry and 
cDNA microarrays. DNA was extracted and the ACE genotype identified post-hoc 
with specific primers. 
Results: The investigated participants fell into two categories:  DD and ID.  The DD 
genotype vs. the ID genotype demonstrated increased mRNA expression of ACE and 
Ang2 receptors, elevated mitochondrial density, capillary density, and reduced fiber 
size (see fig. 1).   Maximal oxygen uptake during bicycle exercise in the DD genotype 
was elevated by 27% and correlated positively and negatively, respectively, with 
mitochondrial volume density (r=0.65) and fiber area (r=-0.53) in the investigated 
knee extensor muscle. 
Figure 1. Ultra-structural and mRNA differences between ACE DD v ID genotype  
 Genotype 
  
Mitochondriaa, z 
(s.e.m.) 
Capillary 
densityb 
(s.e.m.) 
Fiber areac 
(s.e.m.) 
ACE 
mRNAd 
(s.e.m.) 
AGTR1e 
mRNAd 
(s.e.m.) 
AGTR2f 
mRNAd 
(s.e.m.) 
Mean DD  
(n=7) 
4.8  
(0.4) 
869.1  
(38.6) 
3060.0  
(152.7) 
19.5  
(1.9) 
9.1  
(3.4) 
9.7  
(3.2) 
 ID  
(n=5) 
3.3  
(0.3) 
687.0  
(55.0) 
3753.5  
(276.8) 
15.7  
(4.5) 
4.9  
(1.5) 
5.3  
(1.5) 
% change  +47 +27 -18% +25% +86% +83% 
Pg/Qh value  0.04 0.01 0.04 15.2 9.9 9.9 
 
a
Per fiber volume, 
b
mm/mm
3
 of fiber volume, 
cμm2, dnormalised to total (x10-4) 
mRNA per array, 
e
angiotensin receptor-1, 
f
angiotensin receptor-2, 
g
honest significant 
difference for unequal number, 
h
statistical analysis of microarrays (SAM), 
z
only 4 
samples analysed 
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Discussion & Conclusion: The investigated, not-specifically trained population 
demonstrated a shift towards a muscle phenotype with improved substrate supply and 
aerobic metabolism. This points out that expressional alterations in the local Ang2 
signalling system intervene in the manifestation of an endurance phenotype via the 
modulation of capillarity and aerobic capacity in locomotor muscle. 
This work was funded by the Swiss national foundation grant and a start up grant 
from MMU to MF. 
Amir, O., et al. (2007). Experimental Physiology 92, 881-886. 
Montgomery, H. E., et al. (1998). Nature 2. 
Rankinen, T., et al. (2000). Journal of Applied Physiology 5. 
Scanavini, D., et al. (2002). European Journal of Human Genetics 10, 576-577. 
Zhao, B., et al (2003). Life Sciences 73, 2625-2630. 
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